<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xml:lang="EN" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Oncol</journal-id><journal-id journal-id-type="publisher-id">CO</journal-id><journal-title>Current Oncology</journal-title><issn pub-type="ppub">1198-0052</issn><issn pub-type="epub">1718-7729</issn><publisher><publisher-name>Multimed Inc.</publisher-name><publisher-loc>66 Martin St. Milton, ON, Canada L9T 2R2</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">19229369</article-id><article-id pub-id-type="pmc">2644627</article-id><article-id pub-id-type="publisher-id">co16-1-27</article-id><article-categories><subj-group subj-group-type="heading"><subject>Practice Guideline Series</subject></subj-group></article-categories><title-group><article-title>The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national consensus statement</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ellis</surname><given-names>P.M.</given-names></name><degrees>MD, PhD</degrees><xref ref-type="aff" rid="af1-co16-1-27">*</xref><xref ref-type="corresp" rid="c1-co16-1-27"/></contrib><contrib contrib-type="author"><name><surname>Morzycki</surname><given-names>W.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="af2-co16-1-27">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Melosky</surname><given-names>B.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="af3-co16-1-27">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Butts</surname><given-names>C.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="af4-co16-1-27">&#x000a7;</xref></contrib><contrib contrib-type="author"><name><surname>Hirsh</surname><given-names>V.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="af5-co16-1-27">||</xref></contrib><contrib contrib-type="author"><name><surname>Krasnoshtein</surname><given-names>F.</given-names></name><degrees>MSc</degrees><xref ref-type="aff" rid="af6-co16-1-27">#</xref></contrib><contrib contrib-type="author"><name><surname>Murray</surname><given-names>N.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="af3-co16-1-27">&#x02021;</xref></contrib><contrib contrib-type="author"><name><surname>Shepherd</surname><given-names>F.A.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="af7-co16-1-27">**</xref></contrib><contrib contrib-type="author"><name><surname>Soulieres</surname><given-names>D.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="af8-co16-1-27">&#x02020;&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Tsao</surname><given-names>M.S.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="af7-co16-1-27">**</xref></contrib><contrib contrib-type="author"><name><surname>Goss</surname><given-names>G.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="af9-co16-1-27">&#x02021;&#x02021;</xref></contrib></contrib-group><aff id="af1-co16-1-27"><label>*</label> Juravinski Cancer Centre, Hamilton, ON</aff><aff id="af2-co16-1-27"><label>&#x02020;</label> QEII Health Sciences Centre, Nova Scotia Cancer Centre, Halifax, NS</aff><aff id="af3-co16-1-27"><label>&#x02021;</label> BC Cancer Agency, Vancouver, BC</aff><aff id="af4-co16-1-27"><label>&#x000a7;</label> Cross Cancer Institute, Edmonton, AB</aff><aff id="af5-co16-1-27"><label>||</label> Royal Victoria Hospital, Montreal, QC</aff><aff id="af6-co16-1-27"><label>#</label> MedWrite, Montreal, QC</aff><aff id="af7-co16-1-27"><label>**</label> Princess Margaret Hospital, Toronto, ON</aff><aff id="af8-co16-1-27"><label>&#x02020;&#x02020;</label> Centre Hospitalier de l&#x02019;Universit&#x000e9; de Montr&#x000e9;al, Montreal, QC</aff><aff id="af9-co16-1-27"><label>&#x02021;&#x02021;</label> The Ottawa Hospital Cancer Centre, Ottawa, ON</aff><author-notes><corresp id="c1-co16-1-27">Correspondence to: Peter Ellis, Juravinski Cancer Centre, 699 Concession Street, Hamilton, Ontario L8V 5C2. <italic>E-mail:</italic><email>peter.ellis@jcc.hhsc.ca</email></corresp></author-notes><pub-date pub-type="ppub"><month>1</month><year>2009</year></pub-date><volume>16</volume><issue>1</issue><fpage>27</fpage><lpage>48</lpage><copyright-statement>2009 Multimed Inc.</copyright-statement><copyright-year>2009</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license><abstract><sec><title>Purpose</title><p>To provide consensus recommendations on the use of epidermal growth factor receptor tyrosine kinase inhibitors (<sc>egfr</sc>-<sc>tkis</sc>) in patients with advanced or meta-static non-small-cell lung cancer (<sc>nsclc</sc>).</p></sec><sec sec-type="methods"><title>Methods</title><p>Using a systematic literature search, phase <sc>ii</sc> trials, randomized phase <sc>iii</sc> trials, and meta-analyses were identified for inclusion.</p></sec><sec><title>Results</title><p>A total of forty-six trials were included. Clear evidence is available that <sc>egfr</sc>-<sc>tkis</sc> should not be administered concurrently with platinum-based chemotherapy as first-line therapy in advanced or metastatic <sc>nsclc</sc>. Evidence is currently insufficient to recommend single-agent <sc>egfr</sc>-<sc>tkis</sc> as first-line therapy either in unselected populations or in populations selected on the basis of molecular or clinical characteristics. Following failure of platinum-based chemotherapy, the evidence suggests that second-line <sc>egfr</sc>-<sc>tkis</sc> or second-line chemotherapy result in similar survival. Quality of life and symptom improvement for patients treated with an <sc>egfr</sc>-<sc>tki</sc> appear better than they do for patients treated with second-line docetaxel. Sequence of therapy may not appear to be important, but if survival is the outcome of interest, the goal should be to optimize the number of patients receiving three lines of therapy. Based on available data, molecular markers and clinical characteristics do not appear to be predictive of a differential survival benefit from an <sc>egfr</sc>-<sc>tki</sc> and therefore those factors should not be used to select patients for <sc>egfr</sc>-<sc>tki</sc> therapy.</p></sec><sec><title>Conclusions</title><p>The <sc>egfr</sc>-<sc>tkis</sc> represent an additional therapy in the treatment of advanced or metastatic <sc>nsclc</sc>. The results of ongoing clinical trials may define the optimal role for these agents and the effectiveness of combinations of these agents with other targeted agents.</p></sec></abstract><kwd-group><kwd>Non-small-cell lung cancer</kwd><kwd>targeted therapy</kwd><kwd>epidermal growth factor receptor</kwd><kwd>tyrosine kinase inhibitor</kwd><kwd>molecular marker</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>1. INTRODUCTION</title><p>Lung cancer represents a major health burden in Canada. Approximately 23,300 new lung cancer cases and 19,900 deaths from lung cancer occurred in 2007, most of which were non-small-cell lung cancer (<sc>nsclc</sc>)<xref ref-type="bibr" rid="b1-co16-1-27">1</xref>. Most of these patients either present with or develop metastatic disease at some point during their illness; potentially, they are candidates for systemic therapy approaches such as chemotherapy.</p><p>Until the late 1990s, therapeutic nihilism about the benefit of systemic chemotherapy in the treatment of advanced and metastatic <sc>nsclc</sc> was widespread. Publication of the Non-small Cell Lung Cancer Collaborative Group meta-analysis in 1995 established the association of first-line platinum-based chemotherapy with a modest improvement in survival for patients with metastatic disease<xref ref-type="bibr" rid="b2-co16-1-27">2</xref>. The introduction of newer drugs such as vinorelbine, gemcitabine, paclitaxel, and docetaxel have resulted in further small improvements, although most patients still experience disease progression within a short time, with a median time to progression (<sc>ttp</sc>) of approximately 4 months <xref ref-type="bibr" rid="b3-co16-1-27">3</xref>&#x02013;<xref ref-type="bibr" rid="b5-co16-1-27">5</xref>.</p><p>At the time of progression following platinum-based chemotherapy, many patients maintain a good performance status (<sc>ps</sc>) and may be candidates for further systemic therapy. Recent trials have established that second-line chemotherapy with docetaxel<xref ref-type="bibr" rid="b6-co16-1-27">6</xref>&#x02013;<xref ref-type="bibr" rid="b9-co16-1-27">9</xref> improves survival and quality of life (<sc>qol</sc>) as compared with best supportive care (<sc>bsc</sc>) and that survival of patients treated with docetaxel or pemetrexed is similar<xref ref-type="bibr" rid="b10-co16-1-27">10</xref>. Guidelines for the management of <sc>nsclc</sc>, including those from Cancer Care Ontario&#x02019;s Program in Evidence-Based Care (<sc>cco-pebc</sc>)<xref ref-type="bibr" rid="b11-co16-1-27">11</xref> now recommend either of those agents as second-line chemotherapy options<xref ref-type="bibr" rid="b11-co16-1-27">11</xref>,<xref ref-type="bibr" rid="b12-co16-1-27">12</xref>.</p><p>Despite these advancements in the treatment of <sc>nsclc</sc>, there is still a strong need for additional and better treatment options. Recently, a greater understanding of the molecular abnormalities associated with <sc>nsclc</sc> has led to evaluation of new therapeutic targets for <sc>nsclc</sc>. The epidermal growth factor receptor (<sc>egfr</sc>) is one target commonly overexpressed in <sc>nsclc</sc><xref ref-type="bibr" rid="b13-co16-1-27">13</xref>&#x02013;<xref ref-type="bibr" rid="b15-co16-1-27">15</xref>. Early-phase clinical trials showed that <sc>egfr</sc> tyrosine kinase inhibitors (<sc>tkis</sc>) such as erlotinib and gefitinib had antitumour activity, and this finding prompted their further evaluation in advanced <sc>nsclc</sc><xref ref-type="bibr" rid="b16-co16-1-27">16</xref> These agents have been evaluated extensively in phase <sc>ii</sc> and <sc>iii</sc> trials over the last few years, confirming the promising activity seen in phase <sc>i</sc> trials, and the <sc>tkis</sc> have been incorporated into treatment algorithms for patients after progression on standard chemotherapy options<xref ref-type="bibr" rid="b11-co16-1-27">11</xref>.</p><p>Because of a favourable toxicity profile of the <sc>tkis</sc>, many clinicians felt that it might be appropriate to expand their role in the treatment of advanced and metastatic <sc>nsclc</sc>. A need therefore exists to clarify the role of <sc>egfr</sc>-<sc>tkis</sc> in the treatment of <sc>nsclc</sc>. The present paper represents a consensus view of a representative sample of Canadian lung cancer medical oncologists on the role of <sc>egfr</sc>-<sc>tkis</sc> in the treatment of <sc>nsclc</sc> based on a systematic review of currently available evidence.</p></sec><sec sec-type="materials|methods"><title>2. MATERIALS AND METHODS</title><p>Medical oncologists specializing in thoracic oncology from five provinces across Canada were invited to participate in a consensus meeting. Six oncologists attended the consensus meeting, and three additional oncologists, plus one pathologist, provided input into the consensus process. Three key questions were identified to be addressed by the group:</p><list list-type="bullet"><list-item><p>What is the role of <sc>egfr</sc>-<sc>tkis</sc> as first-line therapy of advanced or metastatic <sc>nsclc</sc> as a single agent or in combination with chemotherapy?</p></list-item><list-item><p>What is the role of <sc>egfr</sc>-<sc>tkis</sc> following progression after platinum-based chemotherapy (single-agent <sc>egfr</sc>-<sc>tki</sc> vs. <sc>bsc</sc>, <sc>egfr</sc>-<sc>tki</sc> vs. chemotherapy, and <sc>egfr</sc>-<sc>tki</sc> in combination with another agent)?</p></list-item><list-item><p>Do any patient subpopulations, or clinical and molecular characteristics, predict for additional benefit from <sc>egfr</sc>-<sc>tki</sc> therapy?</p></list-item></list><sec><title>2.1 Literature Search</title><p>A search of the <sc>medline</sc> database for 2000&#x02013;2007 was conducted using the terms &#x0201c;non-small-cell lung cancer,&#x0201d; &#x0201c;epidermal growth factor receptor tyrosine kinase inhibitor,&#x0201d; &#x0201c;erlotinib,&#x0201d; and &#x0201c;gefitinib.&#x0201d; The search excluded articles prior to 2000, because the <sc>egfr</sc>-<sc>tkis</sc> are new agents and their initial phase <sc>i</sc> trials were known to be conducted during the selected time period. Conference proceedings of the American Society of Clinical Oncology 2000&#x02013;2007 and the International Association for the Study of Lung Cancer 2007 World Conference on Lung Cancer were also searched. Finally, the list of included articles was reviewed by the consensus panel for omissions.</p></sec><sec><title>2.2 Study Selection Criteria</title><p>Articles published as full reports or as abstracts and conference presentations were included if they focused on</p><list list-type="bullet"><list-item><p><sc>egfr</sc>-<sc>tki</sc> alone or in combination with chemotherapy in the first-line setting,</p></list-item><list-item><p><sc>egfr</sc>-<sc>tki</sc> as second- or third-line therapy following progression of platinum-based chemotherapy, or</p></list-item><list-item><p>clinical and molecular characteristics that may predict additional benefit from <sc>egfr</sc>-<sc>tki</sc> therapy.</p></list-item></list><p>The literature search results were reviewed by two authors (PE, FK), and articles that met the foregoing criteria were selected for retrieval. The outcomes of interest were overall survival (<sc>os</sc>), time to disease progression, tumour response rate, molecular and clinical predictors of benefit from <sc>egfr</sc>-<sc>tki</sc> therapy, and <sc>qol</sc> or symptom improvement. Single-arm phase <sc>ii</sc> trials were included only if no data from randomized trials were available. Forty-three individual trials (eight phase <sc>iii</sc>, eleven randomized phase <sc>ii</sc>, and twenty-four single-agent phase <sc>ii</sc> trials) met the eligibility criteria for the present consensus statement. Only studies published in English were considered.</p></sec><sec><title>2.3 External Review</title><p>Final consensus statement draft recommendations were distributed electronically to reviewers. The review panel consisted of practitioners who had attended the consensus meeting and others who were not in attendance. The comments resulting from this review were incorporated into the final document.</p></sec></sec><sec><title>3. RECOMMENDATIONS AND KEY EVIDENCE</title><sec><title>3.1 First-Line Treatment</title><p>What is the role of <sc>egfr</sc>-<sc>tkis</sc>as first-line therapy of advanced or metastatic <sc>nsclc</sc> as a single agent or in combination with chemotherapy?</p><sec><title>3.1.1 What Is the Role of Single-Agent EGFR-TKIs in Chemona&#x000ef;ve Patients with NSCLC?</title><sec><title>Key Evidence</title><p>Fourteen single-arm phase <sc>ii</sc> trials (<italic>n</italic> = 1026) and one randomized phase <sc>ii</sc> trial (<italic>n</italic> = 201) evaluated single-agent erlotinib 150 mg or gefitinib 250 mg daily as first-line therapy of stage <sc>iiib</sc>/<sc>iv nsclc</sc> (<xref ref-type="table" rid="tI-co16-1-27">TABLE I</xref>). In general, patients had an Eastern Cooperative Oncology Group <sc>ps</sc> of 0&#x02013;2 and were not selected for clinical or molecular characteristics reported to be associated with improved response to an <sc>egfr</sc>-<sc>tki</sc>. Substantial variability was observed in the response rate to single-agent <sc>egfr</sc>-<sc>tkis</sc> (range: 4%&#x02013;55%, with an additional 20%&#x02013;46% achieving disease stabilization). The time to disease progression ranged from 1 month to 6.6 months, with median survival varying between 2.9 months and 14.1 months, and 1-year survival being 24%&#x02013;58.2% <xref ref-type="bibr" rid="b17-co16-1-27">17</xref>&#x02013;<xref ref-type="bibr" rid="b22-co16-1-27">22</xref>,<xref ref-type="bibr" rid="b24-co16-1-27">24</xref>,<xref ref-type="bibr" rid="b26-co16-1-27">26</xref>,<xref ref-type="bibr" rid="b27-co16-1-27">27</xref>,<xref ref-type="bibr" rid="b30-co16-1-27">30</xref>&#x02013;<xref ref-type="bibr" rid="b36-co16-1-27">36</xref>,<xref ref-type="bibr" rid="b38-co16-1-27">38</xref>,<xref ref-type="bibr" rid="b39-co16-1-27">39</xref>.</p><p>A single randomized placebo-controlled trial compared gefitinib to <sc>bsc</sc> in patients with poor performance (<sc>ps</sc> 2&#x02013;3) unsuitable for chemotherapy. The observed response rate was only 6%, and the trial failed to demonstrate significant improvement in either TTP or OS<xref ref-type="bibr" rid="b33-co16-1-27">33</xref>.</p><p>Among the trials in unselected populations, <sc>qol</sc> and symptom improvement data were inconclusive <xref ref-type="bibr" rid="b17-co16-1-27">17</xref>&#x02013;<xref ref-type="bibr" rid="b22-co16-1-27">22</xref>,<xref ref-type="bibr" rid="b24-co16-1-27">24</xref>,<xref ref-type="bibr" rid="b26-co16-1-27">26</xref>,<xref ref-type="bibr" rid="b27-co16-1-27">27</xref>,<xref ref-type="bibr" rid="b30-co16-1-27">30</xref>&#x02013;<xref ref-type="bibr" rid="b36-co16-1-27">36</xref>,<xref ref-type="bibr" rid="b38-co16-1-27">38</xref>,<xref ref-type="bibr" rid="b39-co16-1-27">39</xref>. In the single randomized trial, the proportion of patients reporting <sc>qol</sc> and symptom improvement appeared similar for gefitinib and <sc>bsc</sc> (21.1% vs. 20.0% and 28.3% vs. 23.3% respectively)<xref ref-type="bibr" rid="b33-co16-1-27">33</xref>. Several other authors also reported no significant improvement in <sc>qol</sc> over time <xref ref-type="bibr" rid="b24-co16-1-27">24</xref>,<xref ref-type="bibr" rid="b31-co16-1-27">31</xref>. However, Spigel reported improvement or no change in <sc>qol</sc> [using the Functional Assessment of Cancer Therapy&#x02013;Lung (<sc>fact</sc>-<sc>l</sc>)] in 82% of patients, and improvement or control in lung cancer symptom (<sc>lcs</sc>) response in 48% of patients<xref ref-type="bibr" rid="b19-co16-1-27">19</xref>. P&#x000e9;rez&#x02013;Soler reported significant improvements in pain scores at 2 weeks and improvement in emotional functioning during the first 4 weeks of therapy<xref ref-type="bibr" rid="b17-co16-1-27">17</xref> (<xref ref-type="table" rid="tI-co16-1-27">TABLE I</xref>). In general, these <sc>qol</sc> analyses involved small numbers of patients in the absence of control groups and should be interpreted cautiously.</p><p>The remaining five phase <sc>ii</sc> trials selected patients based on the presence of activating mutations of the <italic>EGFR</italic> gene (<italic>n</italic> = 85) or of clinical characteristics associated with high response rate to treatment (<italic>n</italic> = 40). The trials included patients with stage <sc>iii</sc> or <sc>iv nsclc</sc> and <sc>ps</sc> 0&#x02013;2, and evaluated either erlotinib 150 mg or gefitinib 250 mg daily. Higher response rates were observed in these selected populations (range: 30%&#x02013;90%) as compared with the unselected populations described earlier<xref ref-type="bibr" rid="b23-co16-1-27">23</xref>,<xref ref-type="bibr" rid="b25-co16-1-27">25</xref>,<xref ref-type="bibr" rid="b28-co16-1-27">28</xref>,<xref ref-type="bibr" rid="b29-co16-1-27">29</xref>,<xref ref-type="bibr" rid="b37-co16-1-27">37</xref>,<xref ref-type="bibr" rid="b40-co16-1-27">40</xref>. Longer time to disease progression was also observed (5.6&#x02013;13.3 months). Median survival was 15.4 months in one trial<xref ref-type="bibr" rid="b40-co16-1-27">40</xref> and was either not reported or not reached in the others <xref ref-type="bibr" rid="b23-co16-1-27">23</xref>,<xref ref-type="bibr" rid="b25-co16-1-27">25</xref>,<xref ref-type="bibr" rid="b28-co16-1-27">28</xref>,<xref ref-type="bibr" rid="b29-co16-1-27">29</xref>,<xref ref-type="bibr" rid="b37-co16-1-27">37</xref>. This activity appears encouraging, but randomized trials comparing <sc>egfr</sc>-<sc>tki</sc> therapy to chemotherapy are needed to draw firm conclusions.</p></sec></sec><sec><title>Consensus Recommendation</title><p>The evidence is currently insufficient to recommend first-line single-agent <sc>egfr</sc>-<sc>tki</sc> therapy in the treatment of advanced or metastatic <sc>nsclc</sc>. These recommendations apply both to unselected populations and to patients selected on the basis of activating mutations of the <italic>EGFR</italic> gene or of clinical characteristics predictive of higher response to therapy.</p><p>There is evidence of tumour response to single-agent <sc>egfr</sc>-<sc>tki</sc> as first-line therapy for advanced <sc>nsclc</sc>. Response rates to <sc>egfr</sc>-<sc>tki</sc> therapy appear to be higher in patients selected on the basis of activating mutations of the <italic>EGFR</italic> gene.</p><p>Randomized trials are needed to evaluate the effect of first-line <sc>egfr</sc>-<sc>tki</sc> on survival.</p></sec><sec><title>3.1.2 What Is the Role of Single-Agent EGFR-TKIs in Patients with Adenocarcinoma with Bronchioloalveolar Features?</title><sec><title>Key Evidence</title><p>The literature search identified a consensus document on systemic therapy of bronchi oloalveolar carcinoma (<sc>bac</sc>)<xref ref-type="bibr" rid="b41-co16-1-27">41</xref>. It states that there is no evidence to confirm or refute the assertion that the sensitivity of <sc>bac</sc> to chemotherapy is any different from that of other histologic subtypes of <sc>nsclc</sc>.</p><p>Three phase <sc>ii</sc> trials in <sc>ps</sc> 0&#x02013;2 patients with stage <sc>iii</sc>/<sc>iv bac</sc> (<italic>n</italic> = 326) evaluated either erlotinib 150 mg or gefitinib 250 mg daily (<xref ref-type="table" rid="tII-co16-1-27">TABLE II</xref>). Patients were predominantly chemotherapy-na&#x000ef;ve. Response rates ranged from 9% to 21%, with disease stabilization in an additional 16%&#x02013;36%. The survival data demonstrated time to disease progression of between 3.0 months and 3.7 months, and median survival of 13.0&#x02013;17.1 months<xref ref-type="bibr" rid="b42-co16-1-27">42</xref>&#x02013;<xref ref-type="bibr" rid="b45-co16-1-27">45</xref>. In one study, shorter progression-free survival (<sc>pfs</sc>) and <sc>os</sc> were independently associated with non-mucinous as compared with mu-cinous <sc>bac</sc> (<sc>pfs</sc>: 2.6 months vs. 11.3 months, <italic>p</italic>=0.002; <sc>os</sc>: 10.7 months vs. not reached, <italic>p</italic> = 0.003)<xref ref-type="bibr" rid="b44-co16-1-27">44</xref>,<xref ref-type="bibr" rid="b45-co16-1-27">45</xref>.</p></sec><sec><title>Consensus Recommendation</title><p>There is no evidence to suggest that <sc>bac</sc> should be treated differently from other types of <sc>nsclc</sc>. The evidence is currently insufficient to recommend <sc>egfr</sc>-<sc>tkis</sc> as first-line therapy for the treatment of <sc>bac</sc>.</p></sec></sec><sec><title>3.1.3 What Is the Role of First-Line EGFR-TKIs in Combination with Platinum-based Chemotherapy in Patients with NSCLC?</title><sec><title>Key Evidence</title><p>Four large randomized trials evaluated <sc>egfr</sc>-<sc>tkis</sc> in combination with platinum-based chemotherapy in patients with good <sc>ps</sc> with stage <sc>iii</sc>/<sc>iv nsclc</sc> (<italic>n</italic> = 4348, <xref ref-type="table" rid="tIII-co16-1-27">TABLE III</xref>). Patients were treated with either gemcitabine and cisplatin [gemcitabine 1250 mg/m<sup>2</sup> intravenously (IV) on days 1 and 8, and cisplatin 80 mg/m<sup>2</sup> IV on day 1 of a 21-day cycle] or carboplatin and paclitaxel [carboplatin area under the curve (<sc>auc</sc>) 6 IV on day 1, and paclitaxel 200 mg/m<sup>2</sup> IV on day 1 of a 21-day cycle] with or without erlotinib 150 mg or gefitinib 250 mg or 500 mg daily. Response rates varied between the trials; however, all four trials failed to demonstrate any improvement in response rate with the addition of an <sc>egfr</sc>-<sc>tki</sc> to platinum-based chemotherapy<xref ref-type="bibr" rid="b46-co16-1-27">46</xref>&#x02013;<xref ref-type="bibr" rid="b49-co16-1-27">49</xref>. Time to worsening of symptoms did not differ significantly between the groups<xref ref-type="bibr" rid="b46-co16-1-27">46</xref>,<xref ref-type="bibr" rid="b47-co16-1-27">47</xref>,<xref ref-type="bibr" rid="b49-co16-1-27">49</xref>.</p><p>No differences were observed in time to disease progression or in median and 1-year survival between patients randomized to chemotherapy alone and those randomized to chemotherapy plus an <sc>egfr-tki</sc> (see <xref ref-type="table" rid="tIII-co16-1-27">TABLE III</xref>).<xref ref-type="bibr" rid="b46-co16-1-27">46</xref>&#x02013;<xref ref-type="bibr" rid="b49-co16-1-27">49</xref></p></sec><sec><title>Consensus Recommendation</title><p>Clear evidence from four randomized trials shows that concurrent administration of an <sc>egfr</sc>-<sc>tki</sc> with first-line platinum-based chemotherapy does not prolong survival in unselected patients with <sc>nsclc</sc>.</p></sec></sec><sec><title>3.1.4 What Is the Role of Single-Agent EGFR-TKIs Compared with Chemotherapy in Chemona&#x000ef;ve Patients with NSCLC?</title><sec><title>Key Evidence</title><p>Two randomized trials compared first-line therapy with an <sc>egfr</sc>-<sc>tki</sc> with chemotherapy in chemona&#x000ef;ve patients with stage <sc>iii</sc>/<sc>iv nsclc</sc> and <sc>ps</sc> 0&#x02013;2 (<italic>n</italic> = 299, <xref ref-type="table" rid="tIV-co16-1-27">TABLE IV</xref>) <xref ref-type="bibr" rid="b50-co16-1-27">50</xref>,<xref ref-type="bibr" rid="b52-co16-1-27">52</xref>. Lilenbaum randomized patients with poor <sc>ps</sc> (score of 2) to treatment with either carboplatin and paclitaxel (carboplatin <sc>auc</sc> 6 and paclitaxel 200 mg/m<sup>2</sup> for 4 cycles) or erlotinib 150 mg daily <xref ref-type="bibr" rid="b52-co16-1-27">52</xref>; Crin&#x000f2; randomized elderly patients (more than 70 years of age) to vinorelbine 30 mg/m<sup>2</sup> IV on days 1 and 8 of a 21-day cycle or gefitinib 250 mg daily<xref ref-type="bibr" rid="b50-co16-1-27">50</xref>.</p><p>Lilenbaum observed a higher response rate among patients treated with chemotherapy than with erlotinib [overall response (<sc>or</sc>): 12% vs. 2%; <sc>or</sc> + stable disease (<sc>sd</sc>): 53% vs. 39%]. Additionally, patients randomized to carboplatin&#x02013;paclitaxel had a longer time to progression (3.5 months vs. 1.9 months) and a greater survival (9.1 months vs. 6.6 months), although these differences were not statistically significant<xref ref-type="bibr" rid="b52-co16-1-27">52</xref>.</p><p>Crin&#x000f2; observed similar activity from vinorelbine and gefitinib (<sc>or</sc>: 5.1% vs. 3.1%; <sc>or</sc>+<sc>sd</sc>: 53% vs. 43%). The <sc>pfs</sc> favoured vinorelbine, but this difference was not statistically significant [hazard ratio (<sc>hr</sc>): 1.19; 95% confidence interval (<sc>ci</sc>): 0.85 to 1.65]. No difference in overall survival was observed (<sc>hr</sc>: 0.98; 95%<sc>ci</sc>: 0.66 to 1.47). The groups showed no difference in overall <sc>qol</sc> (by <sc>fact</sc>-<sc>l</sc>) and in <sc>lcs</sc>. Gefitinib appeared to be better tolerated than vinorelbine<xref ref-type="bibr" rid="b50-co16-1-27">50</xref>.</p><p>A third trial evaluated various doses and schedules of erlotinib with carboplatin and paclitaxel<xref ref-type="bibr" rid="b51-co16-1-27">51</xref>. No significant differences were observed among the three treatment groups (<xref ref-type="table" rid="tIV-co16-1-27">TABLE IV</xref>).</p></sec><sec><title>Consensus Recommendation</title><p>The evidence is currently insufficient to recommend the use of an <sc>egfr</sc>-<sc>tki</sc> over chemotherapy in the first-line therapy of patients with <sc>nsclc</sc>. Available evidence raises the possibility that survival of patients with poor <sc>ps</sc> treated with first-line <sc>egfr</sc>-<sc>tki</sc> may be less than that of patients treated with platinum-based chemotherapy.</p></sec></sec></sec><sec><title>3.2 Second-Line and Subsequent Treatment for Relapsed or Recurrent Disease</title><p>What is the role of <sc>egfr</sc>-<sc>tkis</sc> following progression after platinum-based chemotherapy (single-agent <sc>egfr</sc>-<sc>tki</sc> vs. <sc>bsc</sc>, <sc>egfr</sc>-<sc>tki</sc> vs. chemotherapy, and <sc>egfr</sc>-<sc>tki</sc> in combination with another agent)?</p><sec><title>3.2.1 What Is the Role of EGFR-TKIs as Second- or Third-Line Therapy Following Progression of Platinum-based Chemotherapy?</title><sec><title>Key Evidence</title><p>Two guidelines developed by <sc>cco</sc>-<sc>pebc</sc>, addressing the role of an <sc>egfr</sc>-<sc>tki</sc> as subsequent therapy for <sc>nsclc</sc>, were identified <xref ref-type="bibr" rid="b11-co16-1-27">11</xref>,<xref ref-type="bibr" rid="b53-co16-1-27">53</xref>. Both documents recommend the use of erlotinib as second- or third-line therapy for <sc>nsclc</sc> in patients who are not candidates for further chemotherapy.</p><p>Four randomized phase <sc>ii</sc> and <sc>iii</sc> trials in <sc>ps</sc> 0&#x02013;2 patients with stage <sc>iii</sc>/<sc>iv nsclc</sc> who were not considered candidates for further chemotherapy examined <sc>egfr</sc>-<sc>tkis</sc> as subsequent therapy following progression of platinum-based chemotherapy (<italic>n</italic> = 2849, <xref ref-type="table" rid="tV-co16-1-27">TABLE V</xref>). Two large phase <sc>iii</sc> studies evaluated erlotinib 150 mg (<sc>br</sc>.21) or gefitinib 250 mg [<sc>isel</sc> (Iressa Survival Evaluation in Lung Cancer)] daily compared with placebo <xref ref-type="bibr" rid="b56-co16-1-27">56</xref>,<xref ref-type="bibr" rid="b57-co16-1-27">57</xref>, and two randomized phase <sc>ii</sc> studies [<sc>ideal</sc> 1 and 2 (Iressa Dose Evaluation in Advanced Lung Cancer 1 and 2)] compared two doses of gefitinib (250 or 500 mg daily)<xref ref-type="bibr" rid="b54-co16-1-27">54</xref>,<xref ref-type="bibr" rid="b55-co16-1-27">55</xref>. In the <sc>ideal</sc> 1 and 2 trials, no differences were observed in any outcomes examined between gefitinib 250 mg and 500 mg daily.</p><p>Results of the <sc>br</sc>.21 and <sc>isel</sc> trials demonstrated that erlotinib (2.2 months vs. 1.8 months) and gefitinib (3.0 months vs. 2.6 months) significantly prolong time to disease progression <xref ref-type="bibr" rid="b56-co16-1-27">56</xref>,<xref ref-type="bibr" rid="b57-co16-1-27">57</xref>. Statistically significant improvements were also seen in <sc>os</sc> with erlotinib as compared with placebo (6.7 months vs. 4.7 months, <italic>p</italic> &#x0003c; 0.001) <xref ref-type="bibr" rid="b56-co16-1-27">56</xref>, and a trend toward improved survival was observed with gefitinib (5.6 months vs. 5.1 months, <italic>p</italic> = 0.087) <xref ref-type="bibr" rid="b57-co16-1-27">57</xref>.</p><p>In the <sc>br</sc>.21 trial, patients receiving erlotinib experienced significantly longer time to deterioration in several lung cancer-related symptoms (cough, pain, dyspnea) and in overall physical function <xref ref-type="bibr" rid="b58-co16-1-27">58</xref>. In the <sc>isel</sc> trial, a greater proportion of patients randomized to gefitinib experienced improvement in disease-related symptoms (27% vs. 22%). Similarly, patients randomized to gefitinib experienced a significantly greater improvement in <sc>lcs</sc> scores (&#x02212;1.38 vs. &#x02212;0.86, <italic>p</italic> = 0.019)<xref ref-type="bibr" rid="b57-co16-1-27">57</xref>.</p></sec><sec><title>Consensus Recommendation</title><p>In patients with advanced or metastatic <sc>nsclc</sc> who are not candidates for further chemotherapy, the use of an <sc>egfr</sc>-<sc>tki</sc> (as compared with placebo) can result in improved survival. The use of an <sc>egfr</sc>-<sc>tki</sc> in patients with <sc>nsclc</sc> who are not candidates for further chemotherapy can result in significant improvements in disease-related symptoms, and as compared with <sc>bsc</sc> alone, can delay time to symptom progression.</p></sec></sec><sec><title>3.2.2 What Is the Role of EGFR-TKIs Compared with Chemotherapy Following Progression of Platinum-based Chemotherapy?</title><sec><title>Key Evidence</title><p>Seven randomized phase <sc>ii</sc> and <sc>iii</sc> trials examined an <sc>egfr</sc>-<sc>tki</sc> as compared with chemotherapy following progression of platinum-based chemotherapy in patients with stage <sc>iii</sc>/<sc>iv nsclc</sc> and <sc>ps</sc> 0&#x02013;2 (<italic>n</italic> = 2482, <xref ref-type="table" rid="tVI-co16-1-27">TABLE VI</xref>).</p><p>One randomized phase <sc>ii</sc> trial<xref ref-type="bibr" rid="b59-co16-1-27">59</xref> and two randomized <sc>iii</sc> trials phase <xref ref-type="bibr" rid="b62-co16-1-27">62</xref>,<xref ref-type="bibr" rid="b65-co16-1-27">65</xref>,<xref ref-type="bibr" rid="b66-co16-1-27">66</xref> evaluated gefitinib 250 mg daily vs. docetaxel 60 or 75 mg/m<sup>2</sup> IV every 3 weeks (<italic>n</italic> = 2096). The response rate with gefitinib was significantly higher than that with docetaxel in a Japanese population (22.5% vs. 12.8%, <italic>p</italic> = 0.009)<xref ref-type="bibr" rid="b65-co16-1-27">65</xref>,<xref ref-type="bibr" rid="b66-co16-1-27">66</xref>. However no differences were observed in response rate between gefitinib and docetaxel in the other two trials<xref ref-type="bibr" rid="b59-co16-1-27">59</xref>,<xref ref-type="bibr" rid="b62-co16-1-27">62</xref>. No significant differences were observed in <sc>ttp</sc> or <sc>os</sc> in patients treated with gefitinib or docetaxel. In the trial by Niho <italic>et al.,</italic> the proportion of patients randomized to docetaxel who received third-line <sc>egfr</sc>-<sc>tki</sc> therapy was greater than the proportion of patients randomized to gefitinib who received third-line chemotherapy. That trial did not meet its primary outcome of non-inferiority of gefitinib (upper limit of 95% <sc>ci</sc> &#x02264; 1.25) as compared with docetaxel (<sc>hr</sc>: 1.12; 95% <sc>ci</sc>: 0.89 to 1.40)<xref ref-type="bibr" rid="b65-co16-1-27">65</xref>,<xref ref-type="bibr" rid="b66-co16-1-27">66</xref>. However, the larger <sc>interest</sc> trial (Iressa non-small-cell lung cancer trial evaluating response and survival against Taxotere) demonstrates that gefitinib was non-inferior to docetaxel (<sc>hr</sc>: 1.02; 95% <sc>ci</sc>: 0.905 to 1.15), in which the definition of non-inferiority accepted a <sc>ci</sc> going up to 1.154<xref ref-type="bibr" rid="b62-co16-1-27">62</xref>. The proportion of patients receiving effective third-line therapy was similar between the two treatment arms in that trial.</p><p>Another four randomized phase <sc>ii</sc> studies evaluated gefitinib 250 mg or erlotinib 150 mg daily with other agents (oral vandetanib 300 mg daily<xref ref-type="bibr" rid="b60-co16-1-27">60</xref>; bortezomib 1.6 mg/m<sup>2</sup> IV on days 1 and 8 of a 21-day cycle<xref ref-type="bibr" rid="b64-co16-1-27">64</xref>; vinorelbine 15 mg/m<sup>2</sup> IV on day 1, and gefitinib 250 mg daily on days 2&#x02013;14 every 2 weeks<xref ref-type="bibr" rid="b61-co16-1-27">61</xref>; bevacizumab 15 mg IV on day 1 every 3weeks; docetaxel 75 mg/m<sup>2</sup> on day 1 of a 3-week cycle; pemetrexed 500 mg/m<sup>2</sup> on day 1 of a 3-week cycle)<xref ref-type="bibr" rid="b63-co16-1-27">63</xref> either as single agents or in combination (<italic>n</italic> = 386, <xref ref-type="table" rid="tVI-co16-1-27">TABLE VI</xref>). No firm conclusions can be drawn from any of these trials, although compared with erlotinib alone, the combination of erlotinib plus bevacizumab demonstrated improvement in response rate (17.9% vs. 12.2%), <sc>ttp</sc> (4.4 months vs. 3.0 months), and <sc>os</sc> (13.7 months vs. 8.6 months)<xref ref-type="bibr" rid="b63-co16-1-27">63</xref>. A phase <sc>iii</sc> trial of that combination is ongoing. Fully powered phase <sc>iii</sc> trials are ongoing to compare gefitinib with vandetanib and to assess whether bevacizumab adds to the efficacy of single-agent erlotinib.</p></sec><sec><title>Consensus Recommendation</title><p>The evidence suggests that second-line <sc>egfr</sc>-<sc>tki</sc> or second-line chemotherapy results in similar survival. Sequence does not appear to be important, but if survival is the outcome of interest, the goal should be to optimize the number of patients receiving three lines of effective therapy. The evidence is currently insufficient to recommend second-line therapy with a combination of an <sc>egfr</sc>-<sc>tki</sc> and another targeted agent. Ongoing randomized phase <sc>iii</sc> trials are currently addressing these questions.</p></sec></sec><sec><title>3.2.3 How Do QOL and Symptom Control Compare in Patients Treated with Chemotherapy as Compared with EGFR-TKIs?</title><sec><title>Key Evidence</title><p>Two of the three trials that compared gefitinib and docetaxel also examined <sc>qol</sc> and symptom improvement<xref ref-type="bibr" rid="b59-co16-1-27">59</xref>,<xref ref-type="bibr" rid="b62-co16-1-27">62</xref>.</p><p>In the <sc>sign</sc> trial (Second-Line Indication of Gefitinib in <sc>nsclc</sc>), a greater proportion of patients randomized to gefitinib experienced symptom improvement as assessed by <sc>lcs</sc> (36.8% vs. 26%) and <sc>qol</sc> improvement as assessed by the <sc>fact</sc>-<sc>l</sc> (33.8% vs. 26%)<xref ref-type="bibr" rid="b59-co16-1-27">59</xref>. In addition, in the <sc>interest</sc> trial, significantly more patients randomized to the gefitinib arm showed improvements in <sc>fact</sc>-<sc>l</sc> score (25.1% vs. 14.7%, <italic>p</italic> &#x0003c; 0.0001) and trial outcome index (17.3% vs. 10.3%, <italic>p</italic> = 0.0026). Symptom improvement rates were also better with gefitinib than with docetaxel, but this difference was not statistically significant<xref ref-type="bibr" rid="b62-co16-1-27">62</xref>.</p></sec><sec><title>Key Recommendation</title><p>Symptom control and <sc>qol</sc> appear to be better in patients treated with an <sc>egfr</sc>-<sc>tki</sc> than in those treated with either <sc>bsc</sc> or second-line chemotherapy with docetaxel. In decisions about treatment following failure of platinum-based chemotherapy, <sc>qol</sc> and patient choice are important.</p></sec></sec><sec><title>3.2.4 What Is the Role of Single-Agent EGFR-TKI Therapy in Previously Treated Patients with EGFR Gene Mutations or High Gene Copy, or EGFR Protein Expression?</title><sec><title>Key Evidence</title><p>Four single-arm phase <sc>ii</sc> trials evaluated gefitinib 250 mg daily in patient populations (n = 117) selected for the presence of activating mutations of the <italic>EGFR</italic> gene assessed by polymerase chain reaction (<sc>pcr</sc>) analysis or for high <italic>EGFR</italic> gene copy assessed using fluorescence <italic>in situ</italic> hybridization (<sc>fish</sc>). Patients had stage <sc>iii</sc>/<sc>iv</sc> disease and <sc>ps</sc> 0&#x02013;2, and most had received prior chemotherapy. High response rates were observed (48%&#x02013;90%)<xref ref-type="bibr" rid="b67-co16-1-27">67</xref>&#x02013;<xref ref-type="bibr" rid="b70-co16-1-27">70</xref>. Time to disease progression ranged from 6.4 months to 12.9 months, with a median survival of 15.5 months reported in one study<xref ref-type="bibr" rid="b69-co16-1-27">69</xref>. Given that <italic>EGFR</italic> mutations are thought to represent a favourable prognostic factor, the significance of these data are unclear, and randomized trials are needed to determine if the survival of patients with <italic>EGFR</italic> mutations or high <italic>EGFR</italic> gene copy treated with an <sc>egfr</sc>-<sc>tki</sc> is superior to that of similar patients treated with second-line chemotherapy.</p></sec><sec><title>Consensus Recommendations</title><p>There is evidence that patients with previously treated <sc>nsclc</sc> and <italic>EGFR</italic> mutations or increased <italic>EGFR</italic> gene copy respond to an <sc>egfr</sc>-<sc>tki</sc>. However, the evidence is insufficient at this time to select patients for <sc>egfr</sc>-<sc>tki</sc> therapy rather than for second-line chemotherapy based on any <italic>EGFR</italic> marker.</p></sec></sec></sec><sec><title>3.3 Clinical and Molecular Predictors of Benefit</title><p>Do any patient subpopulations, or clinical and molecular characteristics, predict for additional benefit from <sc>egfr</sc>-<sc>tki</sc> therapy?</p><sec><title>3.3.1 What Are the Molecular Characteristics that Predict Additional Benefit from egfr-tki Therapy?</title><sec><title>Key Evidence</title><sec><title>Clinical Predictors of Response to an <sc>egfr</sc><italic>-</italic><sc>tki</sc></title><p><xref ref-type="table" rid="tVII-co16-1-27">TABLE VII</xref> summarizes the trials examining clinical predictors of response. Data are available from the <sc>ideal</sc> 1, <sc>ideal</sc> 2, <sc>br</sc>.21, and <sc>isel</sc> trials. Analyses from the <sc>ideal</sc> 1 and 2 trials demonstrated that ad-enocarcinoma (13% vs.4%) and female sex (19% vs. 3%) both significantly predict response to gefitinib<xref ref-type="bibr" rid="b55-co16-1-27">55</xref>. Additional clinical predictors of response were observed in the <sc>br</sc>.21 trial. In that study, clinical characteristics associated with higher response to erlotinib included adenocarcinoma (13.9% vs. 4.1%, <italic>p</italic> &#x0003c; 0.001), never smokers (24.7% vs. 3.9%, <italic>p</italic> &#x0003c; 0.001), female sex (14.4% vs. 6%, <italic>p</italic> = 0.006), and Asian ethnicity (<italic>n</italic> = 427: 18.9% vs. 7.5%, <italic>p</italic> = 0.002)<xref ref-type="bibr" rid="b56-co16-1-27">56</xref>,<xref ref-type="bibr" rid="b71-co16-1-27">71</xref>&#x02013;<xref ref-type="bibr" rid="b73-co16-1-27">73</xref>. Consistent with the <sc>br</sc>.21 results, subset analysis from the <sc>isel</sc> trial also demonstrated that adenocarcinoma (11.9% vs. 4.8%), never smokers (18.1% vs. 5.3%), female sex (14.7% vs. 5.1%), and Asian ethnicity (12.4% vs. 7.5%) were predictors of response to gefitinib (<italic>n</italic> = 1439)<xref ref-type="bibr" rid="b57-co16-1-27">57</xref>.</p></sec><sec><title>Clinical Predictors of Survival with an <sc>egfr</sc>-<sc>tki</sc></title><p><xref ref-type="table" rid="tVIII-co16-1-27">TABLE VIII</xref> summarizes clinical predictors of survival for patients receiving therapy with an <sc>egfr</sc>-<sc>tki</sc> <xref ref-type="bibr" rid="b57-co16-1-27">57</xref>,<xref ref-type="bibr" rid="b71-co16-1-27">71</xref>&#x02013;<xref ref-type="bibr" rid="b79-co16-1-27">79</xref>. In the <sc>br</sc>.21 trial, the only clinical characteristic that predicted greater effect on survival for erlotinib as compared with supportive care alone was a history of never having smoked (<sc>hr</sc>: 0.4 vs. 0.9; <italic>p</italic> = 0.02). There was no evidence of any differential survival effect for histology (<sc>hr</sc>: 0.7 adenocarcinoma vs. 0.8 non-adenocarcinoma), sex (<sc>hr</sc>: 0.8 males vs. 0.8 females), or ethnicity (<sc>hr</sc>: 0.6 Asian vs. 0.8 non-Asian) <xref ref-type="bibr" rid="b71-co16-1-27">71</xref>&#x02013;<xref ref-type="bibr" rid="b73-co16-1-27">73</xref>,<xref ref-type="bibr" rid="b77-co16-1-27">77</xref>,<xref ref-type="bibr" rid="b78-co16-1-27">78</xref>. The <sc>isel</sc> trial demonstrated significantly improved survival among patients randomized to gefitinib for never smokers (<sc>hr</sc>: 0.67; 95% <sc>ci</sc>: 0.49 to 0.92) and for patients of Asian ethnicity (<sc>hr</sc>: 0.66; 95%<sc>ci</sc>: 0.48 to 0.91)<xref ref-type="bibr" rid="b57-co16-1-27">57</xref>. There was a trend toward improved survival for patients with adenocarcinoma treated with gefitinib (<sc>hr</sc>: 0.84; 95% <sc>ci</sc>: 0.70 to 1.02). In a subset analysis of all Asian patients from the <sc>isel</sc> trial, significant improvements in survival were seen for patients with adenocarcinoma (<sc>hr</sc>: 0.66 vs. 0.86), never smokers (<sc>hr</sc>: 0.37 vs. 0.85), and female sex (<sc>hr</sc>: 0.46 vs. 0.80)<xref ref-type="bibr" rid="b76-co16-1-27">76</xref>.</p><p>No data were available concerning clinical predictors of survival from the <sc>intact</sc> (Iressa <sc>nsclc</sc> Trial Assessing Combination Treatment) 1 and 2 trials<xref ref-type="bibr" rid="b80-co16-1-27">80</xref>. In a subset analysis of never smokers (<italic>n</italic> = 113) from the <sc>tribute</sc> (Tarceva Responses in Conjunction with Paclitaxel and Carboplatin) trial, a significant improvement in survival was observed from the addition of erlotinib (<sc>hr</sc>: 0.49; 95% <sc>ci</sc>: 0.28 to 0.85) <xref ref-type="bibr" rid="b81-co16-1-27">81</xref>. Similar findings were observed in <sc>talent</sc> (Tarceva Lung Cancer Investigation Trial). Improved <sc>os</sc> and <sc>pfs</sc> were observed for patients receiving erlotinib who had never smoked (<sc>hr</sc>: 0.39; <italic>p</italic> = 0.25), although this interaction did not achieve statistical significance<xref ref-type="bibr" rid="b74-co16-1-27">74</xref>,<xref ref-type="bibr" rid="b75-co16-1-27">75</xref>.</p><p>In contrast, subgroup analyses from the <sc>interest</sc> trial comparing gefitinib with docetaxel suggest that these clinical variables do not predict a differential benefit for an <sc>egfr</sc>-<sc>tki</sc> over chemotherapy. There was no difference in the survival of patients with adenocarcinoma histology, never smokers, Asian ethnicity, and female sex when treated with either gefitinib or docetaxel<xref ref-type="bibr" rid="b79-co16-1-27">79</xref>.</p></sec><sec><title>Molecular Predictors of Response to an <sc>egfr</sc>-<sc>tki</sc></title><p>The predictive value of various molecular abnormalities have been examined in the randomized trials included in the present consensus document. These include mutations of the <italic>EGFR</italic> gene, increased <italic>EGFR</italic> gene copy assessed by <sc>fish</sc> or <italic>EGFR</italic> amplification assessed by quantitative <sc>pcr</sc>, <sc>egfr</sc> expression [by immunohistochemistry (<sc>ihc</sc>)], and mutations of the <italic>KRAS</italic> gene. <xref ref-type="table" rid="tIX-co16-1-27">TABLE IX</xref> summarizes predictors of response.</p><p>The presence of an activating mutation of the <italic>EGFR</italic> gene is associated with an increased likelihood of response to single-agent <sc>egfr</sc>-<sc>tki</sc>. Analyses of tumour samples from the <sc>ideal</sc> 1 and 2 trials (<italic>n</italic> = 425) evaluating gefitinib monotherapy demonstrated that patients whose tumour had an <italic>EGFR</italic> mutation had a better <sc>or</sc> with gefitinib than did patients lacking the mutation (<italic>n</italic> = 79: 46% vs.10%, <italic>p</italic> = 0.005)<xref ref-type="bibr" rid="b80-co16-1-27">80</xref>. In the <sc>br</sc>.21 (<italic>n</italic> = 177: 15.8% vs. 7.4%, <italic>p</italic> = 0.35) and <sc>isel</sc> trials (<italic>n</italic> = 215: 37.5% vs. 2.6%), the presence of an <italic>EGFR</italic> mutation was associated with a nonsignificant increase in response rate. In <sc>br</sc>.21, when only exon 19 deletion and L858R mutations were considered, the difference in response rate as compared with wild-type <italic>EGFR</italic> or other mutations was significant (27% vs. 7%, <italic>p</italic> = 0.035)<xref ref-type="bibr" rid="b85-co16-1-27">85</xref>. The subset analysis of tumour samples from the <sc>intact</sc> 1 and 2 trials evaluating the addition of gefitinib to standard first-line chemotherapies demonstrated that patients whose tumours had an <italic>EGFR</italic> mutation had a higher response to chemotherapy plus gefitinib than did those without a mutation (<italic>n</italic> = 170: 72% vs. 55%, <italic>p</italic> = 0.2)<xref ref-type="bibr" rid="b80-co16-1-27">80</xref>. Similar findings were observed in the <sc>tribute</sc> trial for patients with <italic>EGFR</italic> mutations (<italic>n</italic> = 228: 53% vs. 21%, <italic>p</italic> &#x0003c; 0.01)<xref ref-type="bibr" rid="b82-co16-1-27">82</xref>,<xref ref-type="bibr" rid="b84-co16-1-27">84</xref>, but no statistically significant correlation was observed between response rates and mutation status in the <sc>talent</sc> trial<xref ref-type="bibr" rid="b74-co16-1-27">74</xref>,<xref ref-type="bibr" rid="b75-co16-1-27">75</xref>.</p><p>Increased <italic>EGFR</italic> gene copy or <italic>EGFR</italic> amplification also appears to be associated with an increased response rate to single-agent <sc>egfr</sc>-<sc>tki</sc>. The <sc>ideal</sc> 1 and 2 trials demonstrated that <italic>EGFR</italic> amplification was associated with a higher response to gefitinib than was seen with tumours without <italic>EGFR</italic> amplification; however, this difference was not statistically significant (<italic>n</italic> = 90: risk ratio: 29% vs.15%; <italic>p</italic> = 0.319). Patients with an <italic>EGFR</italic> mutation or gene amplification had a significantly improved response rate as compared with patients with neither <italic>EGFR</italic> amplification nor mutation (60% vs. 10%, <italic>p</italic> = 0.0011)<xref ref-type="bibr" rid="b80-co16-1-27">80</xref>. Within the <sc>br</sc>.21 trial, high <italic>EGFR</italic> gene copy or amplification also was associated with a significantly higher response to erlotinib (<italic>n</italic> = 91: 21% vs. 5%, <italic>p</italic> = 0.02)<xref ref-type="bibr" rid="b71-co16-1-27">71</xref>,<xref ref-type="bibr" rid="b77-co16-1-27">77</xref>,<xref ref-type="bibr" rid="b85-co16-1-27">85</xref>. Similar findings were observed in the <sc>isel</sc> trial (<italic>n</italic> = 317: 16.4% vs. 3.2%)<xref ref-type="bibr" rid="b83-co16-1-27">83</xref>.</p><p>In <sc>intact</sc> 1 and 2, there were no differences in response with and without <italic>EGFR</italic> amplification (n = 235: 56% vs. 53%, <italic>p</italic> &#x0003e; 0.05)<xref ref-type="bibr" rid="b80-co16-1-27">80</xref>. Interestingly, analysis of tumour samples from the <sc>tribute</sc> study demonstrated a lower response rate among patients whose tumours demonstrated <italic>EGFR</italic> amplification<xref ref-type="bibr" rid="b82-co16-1-27">82</xref>,<xref ref-type="bibr" rid="b84-co16-1-27">84</xref>. It is important to note that <sc>fish</sc> was used to assess <italic>EGFR</italic> gene copy status in the <sc>br</sc>.21, <sc>isel</sc>, and <sc>tribute</sc> studies<xref ref-type="bibr" rid="b82-co16-1-27">82</xref>&#x02013;<xref ref-type="bibr" rid="b85-co16-1-27">85</xref>, but that quantitative <sc>pcr</sc> was used in the <sc>ideal</sc> and <sc>intact</sc> studies<xref ref-type="bibr" rid="b80-co16-1-27">80</xref>. High <italic>EGFR</italic> gene copy by <sc>fish</sc> includes cases of <italic>EGFR</italic> high polysomy and of <italic>EGFR</italic> amplification alike<xref ref-type="bibr" rid="b82-co16-1-27">82</xref>&#x02013;<xref ref-type="bibr" rid="b85-co16-1-27">85</xref>, but quantitative <sc>pcr</sc> results include cases of <italic>EGFR</italic> gene amplification only<xref ref-type="bibr" rid="b80-co16-1-27">80</xref>. Thus, the two results are not entirely comparable.</p><p>Fewer data are available concerning the predictive value of <sc>egfr</sc> protein expression. In both the <sc>br</sc>.21 (<italic>n</italic> = 142: 11% vs. 4%, <italic>p</italic>= 0.1)<xref ref-type="bibr" rid="b85-co16-1-27">85</xref> and <sc>isel</sc> trials (<italic>n</italic> = 303: 8.2% vs. 3.2%)<xref ref-type="bibr" rid="b83-co16-1-27">83</xref>, higher response rates to erlotinib were demonstrated for patients with <sc>egfr</sc> expression. However, the presence of <italic>KRAS</italic> mutations appears to be associated with a lower chance of tumour response. Lower response rates were observed in the <sc>br</sc>.21 (<italic>n</italic> = 118: 5% vs. 10%, <italic>p</italic> = 0.069)<xref ref-type="bibr" rid="b85-co16-1-27">85</xref>, <sc>isel</sc> (<italic>n</italic> = 93: 0% vs. 8%)<xref ref-type="bibr" rid="b83-co16-1-27">83</xref>, and <sc>tribute</sc> trials (<italic>n</italic> = 264: 8% vs. 23%, <italic>p</italic> = 0.16)<xref ref-type="bibr" rid="b82-co16-1-27">82</xref>,<xref ref-type="bibr" rid="b84-co16-1-27">84</xref>, although none of those results was statistically significant.</p></sec><sec><title>Molecular Predictors of Survival</title><p><xref ref-type="table" rid="tX-co16-1-27">TABLE X</xref> summarizes trials examining molecular predictors of survival for patients treated with an <sc>egfr</sc>-<sc>tki</sc> <xref ref-type="bibr" rid="b71-co16-1-27">71</xref>,<xref ref-type="bibr" rid="b74-co16-1-27">74</xref>,<xref ref-type="bibr" rid="b75-co16-1-27">75</xref>,<xref ref-type="bibr" rid="b77-co16-1-27">77</xref>,<xref ref-type="bibr" rid="b80-co16-1-27">80</xref>,<xref ref-type="bibr" rid="b82-co16-1-27">82</xref>&#x02013;<xref ref-type="bibr" rid="b86-co16-1-27">86</xref>. No single molecular marker has consistently been associated with improved survival for patients treated with an <sc>egfr</sc>-<sc>tki</sc>.</p><p>The <sc>ideal</sc> 1 and 2 trials, <sc>br</sc>.21, and <sc>isel</sc> all examined single-agent <sc>egfr</sc>-<sc>tkis</sc> <xref ref-type="bibr" rid="b71-co16-1-27">71</xref>,<xref ref-type="bibr" rid="b77-co16-1-27">77</xref>,<xref ref-type="bibr" rid="b83-co16-1-27">83</xref>,<xref ref-type="bibr" rid="b85-co16-1-27">85</xref>. Analysis of tumour samples from <sc>ideal</sc> 1 and 2 showed no significant improvement in <sc>ttp</sc> or survival for patients with <italic>EGFR</italic> mutations or with <italic>EGFR</italic> amplification<xref ref-type="bibr" rid="b80-co16-1-27">80</xref>. However, these trials were not designed to examine predictors of survival, given that both groups of patients received an <sc>egfr</sc>-<sc>tki</sc> <xref ref-type="bibr" rid="b80-co16-1-27">80</xref>.</p><p>The <sc>br</sc>.21 trial generated several reports of molecular analyses<xref ref-type="bibr" rid="b71-co16-1-27">71</xref>,<xref ref-type="bibr" rid="b77-co16-1-27">77</xref>,<xref ref-type="bibr" rid="b85-co16-1-27">85</xref>. On univariate analyses, there was no evidence that the survival benefit of erlotinib was influenced significantly by <sc>egfr</sc> expression (<italic>n</italic> = 325: <sc>ihc</sc> + <sc>hr</sc>: 0.68; <sc>ihc</sc><sup>&#x02212;</sup> <sc>hr</sc>: 0.93; <italic>p</italic> = 0.1), increased <italic>EGFR</italic> gene copy (<italic>n</italic> = 159: <sc>fish</sc><sup>+</sup> <sc>hr</sc>: 0.43; <sc>fish</sc><sup>&#x02212;</sup> <sc>hr</sc>: 0.80; interaction <italic>p</italic> = 0.12), or <italic>EGFR</italic> mutation status (<italic>n</italic> = 204: mut<sup>+</sup> <sc>hr</sc>: 0.55; mut<sup>&#x02212;</sup> <sc>hr</sc>: 0.74; interaction <italic>p</italic> = 0.47). However, in multivariate analysis, increased <italic>EGFR</italic> gene copy was prognostic for poorer survival (<italic>p</italic> = 0.0025) and predictive of a differential survival benefit from erlotinib (<italic>p</italic> = 0.005)<xref ref-type="bibr" rid="b71-co16-1-27">71</xref>,<xref ref-type="bibr" rid="b77-co16-1-27">77</xref>,<xref ref-type="bibr" rid="b85-co16-1-27">85</xref>.</p><p>The molecular analysis of the <sc>isel</sc> trial demonstrated a differential effect of gefitinib on survival according to <italic>EGFR</italic> gene copy (<italic>n</italic> = 370: <sc>fish</sc> + <sc>hr</sc> 0.61 vs. <sc>fish</sc><sup>&#x02212;</sup> <sc>hr</sc> 1.16; interaction <italic>p</italic> = 0.045) and <sc>egfr</sc> expression (<italic>n</italic> = 379: <sc>ihc</sc> + <sc>hr</sc>: 0.77; <sc>ihc</sc><sup>&#x02212;</sup> <sc>hr</sc>: 1.57; interaction <italic>p</italic> = 0.049). The data were insufficient for a survival analysis for patients with and without <italic>EGFR</italic> mutations<xref ref-type="bibr" rid="b83-co16-1-27">83</xref>.</p><p>Molecular analyses are available from all four trials evaluating the addition of an <sc>egfr</sc>-<sc>tki</sc> to platinum-based chemotherapy. The addition of gefitinib to chemotherapy did not significantly improve <sc>os</sc> in patients with (<sc>hr</sc>: 2.03; 95% <sc>ci</sc>: 0.67 to 6.13) or without (<sc>hr</sc>: 1.01; 95% <sc>ci</sc>: 0.79 to 1.29) <italic>EGFR</italic> amplification (<italic>n</italic> = 453), or with (<sc>hr</sc>: 1.77; 95% <sc>ci</sc>: 0.5 to 6.2) and without (<sc>hr</sc>: 0.91; 95% <sc>ci</sc>: 0.67 to 1.23) <italic>EGFR</italic> mutations (<italic>n</italic> = 312)<xref ref-type="bibr" rid="b86-co16-1-27">86</xref>.</p><p>Survival analysis from the <sc>tribute</sc> trial demonstrated a borderline improvement in <sc>ttp</sc> for patients receiving chemotherapy plus erlotinib (<sc>ttp hr</sc>: 0.59; 95% <sc>ci</sc>: 0.35 to 0.99), but no difference in <sc>os</sc> for patients with <italic>EGFR</italic> amplification (<italic>n</italic> = 245) <xref ref-type="bibr" rid="b82-co16-1-27">82</xref>,<xref ref-type="bibr" rid="b84-co16-1-27">84</xref>. In patients with an <italic>EGFR</italic> mutation, there was also a trend toward improved <sc>ttp</sc> (12.5 months vs. 6.6 months, <italic>p</italic> = 0.092), but no difference in <sc>os</sc> was demonstrated (<italic>p</italic> = 0.96, <italic>n</italic> = 274)<xref ref-type="bibr" rid="b82-co16-1-27">82</xref>,<xref ref-type="bibr" rid="b83-co16-1-27">83</xref>. Similar findings were observed in the <sc>talent</sc> study. The presence of <italic>EGFR</italic> mutations did not predict for improved <sc>os</sc> (<italic>p</italic> = 0.65 for placebo vs. <italic>p</italic> = 0.40 for erlotinib) and <sc>pfs</sc> (<italic>p</italic> = 0.74 for placebo vs. <italic>p</italic> = 0.18 for erlotinib) irrespective of treatment<xref ref-type="bibr" rid="b74-co16-1-27">74</xref>,<xref ref-type="bibr" rid="b75-co16-1-27">75</xref>.</p><p>Information is more consistent that the presence of <italic>KRAS</italic> mutations is associated with worse survival for patients receiving an <sc>egfr</sc>-<sc>tki</sc>. Results from <sc>br</sc>.21 demonstrated a trend towards worse survival for patients on erlotinib with <italic>KRAS</italic> mutations (<italic>n</italic> = 206: <italic>KRAS</italic><sup>+</sup> <sc>hr</sc>: 1.67; <italic>KRAS</italic><sup>&#x02212;</sup> <sc>hr</sc>: 0.69; <italic>p</italic> = 0.09) <xref ref-type="bibr" rid="b71-co16-1-27">71</xref>,<xref ref-type="bibr" rid="b77-co16-1-27">77</xref>,<xref ref-type="bibr" rid="b85-co16-1-27">85</xref>. Similarly, <italic>KRAS</italic> mutations predicted poor overall survival in erlotinib-treated patients on the <sc>talent</sc> trial <xref ref-type="bibr" rid="b74-co16-1-27">74</xref>,<xref ref-type="bibr" rid="b75-co16-1-27">75</xref>. In addition, data from the <sc>tribute</sc> trial demonstrated that the presence of <italic>KRAS</italic> mutations was associated with significantly decreased <sc>ttp</sc> and survival in patients randomized to erlotinib plus chemotherapy (<italic>n</italic> = 274: <sc>hr</sc>: 2.1; 95% <sc>ci</sc>: 1.1 to 3.8; 4.4 months vs. 13.5 months <italic>KRAS</italic><sup>+</sup> vs. 12.1 months vs. 11.3 months <italic>KRAS</italic><sup>&#x02212;</sup>, <italic>p</italic> = 0.019]<xref ref-type="bibr" rid="b82-co16-1-27">82</xref>,<xref ref-type="bibr" rid="b84-co16-1-27">84</xref>.</p><p>In contrast, there is no evidence that these molecular markers predict a differential effect on survival from an <sc>egfr</sc>-<sc>tki</sc> than from chemotherapy. The molecular analyses from the <sc>interest</sc> trial showed no significant differences in survival between patients treated with gefitinib or with docetaxel according to <sc>egfr</sc> expression, <italic>EGFR</italic> gene copy, <italic>EGFR</italic> mutational status, or <italic>KRAS</italic> status<xref ref-type="bibr" rid="b79-co16-1-27">79</xref>.</p></sec></sec><sec><title>Consensus Recommendation</title><p>Molecular markers such as <italic>EGFR</italic> high gene copy or <italic>EGFR</italic> mutations and clinical characteristics such as adenocarcinoma, female sex, never smoking, and Asian ethnicity appear to be associated with a higher likelihood of response to an <sc>egfr</sc>-<sc>tki</sc>. The evidence is currently insufficient to select patients based on molecular markers predictive of improved survival with an <sc>egfr</sc>-<sc>tki</sc>. Prospective data will be needed before further recommendations can be made.</p><p>The evidence is conflicting about the predictive value of clinical characteristics for survival. However, the data suggest that the survival benefit of an <sc>egfr</sc>-<sc>tki</sc> may be greater among never smokers. Based on available data, molecular markers and clinical characteristics should not be used to exclude patients from receiving <sc>egfr</sc>-<sc>tki</sc> therapy.</p></sec></sec></sec></sec><sec sec-type="discussion"><title>4. DISCUSSION</title><p>The <sc>egfr</sc>-<sc>tkis</sc> of represent a significant advance in the management of advanced and metastatic <sc>nsclc</sc>. Not only do they have activity in <sc>nsclc</sc>, they also appear to have an improved toxicity profile as compared with standard chemotherapy agents such as docetaxel. As a result, they offer an attractive therapeutic option. Nevertheless, it is important that these agents be incorporated into routine treatment algorithms based on appropriate data from randomized trials.</p><p>It is clear that <sc>egfr</sc>-<sc>tkis</sc> should not be used concomitantly with standard chemotherapy agents in the treatment of <sc>nsclc</sc>. The strongest evidence supporting their use is in patients who have progressed following platinum-based chemotherapy. It is appealing to think that use of an <sc>egfr</sc>-<sc>tki</sc> may spare patients the toxicity of more chemotherapy. However, available data support the use of second-line chemotherapy and third-line <sc>egfr</sc>-<sc>tki</sc> or second-line <sc>egfr</sc>-<sc>tki</sc> and then third-line chemotherapy. Because both approaches prolong survival, the goal of therapy in advanced <sc>nsclc</sc> should be to maximize the number of patients who receive three lines of therapy, if survival is the outcome of interest. However, some patients will choose not to have second-line chemotherapy, and so the sequence of therapies should reflect a discussion between the physician and the patient regarding the relative benefits and side effects of each treatment option.</p><p>Multiple reports in the literature suggest that molecular markers and clinical characteristics can be used to select patients who will be more likely to benefit from an <sc>egfr</sc>-<sc>tki</sc>. However, this literature comes with significant limitations. The term &#x0201c;benefit&#x0201d; creates confusion, because it is used to refer to a variety of outcomes, including tumour response, improved <sc>os</sc>, and improved symptom control and <sc>qol</sc>. The molecular analyses are limited to patients whose tumour samples were available. The percentage of patients whose samples were available for one or more molecular analyses ranged from 25% to 44% of the total study population. As a result, some of these comparisons involve small numbers of patients. In addition, much of the literature has focused on tumour response rates, rather than on survival. Although there is some consistency in factors predicting response, these factors do not correlate directly with variables predicting a <bold>differential</bold> benefit in survival. Considerable variation is found in the variables reported to be associated with a differential improvement in survival from therapy with an <sc>egfr</sc>-<sc>tki</sc>. This variation may exist in part because some of the <sc>egfr</sc> markers are prognostic and associated with trends toward better survival (some <italic>EGFR</italic> mutations) or worse survival (high <italic>EGFR</italic> copy number). Therefore, it is not possible to assess the effect of <sc>egfr</sc>-<sc>tki</sc> therapy on survival in the absence of a no-treatment control arm. Furthermore, markers that seem to predict for a differential survival benefit when <sc>egfr</sc>-<sc>tki</sc> therapy is compared with placebo or no treatment may not be predictive when <sc>egfr</sc>-<sc>tki</sc> therapy is compared with another form of treatment such as chemotherapy. As a result, the evidence is currently insufficient to recommend the routine use of molecular markers and clinical characteristics to select patients for therapy with an <sc>egfr</sc>-<sc>tki</sc>. It is therefore also premature to recommend the use of single-agent <sc>egfr</sc>-<sc>tkis</sc> as first-line therapy for <sc>nsclc</sc>, even in patients selected on basis of molecular and clinical characteristics.</p><p>These results highlight the need for prospective trials in which tumour samples are available for all patients, so as to address correlative questions. Ongoing research will also address questions concerning the sequence of platinum-based chemotherapy or <sc>egfr</sc>-<sc>tki</sc> as first-line therapy.</p><p>Since the literature search for the present review was completed, preliminary data from two trials of maintenance gefitinib or erlotinib in Asian populations were presented at the American Society of Clinical Oncology Annual Scientific Meeting in 2008<xref ref-type="bibr" rid="b87-co16-1-27">87</xref>,<xref ref-type="bibr" rid="b88-co16-1-27">88</xref>. Both trials showed improved <sc>pfs</sc>, but no significant improvements in <sc>os</sc>. In addition, initial results of <sc>ipass</sc> (Iressa Pan ASia Study) were presented at the 2008 meeting of the European Society for Medical Oncology<xref ref-type="bibr" rid="b89-co16-1-27">89</xref>. That trial compared first-line gefitinib with carboplatin and paclitaxel in light- or never-smoking Asian patients. A significant improvement was observed in <sc>pfs</sc>, but no significant difference in <sc>os</sc>. Other ongoing trials are evaluating the role of an <sc>egfr</sc>-<sc>tki</sc> as maintenance therapy in patients responding to first-line platinum-based chemotherapy.</p><p>Lastly, chemotherapy experience suggests that the therapeutic ratio can be improved with combination therapy. Preliminary evidence suggests that combination therapy with an <sc>egfr</sc>-<sc>tki</sc> and agents active against vascular endothelial growth factor may have greater activity. These questions are being addressed in multiple ongoing clinical trials. Participation in these trials should be encouraged.</p></sec></body><back><ack><title>5. ACKNOWLEDGMENTS</title><p>This consensus statement was supported by an unrestricted educational grant from Hoffmann&#x02013;La Roche Limited. The recommendations are those of the participants and are independent of Hoffmann&#x02013;La Roche.</p></ack><ref-list><title>7. REFERENCES</title><ref id="b1-co16-1-27"><label>1</label><citation citation-type="book"><collab>Canadian Cancer Society and the National Cancer Institute of Canada</collab><source>Canadian Cancer Statistics 2007</source><publisher-loc>Toronto</publisher-loc><publisher-name>Canadian Cancer Society</publisher-name><year>2007</year></citation></ref><ref id="b2-co16-1-27"><label>2</label><citation citation-type="journal"><collab>Non-small Cell Lung Cancer Collaborative Group</collab><article-title>Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials</article-title><source>BMJ</source><year>1995</year><volume>311</volume><fpage>899</fpage><lpage>909</lpage><comment>[See comment in: BMJ 1995;311:889&#x02013;90]</comment><pub-id pub-id-type="pmid">7580546</pub-id></citation></ref><ref id="b3-co16-1-27"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fossella</surname><given-names>F</given-names></name><name><surname>Pereira</surname><given-names>JR</given-names></name><name><surname>von Pawel</surname><given-names>J</given-names></name><etal/></person-group><article-title>Randomized, multinational, phase iii study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the tax 326 study group</article-title><source>J Clin Oncol</source><year>2003</year><volume>21</volume><fpage>3016</fpage><lpage>24</lpage><comment>[See comment in: J Clin Oncol 2003;21:3007&#x02013;8]</comment><pub-id pub-id-type="pmid">12837811</pub-id></citation></ref><ref id="b4-co16-1-27"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Scagliotti</surname><given-names>GV</given-names></name><name><surname>De Marinis</surname><given-names>F</given-names></name><name><surname>Rinaldi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Phase iii randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>4285</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">12409326</pub-id></citation></ref><ref id="b5-co16-1-27"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schiller</surname><given-names>JH</given-names></name><name><surname>Harrington</surname><given-names>D</given-names></name><name><surname>Belani</surname><given-names>CP</given-names></name><etal/></person-group><article-title>Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer</article-title><source>N Engl J Med</source><year>2002</year><volume>346</volume><fpage>92</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">11784875</pub-id></citation></ref><ref id="b6-co16-1-27"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shepherd</surname><given-names>FA</given-names></name><name><surname>Dancey</surname><given-names>J</given-names></name><name><surname>Ramlau</surname><given-names>R</given-names></name><etal/></person-group><article-title>Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy</article-title><source>J Clin Oncol</source><year>2000</year><volume>18</volume><fpage>2095</fpage><lpage>103</lpage><comment>[See comment in: J Clin Oncol 2001;19:2108&#x02013;9]</comment><pub-id pub-id-type="pmid">10811675</pub-id></citation></ref><ref id="b7-co16-1-27"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dancey</surname><given-names>J</given-names></name><name><surname>Shepherd</surname><given-names>FA</given-names></name><name><surname>Gralla</surname><given-names>RJ</given-names></name><name><surname>Kim</surname><given-names>YS</given-names></name></person-group><article-title>Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase iii trial</article-title><source>Lung Cancer</source><year>2004</year><volume>43</volume><fpage>183</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">14739039</pub-id></citation></ref><ref id="b8-co16-1-27"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fossella</surname><given-names>FV</given-names></name><name><surname>DeVore</surname><given-names>R</given-names></name><name><surname>Kerr</surname><given-names>RN</given-names></name><etal/></person-group><article-title>Randomized phase iii trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The tax 320 Non-Small Cell Lung Cancer Study Group</article-title><source>J Clin Oncol</source><year>2000</year><volume>18</volume><fpage>2354</fpage><lpage>62</lpage><comment>[See comment in: J Clin Oncol 2001;19:2108&#x02013;9; erratum in: J Clin Oncol 2004;22:209]</comment><pub-id pub-id-type="pmid">10856094</pub-id></citation></ref><ref id="b9-co16-1-27"><label>9</label><citation citation-type="web"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>V</given-names></name><name><surname>Fossella</surname><given-names>F</given-names></name><name><surname>deVore</surname><given-names>R</given-names></name><etal/></person-group><article-title>Docetaxel (<sc>d</sc>) benefits lung cancer symptoms and quality of life (<sc>qol</sc>) in a randomized phase <sc>iii</sc> study of non-small cell lung cancer (<sc>nsclc</sc>) patients previously treated with platinum based therapy [abstract 1895]</article-title><source>Proc Am Soc Clin Oncol</source><year>1999</year><volume>18</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=17&#x00026;abstractID=16144">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=17&#x00026;abstractID=16144</ext-link>; cited December 14, 2008]</comment></citation></ref><ref id="b10-co16-1-27"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hanna</surname><given-names>N</given-names></name><name><surname>Shepherd</surname><given-names>FA</given-names></name><name><surname>Fossella</surname><given-names>FV</given-names></name><etal/></person-group><article-title>Randomized phase iii trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>1589</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">15117980</pub-id></citation></ref><ref id="b11-co16-1-27"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Noble</surname><given-names>J</given-names></name><name><surname>Ellis</surname><given-names>PM</given-names></name><name><surname>Mackay</surname><given-names>JA</given-names></name><name><surname>Evans</surname><given-names>WK</given-names></name></person-group><collab>on behalf of the Lung Cancer Disease Site Group of Cancer Care Ontario&#x02019;s Program in Evidence-based Care</collab><article-title>Second-line or subsequent systemic therapy for recurrent or progressive non-small cell lung cancer: a systematic review and practice guideline</article-title><source>J Thorac Oncol</source><year>2006</year><volume>1</volume><fpage>1042</fpage><lpage>58</lpage><comment>[See comments in: J Thorac Oncol 2006;1:927&#x02013;8 and J Thorac Oncol 2007;2:373]</comment><pub-id pub-id-type="pmid">17409993</pub-id></citation></ref><ref id="b12-co16-1-27"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pfister</surname><given-names>DG</given-names></name><name><surname>Johnson</surname><given-names>DH</given-names></name><name><surname>Azzoli</surname><given-names>CG</given-names></name><etal/></person-group><article-title>American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>330</fpage><lpage>53</lpage><comment>[See comment in: J Clin Oncol 2004;22:5018&#x02013;20, author reply 5020&#x02013;1]</comment><pub-id pub-id-type="pmid">14691125</pub-id></citation></ref><ref id="b13-co16-1-27"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Volm</surname><given-names>M</given-names></name><name><surname>Rittgen</surname><given-names>W</given-names></name><name><surname>Drings</surname><given-names>P</given-names></name></person-group><article-title>Prognostic value of erbb-1, vegf, cyclin A, <italic>fos, jun</italic> and <italic>myc</italic> in patients with squamous cell lung carcinomas</article-title><source>Br J Cancer</source><year>1998</year><volume>77</volume><fpage>663</fpage><lpage>9</lpage><comment>[Erratum in: Br J Cancer 1998;77:1198]</comment><pub-id pub-id-type="pmid">9484827</pub-id></citation></ref><ref id="b14-co16-1-27"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fujino</surname><given-names>S</given-names></name><name><surname>Enokibori</surname><given-names>T</given-names></name><name><surname>Tezuka</surname><given-names>N</given-names></name><etal/></person-group><article-title>A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer</article-title><source>Eur J Cancer</source><year>1996</year><volume>32A</volume><fpage>2070</fpage><lpage>4</lpage><pub-id pub-id-type="pmid">9014747</pub-id></citation></ref><ref id="b15-co16-1-27"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pavelic</surname><given-names>K</given-names></name><name><surname>Banjac</surname><given-names>Z</given-names></name><name><surname>Pavelic</surname><given-names>J</given-names></name><name><surname>Spaventi</surname><given-names>S</given-names></name></person-group><article-title>Evidence for a role of egf receptor in the progression of human lung carcinoma</article-title><source>Anticancer Res</source><year>1993</year><volume>13</volume><fpage>1133</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">8394672</pub-id></citation></ref><ref id="b16-co16-1-27"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ranson</surname><given-names>M</given-names></name><name><surname>Hammond</surname><given-names>LA</given-names></name><name><surname>Ferry</surname><given-names>D</given-names></name><etal/></person-group><article-title>ZD1839, a selective oral epidermal growth factor receptor&#x02013;tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase i trial</article-title><source>J Clin Oncol</source><year>2002</year><volume>20</volume><fpage>2240</fpage><lpage>50</lpage><comment>[See comment in: J Clin Oncol 2002;20:2217&#x02013;19]</comment><pub-id pub-id-type="pmid">11980995</pub-id></citation></ref><ref id="b17-co16-1-27"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>P&#x000e9;rez&#x02013;Soler</surname><given-names>R</given-names></name><name><surname>Chachoua</surname><given-names>A</given-names></name><name><surname>Hammond</surname><given-names>LA</given-names></name><etal/></person-group><article-title>Determinants of tumor response and survival with erlotinib in patients with non&#x02013;small-cell lung cancer</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>3238</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">15310767</pub-id></citation></ref><ref id="b18-co16-1-27"><label>18</label><citation citation-type="web"><person-group person-group-type="author"><name><surname>Kasahara</surname><given-names>K</given-names></name><name><surname>Kimura</surname><given-names>H</given-names></name><name><surname>Yoshimoto</surname><given-names>A</given-names></name><etal/></person-group><article-title>A phase <sc>ii</sc> study of gefitinib monotherapy for chemotherapy-na&#x000ef;ve patients with non-small cell lung cancer [abstract 7074]</article-title><source>Proc Am Soc Clin Oncol</source><year>2005</year><volume>23</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=34&#x00026;abstractID=30444">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=34&#x00026;abstractID=30444</ext-link>; cited December 14, 2008]</comment></citation></ref><ref id="b19-co16-1-27"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Spigel</surname><given-names>DR</given-names></name><name><surname>Hainsworth</surname><given-names>JD</given-names></name><name><surname>Burkett</surname><given-names>ER</given-names></name><etal/></person-group><article-title>Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase ii Trial</article-title><source>Clin Lung Cancer</source><year>2005</year><volume>7</volume><fpage>127</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">16179100</pub-id></citation></ref><ref id="b20-co16-1-27"><label>20</label><citation citation-type="web"><person-group person-group-type="author"><name><surname>Swinson</surname><given-names>D</given-names></name><name><surname>Williams</surname><given-names>S</given-names></name><name><surname>Beddard</surname><given-names>K</given-names></name><etal/></person-group><article-title>Phase <sc>ii</sc> trial of first-line gefitinib in patients unsuitable for chemotherapy with stage <sc>iii</sc>/<sc>iv</sc> non-small-cell lung cancer [abstract 7256]</article-title><source>Proc Am Soc Clin Oncol</source><year>2005</year><volume>23</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=34&#x00026;abstractID=32139">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=34&#x00026;abstractID=32139</ext-link>; cited De-cember 14, 2008]</comment></citation></ref><ref id="b21-co16-1-27"><label>21</label><citation citation-type="web"><person-group person-group-type="author"><name><surname>Akerley</surname><given-names>WL</given-names></name></person-group><article-title>Erlotinib as first-line treatment for untreated advance stage <sc>nsclc</sc> with good prognosis [abstract 7178]</article-title><source>Proc Am Soc Clin Oncol</source><year>2006</year><volume>24</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCOAbstracts+%26+Virtual+Meetingabstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=40&#x00026;abstractID=34775">www.asco.org/ASCOAbstracts+%26+Virtual+Meetingabstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=40&#x00026;abstractID=34775</ext-link>; cited December 14, 2008]</comment></citation></ref><ref id="b22-co16-1-27"><label>22</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Akerley</surname><given-names>WL</given-names></name><name><surname>Majer</surname><given-names>M</given-names></name><name><surname>Jackson</surname><given-names>K</given-names></name><name><surname>Buys</surname><given-names>S</given-names></name><name><surname>Ward</surname><given-names>J</given-names></name></person-group><source>Erlotinib as first-line treatment for untreated stage <sc>iv nsclc</sc> with good prognosis [slideshow]</source><publisher-loc>Alexandria, VA</publisher-loc><publisher-name>American Society of Clinical Oncology</publisher-name><year>2006</year></citation></ref><ref id="b23-co16-1-27"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Asahina</surname><given-names>H</given-names></name><name><surname>Yamazaki</surname><given-names>K</given-names></name><name><surname>Kinoshita</surname><given-names>I</given-names></name><etal/></person-group><article-title>A phase ii trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations</article-title><source>Br J Cancer</source><year>2006</year><volume>95</volume><fpage>998</fpage><lpage>1004</lpage><pub-id pub-id-type="pmid">17047648</pub-id></citation></ref><ref id="b24-co16-1-27"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giaccone</surname><given-names>G</given-names></name><name><surname>Gallegos Ruiz</surname><given-names>M</given-names></name><name><surname>Le Chevalier</surname><given-names>T</given-names></name><etal/></person-group><article-title>Erlotinib for frontline treatment of advanced non-small cell lung cancer: a phase ii study</article-title><source>Clin Cancer Res</source><year>2006</year><volume>12</volume><fpage>6049</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">17062680</pub-id></citation></ref><ref id="b25-co16-1-27"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Inoue</surname><given-names>A</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Fukuhara</surname><given-names>T</given-names></name><etal/></person-group><article-title>Prospective phase ii study of gefitinib for chemotherapy-na&#x000ef;ve patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>3340</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">16785471</pub-id></citation></ref><ref id="b26-co16-1-27"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>WC</given-names></name><name><surname>Chiu</surname><given-names>CH</given-names></name><name><surname>Liou</surname><given-names>JL</given-names></name><name><surname>Chen</surname><given-names>YM</given-names></name><name><surname>Perng</surname><given-names>RP</given-names></name><name><surname>Tsai</surname><given-names>CM</given-names></name></person-group><article-title>Gefitinib as front-line treatment in Chinese patients with advanced non-small-cell lung cancer</article-title><source>Lung Cancer</source><year>2006</year><volume>54</volume><fpage>193</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16996166</pub-id></citation></ref><ref id="b27-co16-1-27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Niho</surname><given-names>S</given-names></name><name><surname>Kubota</surname><given-names>K</given-names></name><name><surname>Goto</surname><given-names>K</given-names></name><etal/></person-group><article-title>First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase ii study</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>64</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16382114</pub-id></citation></ref><ref id="b28-co16-1-27"><label>28</label><citation citation-type="web"><person-group person-group-type="author"><name><surname>Paz&#x02013;Ares</surname><given-names>L</given-names></name><name><surname>Sanchez</surname><given-names>JM</given-names></name><name><surname>Garc&#x000ed;a&#x02013;Velasco</surname><given-names>A</given-names></name><etal/></person-group><collab>on behalf of the Spanish Lung Cancer Group</collab><article-title>A prospective phase <sc>ii</sc> trial of erlotinib in advanced non-small cell lung cancer (<sc>nsclc</sc>) patients (p) with mutations in the tyrosine kinase (<sc>tk</sc>) domain of the epidermal growth factor receptor (<sc>egfr</sc>) [abstract 7020]</article-title><source>Proc Am Soc Clin Oncol</source><year>2006</year><volume>24</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=40&#x00026;abstractID=32575">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=40&#x00026;abstractID=32575</ext-link>; cited December 14, 2008]</comment></citation></ref><ref id="b29-co16-1-27"><label>29</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Paz&#x02013;Ares</surname><given-names>L</given-names></name><name><surname>Sanchez</surname><given-names>JM</given-names></name><name><surname>Garc&#x000ed;a&#x02013;Velasco</surname><given-names>A</given-names></name><etal/></person-group><collab>on behalf of the Spanish Lung Cancer Group (SLCG) and Target Trial Investigators</collab><source>A prospective phase <sc>ii</sc> trial of erlotinib in advanced non-small cell lung cancer (<sc>nsclc</sc>) patients with mutations in the tyrosine kinase (<sc>tk</sc>) domain of the epidermal growth factor receptor (<sc>egfr</sc>) [slideshow]</source><publisher-loc>Alexandria, VA</publisher-loc><publisher-name>American Society of Clinical Oncology</publisher-name><year>2007</year></citation></ref><ref id="b30-co16-1-27"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Reck</surname><given-names>M</given-names></name><name><surname>Buchholz</surname><given-names>E</given-names></name><name><surname>Romer</surname><given-names>KS</given-names></name><name><surname>Krutzfeldt</surname><given-names>K</given-names></name><name><surname>Gatzemeier</surname><given-names>U</given-names></name><name><surname>Manegold</surname><given-names>C</given-names></name></person-group><article-title>Gefitinib monotherapy in chemotherapy-na&#x000ef;ve patients with inoperable stage iii/iv non-small-cell lung cancer</article-title><source>Clin Lung Cancer</source><year>2006</year><volume>7</volume><fpage>406</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">16800967</pub-id></citation></ref><ref id="b31-co16-1-27"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>R</given-names></name><name><surname>Hasegawa</surname><given-names>Y</given-names></name><name><surname>Baba</surname><given-names>K</given-names></name><etal/></person-group><article-title>A phase ii study of single-agent gefitinib as first-line therapy in patients with stage iv non-small-cell lung cancer</article-title><source>Br J Cancer</source><year>2006</year><volume>94</volume><fpage>1599</fpage><lpage>603</lpage><pub-id pub-id-type="pmid">16670714</pub-id></citation></ref><ref id="b32-co16-1-27"><label>32</label><citation citation-type="web"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><etal/></person-group><article-title>A phase <sc>ii</sc> study of gefitinib as first line treatment for good performance advanced or metastatic non-small cell lung cancer in East Asian patients [abstract 7167]</article-title><source>Proc Am Soc Clin Oncol</source><year>2006</year><volume>24</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=40&#x00026;abstractID=31211">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=40&#x00026;abstractID=31211</ext-link>; cited December 14, 2008]</comment></citation></ref><ref id="b33-co16-1-27"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goss</surname><given-names>G</given-names></name><name><surname>Ferry</surname><given-names>D</given-names></name><name><surname>Laurie</surname><given-names>S</given-names></name><etal/></person-group><article-title>Randomized, double-blind, multicenter, parallel-group, phase ii study of gefitinib (Iressa) plus best supportive care (bsc) versus placebo plus bsc in chemotherapy-na&#x000ef;ve patients with advanced non-small-cell lung cancer and poor performance status (instep) [abstract]</article-title><source>J Thorac Oncol</source><year>2007</year><volume>2</volume><issue>suppl 4</issue><fpage>S340</fpage><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.meet-ics.com/wlc2007/pdf/Oral_Abstracts.pdf">www.meet-ics.com/wlc2007/pdf/Oral_Abstracts.pdf</ext-link>; cited December16, 2008]</comment></citation></ref><ref id="b34-co16-1-27"><label>34</label><citation citation-type="web"><person-group person-group-type="author"><name><surname>Hesketh</surname><given-names>PJ</given-names></name><name><surname>Chansky</surname><given-names>K</given-names></name><name><surname>Wozniak</surname><given-names>AJ</given-names></name><etal/></person-group><collab>on behalf of the Southwest Oncology Group</collab><article-title>Erlotinib as initial therapy in patients with advanced non-small cell lung cancer (<sc>nsclc</sc>) and a performance status (<sc>ps</sc>) of 2: a <sc>swog</sc> phase <sc>ii</sc> trial (S0341) [abstract 7536]</article-title><source>Proc Am Soc Clin Oncol</source><year>2007</year><volume>25</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=47&#x00026;abstractID=30426">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=47&#x00026;abstractID=30426</ext-link>; cited December 14, 2008]</comment></citation></ref><ref id="b35-co16-1-27"><label>35</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Hesketh</surname><given-names>PJ</given-names></name><name><surname>Chansky</surname><given-names>K</given-names></name><name><surname>Wozniak</surname><given-names>AJ</given-names></name><etal/></person-group><collab>on behalf of the Southwest Oncology Group</collab><source>Erlotinib as initial therapy in patients with advanced non-small cell lung cancer (<sc>nsclc</sc>) and a performance status (<sc>ps</sc>) of 2: a <sc>swog</sc> phase <sc>ii</sc> trial (S0341) [slideshow]</source><publisher-loc>Alexandria, VA</publisher-loc><publisher-name>American Society of Clinical Oncology</publisher-name><year>2007</year></citation></ref><ref id="b36-co16-1-27"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jackman</surname><given-names>DM</given-names></name><name><surname>Yeap</surname><given-names>BY</given-names></name><name><surname>Lindeman</surname><given-names>NI</given-names></name><etal/></person-group><article-title>Phase ii clinical trial of chemotherapy-na&#x000ef;ve patients &#x0003e; or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>760</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">17228019</pub-id></citation></ref><ref id="b37-co16-1-27"><label>37</label><citation citation-type="web"><person-group person-group-type="author"><name><surname>Jackman</surname><given-names>D</given-names></name><name><surname>Lindeman</surname><given-names>NI</given-names></name><name><surname>Lucca</surname><given-names>J</given-names></name><etal/></person-group><article-title>Phase <sc>ii</sc> study of erlotinib in chemo-na&#x000ef;ve women with advanced pulmonary adenocarcinoma [abstract 7591]</article-title><source>Proc Am Soc Clin Oncol</source><year>2007</year><volume>25</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=47&#x00026;abstractID=31633">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=47&#x00026;abstractID=31633</ext-link>; cited December 14, 2008]</comment></citation></ref><ref id="b38-co16-1-27"><label>38</label><citation citation-type="web"><person-group person-group-type="author"><name><surname>Jimenez</surname><given-names>U</given-names></name><name><surname>Gurpide</surname><given-names>A</given-names></name><name><surname>Isla</surname><given-names>S</given-names></name><etal/></person-group><article-title>Erlotinib for first line treatment in unselected patients (p) with advanced or meta-static non-small cell lung carcinoma (<sc>nsclc</sc>) [abstract 7639]</article-title><source>Proc Am Soc Clin Oncol</source><year>2007</year><volume>25</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=47&#x00026;abstractID=33407">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=47&#x00026;abstractID=33407</ext-link>; cited December 14, 2008]</comment></citation></ref><ref id="b39-co16-1-27"><label>39</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Jimenez</surname><given-names>U</given-names></name><name><surname>Gurpide</surname><given-names>A</given-names></name><name><surname>Isla</surname><given-names>S</given-names></name><etal/></person-group><collab>on behalf of the Spanish TargeT Trial Investigators</collab><article-title>Erlotinib for first line treatment in unselected patients (p) with advanced or metastatic non-small-cell lung carcinoma (<sc>nsclc</sc>) [slideshow]</article-title><publisher-loc>Alexandria, VA</publisher-loc><publisher-name>American Society of Clinical Oncology</publisher-name><year>2007</year></citation></ref><ref id="b40-co16-1-27"><label>40</label><citation citation-type="web"><person-group person-group-type="author"><name><surname>Sugio</surname><given-names>K</given-names></name><name><surname>Uramoto</surname><given-names>H</given-names></name><name><surname>Oyama</surname><given-names>T</given-names></name><etal/></person-group><article-title>A prospective phase <sc>ii</sc> study of gefitinib in non-small cell cancer patients with epidermal growth factor receptor gene (<italic>EGFR</italic>) mutations [abstract 18081]</article-title><source>Proc Am Soc Clin Oncol</source><year>2007</year><volume>25</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=47&#x00026;abstracted=32553">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=47&#x00026;abstracted=32553</ext-link>; cited December 14, 2008]</comment></citation></ref><ref id="b41-co16-1-27"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kris</surname><given-names>MG</given-names></name><name><surname>Giacone</surname><given-names>G</given-names></name><name><surname>Davies</surname><given-names>A</given-names></name><etal/></person-group><article-title>Systemic therapy of bronchioloalveolar carcinoma: results of the first iaslc/asco consensus conference on bronchioloalveolar carcinoma</article-title><source>J Thorac Oncol</source><year>2006</year><volume>1</volume><issue>suppl</issue><fpage>S32</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">17409999</pub-id></citation></ref><ref id="b42-co16-1-27"><label>42</label><citation citation-type="web"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>VA</given-names></name><name><surname>Zakowski</surname><given-names>M</given-names></name><name><surname>Riely</surname><given-names>GJ</given-names></name><etal/></person-group><article-title><italic>EGFR</italic> mutation and copy number, <sc>egfr</sc> protein expression and <italic>KRAS</italic> mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (<sc>bac</sc>): results of a prospective phase <sc>ii</sc> trial [abstract 7003]</article-title><source>Proc Am Soc Clin Oncol</source><year>2006</year><volume>24</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=40&#x00026;abstractID=31714">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=40&#x00026;abstractID=31714</ext-link>; cited December 14, 2008]</comment></citation></ref><ref id="b43-co16-1-27"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>West</surname><given-names>HL</given-names></name><name><surname>Franklin</surname><given-names>WA</given-names></name><name><surname>McCoy</surname><given-names>J</given-names></name><etal/></person-group><article-title>Gefitinib therapy in advanced bronchioloalveolar carcinoma: Southwest Oncology Group Study S0126</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>1807</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">16622257</pub-id></citation></ref><ref id="b44-co16-1-27"><label>44</label><citation citation-type="web"><person-group person-group-type="author"><name><surname>Cadranel</surname><given-names>J</given-names></name><name><surname>Quoix</surname><given-names>E</given-names></name><name><surname>Debove</surname><given-names>P</given-names></name><etal/></person-group><collab>on behalf of the Intergroupe Francophone de Cancerologie Thoracique (IFCT)</collab><article-title>IFCT0401 trial: phase <sc>ii</sc> study of gefitinib administered as first-line treatment in non-resectable adenocarcinoma with bronchioloalveolar carcinoma features (<sc>adc</sc>-<sc>bac</sc>): final results on efficacy and survival [abstract 7560]</article-title><source>Proc Am Soc Clin Oncol</source><year>2007</year><volume>25</volume><comment>[Available onlineat:<ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCOAbstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=47&#x00026;abstractID=30942">www.asco.org/ASCOAbstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=47&#x00026;abstractID=30942</ext-link>; cited December 14, 2008]</comment></citation></ref><ref id="b45-co16-1-27"><label>45</label><citation citation-type="book"><collab>Intergroupe Francophone de Cancerologie Thoracique (IFCT)</collab><source>IFCT-0401 trial: phase <sc>ii</sc> study of gefitinib administered as first-line treatment in non-resectable adenocarcinoma with bronchioloalveolar carcinoma features (<sc>adc</sc>-<sc>bac</sc>) [slideshow]</source><publisher-loc>Alexandria, VA</publisher-loc><publisher-name>American Society of Clinical Oncology</publisher-name><year>2007</year></citation></ref><ref id="b46-co16-1-27"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Giaccone</surname><given-names>G</given-names></name><name><surname>Herbst</surname><given-names>RS</given-names></name><name><surname>Manegold</surname><given-names>C</given-names></name><etal/></person-group><article-title>Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase iii trial&#x02014;intact 1</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>777</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">14990632</pub-id></citation></ref><ref id="b47-co16-1-27"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Herbst</surname><given-names>RS</given-names></name><name><surname>Giaccone</surname><given-names>G</given-names></name><name><surname>Schiller</surname><given-names>JH</given-names></name><etal/></person-group><article-title>Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase iii trial&#x02014;intact 2</article-title><source>J Clin Oncol</source><year>2004</year><volume>22</volume><fpage>785</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">14990633</pub-id></citation></ref><ref id="b48-co16-1-27"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Herbst</surname><given-names>RS</given-names></name><name><surname>Prager</surname><given-names>D</given-names></name><name><surname>Hermann</surname><given-names>R</given-names></name><etal/></person-group><collab>on behalf of the tribute Investigator Group</collab><article-title>tribute: a phase iii trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>5892</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16043829</pub-id></citation></ref><ref id="b49-co16-1-27"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gatzemeier</surname><given-names>U</given-names></name><name><surname>Pluzanska</surname><given-names>A</given-names></name><name><surname>Szczesna</surname><given-names>A</given-names></name><etal/></person-group><article-title>Phase iii study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>1545</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">17442998</pub-id></citation></ref><ref id="b50-co16-1-27"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Crin&#x000f2;</surname><given-names>L</given-names></name><name><surname>Zatloukal</surname><given-names>P</given-names></name><name><surname>Reck</surname><given-names>M</given-names></name><etal/></person-group><article-title>Gefitinib (Iressa) versus vinorelbine in chemona&#x000ef;ve elderly patients with advanced non-small-cell lung cancer (invite): a randomized phase ii study [abstract]</article-title><source>J Thorac Oncol</source><year>2007</year><volume>2</volume><issue>suppl 4</issue><fpage>S341</fpage><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.meet-ics.com/wlc2007/pdf/Oral_Abstracts.pdf">www.meet-ics.com/wlc2007/pdf/Oral_Abstracts.pdf</ext-link>; cited December 14, 2008]</comment></citation></ref><ref id="b51-co16-1-27"><label>51</label><citation citation-type="web"><person-group person-group-type="author"><name><surname>Riely</surname><given-names>GJ</given-names></name><name><surname>Rudin</surname><given-names>CM</given-names></name><name><surname>Kris</surname><given-names>MG</given-names></name><etal/></person-group><article-title>A randomized phase <sc>ii</sc> trial comparing pulsed erlotinib before or after carboplatin and paclitaxel in patients with stage <sc>iiib</sc> or <sc>iv</sc> non-small cell lung cancer [abstract 7619]</article-title><source>Proc Am Soc Clin Oncol</source><year>2007</year><volume>25</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=47&#x00026;abstractID=35044">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=47&#x00026;abstractID=35044</ext-link>; cited December 14, 2008]</comment></citation></ref><ref id="b52-co16-1-27"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lilenbaum</surname><given-names>R</given-names></name><name><surname>Axelrod</surname><given-names>R</given-names></name><name><surname>Thomas</surname><given-names>S</given-names></name><etal/></person-group><article-title>Randomized phase ii trial of erlotinib or standard chemotherapy in patients with advanced non&#x02013;small-cell lung cancer and a performance status of 2</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>863</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">18281658</pub-id></citation></ref><ref id="b53-co16-1-27"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feld</surname><given-names>R</given-names></name><name><surname>Sridhar</surname><given-names>SS</given-names></name><name><surname>Shepherd</surname><given-names>FA</given-names></name><etal/></person-group><article-title>Use of the epidermal growth factor receptor inhibitors gefitinib and erlotinib in the treatment of non-small cell lung cancer: a systematic review</article-title><source>J Thorac Oncol</source><year>2006</year><volume>1</volume><fpage>367</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">17409886</pub-id></citation></ref><ref id="b54-co16-1-27"><label>54</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fukuoka</surname><given-names>M</given-names></name><name><surname>Yano</surname><given-names>S</given-names></name><name><surname>Giaccone</surname><given-names>G</given-names></name><etal/></person-group><article-title>Multi-institutional randomized phase ii trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (the ideal 1 Trial) [corrected]</article-title><source>J Clin Oncol</source><year>2003</year><volume>21</volume><fpage>2237</fpage><lpage>46</lpage><comment>[Erratum in: J Clin Oncol 2004;22:4811]</comment><pub-id pub-id-type="pmid">12748244</pub-id></citation></ref><ref id="b55-co16-1-27"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kris</surname><given-names>MG</given-names></name><name><surname>Natale</surname><given-names>RB</given-names></name><name><surname>Herbst</surname><given-names>RS</given-names></name><etal/></person-group><article-title>Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial</article-title><source>JAMA</source><year>2003</year><volume>290</volume><fpage>2149</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">14570950</pub-id></citation></ref><ref id="b56-co16-1-27"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shepherd</surname><given-names>FA</given-names></name><name><surname>Rodrigues Pereira</surname><given-names>J</given-names></name><name><surname>Ciuleanu</surname><given-names>T</given-names></name><etal/></person-group><collab>on behalf of the National Cancer Institute of Canada Clinical Trials Group</collab><article-title>Erlotinib in previously treated non-small-cell lung cancer</article-title><source>N Engl J Med</source><year>2005</year><volume>353</volume><fpage>123</fpage><lpage>32</lpage><pub-id pub-id-type="pmid">16014882</pub-id></citation></ref><ref id="b57-co16-1-27"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thatcher</surname><given-names>N</given-names></name><name><surname>Chang</surname><given-names>A</given-names></name><name><surname>Parikh</surname><given-names>P</given-names></name><etal/></person-group><article-title>Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)</article-title><source>Lancet</source><year>2005</year><volume>366</volume><fpage>1527</fpage><lpage>37</lpage><pub-id pub-id-type="pmid">16257339</pub-id></citation></ref><ref id="b58-co16-1-27"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bezjak</surname><given-names>A</given-names></name><name><surname>Tu</surname><given-names>D</given-names></name><name><surname>Seymour</surname><given-names>L</given-names></name><etal/></person-group><article-title>Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study br.21</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>3831</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">16921034</pub-id></citation></ref><ref id="b59-co16-1-27"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cufer</surname><given-names>T</given-names></name><name><surname>Vrdoljak</surname><given-names>E</given-names></name><name><surname>Gaafar</surname><given-names>R</given-names></name><name><surname>Erensoy</surname><given-names>I</given-names></name><name><surname>Pemberton</surname><given-names>K</given-names></name></person-group><collab>on behalf of the sign Study Group</collab><article-title>Phase ii, open-label, randomized study (sign) of single-agent gefitinib (Iressa) or docetaxel as second-line therapy in patients with advanced (stage iiib or iv) non-small-cell lung cancer</article-title><source>Anticancer Drugs</source><year>2006</year><volume>17</volume><fpage>401</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16549997</pub-id></citation></ref><ref id="b60-co16-1-27"><label>60</label><citation citation-type="web"><person-group person-group-type="author"><name><surname>Natale</surname><given-names>RB</given-names></name><name><surname>Bodkin</surname><given-names>D</given-names></name><name><surname>Govindan</surname><given-names>R</given-names></name><etal/></person-group><article-title>ZD6474 versus gefitinib in patients with advanced <sc>nsclc</sc>: final results from a two-part, double-blind, randomized phase <sc>ii</sc> trial [abstract 7000]</article-title><source>Proc Am Soc Clin Oncol</source><year>2006</year><volume>24</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=40&#x00026;abstractID=31016">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=40&#x00026;abstractID=31016</ext-link>; cited December 14, 2008]</comment></citation></ref><ref id="b61-co16-1-27"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YM</given-names></name><name><surname>Liu</surname><given-names>JM</given-names></name><name><surname>Chou</surname><given-names>TY</given-names></name><name><surname>Perng</surname><given-names>RP</given-names></name><name><surname>Tsai</surname><given-names>CM</given-names></name><name><surname>Whang&#x02013;Peng</surname><given-names>J</given-names></name></person-group><article-title>Phase ii randomized study of daily gefitinib treatment alone or with vinorelbine every 2 weeks in patients with adenocarcinoma of the lung who failed at least 2 regimens of chemotherapy</article-title><source>Cancer</source><year>2007</year><volume>109</volume><fpage>1821</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17351950</pub-id></citation></ref><ref id="b62-co16-1-27"><label>62</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Douillard</surname><given-names>JY</given-names></name><name><surname>Kim</surname><given-names>E</given-names></name><name><surname>Hirsh</surname><given-names>V</given-names></name><etal/></person-group><article-title>Gefitinib (Iressa) versus docetaxel in patients with locally advanced or metastatic non-small-cell lung cancer pre-treated with platinum-based chemotherapy: a randomized, open-label phase iii study (interest) [abstract]</article-title><source>J Thorac Oncol</source><year>2007</year><volume>2</volume><issue>suppl 4</issue><fpage>S305</fpage><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.meet-ics.com/wlc2007/pdf/Oral_Abstracts.pdf">www.meet-ics.com/wlc2007/pdf/Oral_Abstracts.pdf</ext-link>; cited December16, 2008]</comment></citation></ref><ref id="b63-co16-1-27"><label>63</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Herbst</surname><given-names>RS</given-names></name><name><surname>O&#x02019;Neill</surname><given-names>VJ</given-names></name><name><surname>Fehrenbacher</surname><given-names>L</given-names></name><etal/></person-group><article-title>Phase ii study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>4743</fpage><lpage>50</lpage><pub-id pub-id-type="pmid">17909199</pub-id></citation></ref><ref id="b64-co16-1-27"><label>64</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lynch</surname><given-names>TJ</given-names></name><name><surname>Fenton</surname><given-names>DW</given-names></name><name><surname>Hirsh</surname><given-names>V</given-names></name><etal/></person-group><article-title>Randomized phase <sc>ii</sc> study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer (<sc>nsclc</sc>) [abstract 7680]</article-title><source>Proc Am Soc Clin Oncol</source><year>2007</year><volume>25</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=47&#x00026;abstractID=34738">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=47&#x00026;abstractID=34738</ext-link>; cited December 14, 2008]</comment></citation></ref><ref id="b65-co16-1-27"><label>65</label><citation citation-type="web"><person-group person-group-type="author"><name><surname>Niho</surname><given-names>S</given-names></name><name><surname>Ichinose</surname><given-names>Y</given-names></name><name><surname>Tamura</surname><given-names>T</given-names></name><etal/></person-group><article-title>Results of a randomized Phase <sc>iii</sc> study to compare the overall survival of gefitinib (Iressa) versus docetaxel in Japanese patients with non-small-cell lung cancer who failed one or two chemotherapy regimens [abstract LBA7509]</article-title><source>Proc Am Soc Clin Oncol</source><year>2007</year><volume>25</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=47&#x00026;abstractID=30412">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=47&#x00026;abstractID=30412</ext-link>; cited December 14, 2008]</comment></citation></ref><ref id="b66-co16-1-27"><label>66</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Niho</surname><given-names>S</given-names></name><name><surname>Ichinose</surname><given-names>Y</given-names></name><name><surname>Tamura</surname><given-names>T</given-names></name><etal/></person-group><source>Results of a randomized phase <sc>iii</sc> study to compare the overall survival of gefitinib (Iressa) versus docetaxel in Japanese patients with pretreated advanced <sc>nsclc</sc> [slideshow]</source><publisher-loc>Alexandria, VA</publisher-loc><publisher-name>American Society of Clinical Oncology</publisher-name><year>2007</year></citation></ref><ref id="b67-co16-1-27"><label>67</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cappuzzo</surname><given-names>F</given-names></name><name><surname>Ligorio</surname><given-names>C</given-names></name><name><surname>J&#x000e4;nne</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Prospective study of gefitinib in epidermal growth factor receptor fluorescence <italic>in situ</italic> hybridization-positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the oncobell trial</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>2248</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">17538169</pub-id></citation></ref><ref id="b68-co16-1-27"><label>68</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sunaga</surname><given-names>N</given-names></name><name><surname>Tomizawa</surname><given-names>Y</given-names></name><name><surname>Yanagitani</surname><given-names>N</given-names></name><etal/></person-group><article-title>Phase ii prospective study of the efficacy of gefitinib for the treatment of stage iii/iv non-small cell lung cancer with <italic>EGFR</italic> mutations, irrespective of previous chemotherapy</article-title><source>Lung Cancer</source><year>2007</year><volume>56</volume><fpage>383</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17368623</pub-id></citation></ref><ref id="b69-co16-1-27"><label>69</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sutani</surname><given-names>A</given-names></name><name><surname>Nagai</surname><given-names>Y</given-names></name><name><surname>Udagawa</surname><given-names>K</given-names></name><etal/></person-group><article-title>Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid&#x02013;locked nucleic acid pcr clamp</article-title><source>Br J Cancer</source><year>2006</year><volume>95</volume><fpage>1483</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">17106442</pub-id></citation></ref><ref id="b70-co16-1-27"><label>70</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yoshida</surname><given-names>K</given-names></name><name><surname>Yatabe</surname><given-names>Y</given-names></name><name><surname>Park</surname><given-names>JY</given-names></name><etal/></person-group><article-title>Prospective validation for prediction of gefitinib sensitivity by epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer</article-title><source>J Thorac Oncol</source><year>2007</year><volume>2</volume><fpage>22</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">17410005</pub-id></citation></ref><ref id="b71-co16-1-27"><label>71</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>GM</given-names></name><name><surname>Zborowski</surname><given-names>DM</given-names></name><name><surname>Culbertson</surname><given-names>JL</given-names></name><etal/></person-group><article-title>Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib</article-title><source>J Thorac Oncol</source><year>2006</year><volume>1</volume><fpage>837</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">17409968</pub-id></citation></ref><ref id="b72-co16-1-27"><label>72</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Florescu</surname><given-names>M</given-names></name><name><surname>Hasan</surname><given-names>B</given-names></name><name><surname>Seymour</surname><given-names>L</given-names></name><etal/></person-group><article-title>A clinical prognostic index for patients treated with erlotinib in National Cancer Institute of Canada Clinical Trials Group study br.21</article-title><source>J Thorac Oncol</source><year>2008</year><volume>3</volume><fpage>590</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">18520796</pub-id></citation></ref><ref id="b73-co16-1-27"><label>73</label><citation citation-type="web"><person-group person-group-type="author"><name><surname>Tsao</surname><given-names>M</given-names></name><name><surname>Zhu</surname><given-names>C</given-names></name><name><surname>Sakurada</surname><given-names>A</given-names></name><etal/></person-group><article-title>An analysis of the prognostic and predictive importance of K<italic>-ras</italic> mutation status in the National Cancer Institute of Canada Clinical Trials Group <sc>br</sc>.21 study of erlotinib versus placebo in the treatment of non-small cell lung cancer [abstract 7005]</article-title><source>Proc Am Soc Clin Oncol</source><year>2006</year><volume>24</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=40&#x00026;abstractID=34061">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=40&#x00026;abstractID=34061</ext-link>; cited December 14, 2008]</comment></citation></ref><ref id="b74-co16-1-27"><label>74</label><citation citation-type="web"><person-group person-group-type="author"><name><surname>Gatzemeier</surname><given-names>U</given-names></name><name><surname>Heller</surname><given-names>A</given-names></name><name><surname>Foernzler</surname><given-names>D</given-names></name><etal/></person-group><article-title>Exploratory analyses <italic>EGFR, kRAS</italic> mutations and other molecular markers in tumors of <sc>nsclc</sc> patients (pts) treated with chemotherapy +/&#x02212; erlotinib (<sc>talent</sc>) [abstract 7028]</article-title><source>Proc Am Soc Clin Oncol</source><year>2005</year><volume>23</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=34&#x00026;abstractID=31779">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=34&#x00026;abstractID=31779</ext-link>; cited December 14, 2008]</comment></citation></ref><ref id="b75-co16-1-27"><label>75</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Gatzemeier</surname><given-names>U</given-names></name><name><surname>Heller</surname><given-names>A</given-names></name><name><surname>Foernzler</surname><given-names>D</given-names></name><etal/></person-group><source>Exploratory analyses of <italic>HER1</italic>/<italic>EGFR</italic>, K<italic>-ras</italic> mutations and other molecular markers in tumors of patients with non-small-cell lung cancer treated with chemotherapy with or without erlotinib (Tarceva) (<sc>talent</sc>&#x02014;phase <sc>iii</sc>) [slideshow]</source><publisher-loc>Alexandria, VA</publisher-loc><publisher-name>American Society of Clinical Oncology</publisher-name><year>2005</year></citation></ref><ref id="b76-co16-1-27"><label>76</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>A</given-names></name><name><surname>Parikh</surname><given-names>P</given-names></name><name><surname>Thongprasert</surname><given-names>S</given-names></name><etal/></person-group><article-title>Gefitinib (Iressa) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the isel study</article-title><source>J Thorac Oncol</source><year>2006</year><volume>1</volume><fpage>847</fpage><lpage>55</lpage><pub-id pub-id-type="pmid">17409969</pub-id></citation></ref><ref id="b77-co16-1-27"><label>77</label><citation citation-type="web"><person-group person-group-type="author"><name><surname>Clark</surname><given-names>GM</given-names></name><name><surname>Cameron</surname><given-names>T</given-names></name><name><surname>Das Gupta</surname><given-names>A</given-names></name></person-group><article-title>Clinical benefit of erlotinib in male smokers with squamous-cell <sc>nsclc</sc> [abstract 7166]</article-title><source>Proc Am Soc Clin Oncol</source><year>2006</year><volume>24</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=40&#x00026;abstractID=34675">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=40&#x00026;abstractID=34675</ext-link>; cited December 14, 2008]</comment></citation></ref><ref id="b78-co16-1-27"><label>78</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Shepherd</surname><given-names>FA</given-names></name><name><surname>Ding</surname><given-names>K</given-names></name><name><surname>Sakurada</surname><given-names>A</given-names></name><etal/></person-group><article-title>Updated molecular analyses of exons 19 and 21 of the epidermal growth factor receptor (<italic>EGFR</italic>) gene and codons 12 and 13 of the <italic>KRAS</italic> gene in non-small cell lung cancer (<sc>nsclc</sc>) patients treated with erlotinib in National Cancer Institute of Cancer [abstract 7571]</article-title><source>Proc Am Soc Clin Oncol</source><year>2007</year><volume>25</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=47&#x00026;abstractID=31334">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=47&#x00026;abstractID=31334</ext-link>; cited December 14, 2008]</comment></citation></ref><ref id="b79-co16-1-27"><label>79</label><citation citation-type="web"><person-group person-group-type="author"><name><surname>Douillard</surname><given-names>J</given-names></name><name><surname>Hirsh</surname><given-names>V</given-names></name><name><surname>Mok</surname><given-names>TS</given-names></name><etal/></person-group><article-title>Molecular and clinical subgroup analyses from a phase <sc>iii</sc> trial comparing gefitinib with docetaxel in previously treated non-small cell lung cancer (<sc>interest</sc>) [abstract 8001]</article-title><source>Proc Am Soc Clin Oncol</source><year>2008</year><volume>26</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=55&#x00026;abstractID=34724">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=55&#x00026;abstractID=34724</ext-link>; cited December 14, 2008]</comment></citation></ref><ref id="b80-co16-1-27"><label>80</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bell</surname><given-names>DW</given-names></name><name><surname>Lynch</surname><given-names>TJ</given-names></name><name><surname>Haserlat</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the ideal/intact gefitinib trials</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>8081</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">16204011</pub-id></citation></ref><ref id="b81-co16-1-27"><label>81</label><citation citation-type="web"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>VA</given-names></name><name><surname>Herbst</surname><given-names>R</given-names></name><name><surname>Prager</surname><given-names>D</given-names></name><etal/></person-group><article-title>Long survival of never smoking non-small cell lung cancer (<sc>nsclc</sc>) patients (pts) treated with erlotinib HCl (OSI-774) and chemotherapy: sub-group analysis of <sc>tribute</sc> [abstract 7061]</article-title><source>Proc Am Soc Clin Oncol</source><year>2004</year><volume>22</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=26&#x00026;abstractID=1470">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=26&#x00026;abstractID=1470</ext-link>; cited December 14, 2008]</comment></citation></ref><ref id="b82-co16-1-27"><label>82</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eberhard</surname><given-names>DA</given-names></name><name><surname>Johnson</surname><given-names>BE</given-names></name><name><surname>Amler</surname><given-names>LC</given-names></name><etal/></person-group><article-title>Mutations in the epidermal growth factor receptor and in <italic>KRAS</italic> are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib</article-title><source>J Clin Oncol</source><year>2005</year><volume>23</volume><fpage>5900</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">16043828</pub-id></citation></ref><ref id="b83-co16-1-27"><label>83</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hirsch</surname><given-names>FR</given-names></name><name><surname>Varella&#x02013;Garcia</surname><given-names>M</given-names></name><name><surname>Bunn</surname><given-names>PA</given-names><suffix>Jr</suffix></name><etal/></person-group><article-title>Molecular predictors of outcome with gefitinib in a phase iii placebo-controlled study in advanced non-small-cell lung cancer</article-title><source>J Clin Oncol</source><year>2006</year><volume>24</volume><fpage>5034</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">17075123</pub-id></citation></ref><ref id="b84-co16-1-27"><label>84</label><citation citation-type="web"><person-group person-group-type="author"><name><surname>Hirsch</surname><given-names>FR</given-names></name><name><surname>Varella&#x02013;Garcia</surname><given-names>M</given-names></name><name><surname>Bunn</surname><given-names>PA</given-names></name><etal/></person-group><article-title>Fluorescence <italic>in situ</italic> hybridization (<sc>fish</sc>) subgroup analysis of <sc>tribute</sc>, a phase <sc>iii</sc> trial of erlotinib plus carboplatin and paclitaxel in <sc>nsclc</sc> [abstract 7570]</article-title><source>Proc Am Soc Clin Oncol</source><year>2007</year><volume>25</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=47&#x00026;abstractID=33716">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=47&#x00026;abstractID=33716</ext-link>; cited December 14, 2008]</comment></citation></ref><ref id="b85-co16-1-27"><label>85</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>CQ</given-names></name><name><surname>Santos</surname><given-names>GC</given-names></name><name><surname>Ding</surname><given-names>K</given-names></name><etal/></person-group><article-title>Role of kras and egfr as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study br. 21</article-title><source>J Clin Oncol</source><year>2008</year><volume>26</volume><fpage>4268</fpage><lpage>75</lpage><pub-id pub-id-type="pmid">18626007</pub-id></citation></ref><ref id="b86-co16-1-27"><label>86</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Garassino</surname><given-names>M</given-names></name><name><surname>Borgonovo</surname><given-names>K</given-names></name><name><surname>Cinquini</surname><given-names>M</given-names></name><etal/></person-group><article-title>Predictive role of biological markers in nsclc patients (pts) treated with egfr tyrosine kinase inhibitors (tkis): a metanalysis of randomized trials [abstract P6535]</article-title><source>Eur J Cancer Suppl</source><year>2007</year><volume>5</volume><fpage>368</fpage></citation></ref><ref id="b87-co16-1-27"><label>87</label><citation citation-type="web"><person-group person-group-type="author"><name><surname>Hida</surname><given-names>T</given-names></name><name><surname>Okamoto</surname><given-names>I</given-names></name><name><surname>Kashii</surname><given-names>T</given-names></name><etal/></person-group><article-title>Randomized phase <sc>iii</sc> study of platinum-doublet chemotherapy followed by gefitinib versus continued platinum-doublet chemotherapy in patients (pts) with advanced non-small cell lung cancer (<sc>nsclc</sc>): results of West Japan Thoracic Oncology Group trial (<sc>wjtog</sc>) [abstract LBA8012]</article-title><source>Proc Am Soc Clin Oncol</source><year>2008</year><volume>26</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=55&#x00026;abstractID=31815">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=55&#x00026;abstractID=31815</ext-link>; cited December 14, 2008]</comment></citation></ref><ref id="b88-co16-1-27"><label>88</label><citation citation-type="web"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JS</given-names></name><name><surname>Ignacio</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>C</given-names></name><etal/></person-group><article-title><sc>fast</sc>-<sc>act</sc>: a phase <sc>ii</sc> randomized double-blind trial of sequential erlotinib and chemotherapy as first-line treatment in patients (pts) with stage <sc>iiib</sc>/<sc>iv</sc> non-small cell lung cancer (<sc>nsclc</sc>) [abstract 8031]</article-title><source>Proc Am Soc Clin Oncol</source><year>2008</year><volume>26</volume><comment>[Available online at: <ext-link ext-link-type="uri" xlink:href="www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=55&#x00026;abstractID=35241">www.asco.org/ASCO/Abstracts+%26+Virtual+Meeting/Abstracts?&#x00026;vmview=abst_detail_view&#x00026;confID=55&#x00026;abstractID=35241</ext-link>; cited December 14, 2008]</comment></citation></ref><ref id="b89-co16-1-27"><label>89</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mok</surname><given-names>T</given-names></name><name><surname>Wu</surname><given-names>YL</given-names></name><name><surname>Thongprasert</surname><given-names>S</given-names></name><etal/></person-group><article-title>Phase <sc>iii</sc> randomized open label first line study of gefitinib vs carboplatin/paclitaxel in clinically selected patients with advanced non small cell lung cancer (<sc>ipass</sc>) [abstract]</article-title><source>Ann Oncol</source><year>2008</year><volume>19</volume><issue>suppl 8</issue><fpage>LBA2</fpage></citation></ref></ref-list></back><floats-wrap><table-wrap id="tI-co16-1-27" position="float"><label>TABLE I</label><caption><p>Trials of single-agent epidermal growth factor receptor tyrosine kinase inhibitors (<sc>egfr</sc>-<sc>tkis</sc>) in chemona&#x000ef;ve patients with non-small-cell lung cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th colspan="2" align="center" rowspan="1">Survival</th></tr><tr><th align="left" rowspan="1" colspan="1">Reference</th><th align="center" rowspan="1" colspan="1">Design</th><th align="center" rowspan="1" colspan="1">Treatment (daily dose)</th><th align="center" rowspan="1" colspan="1">Population</th><th align="center" rowspan="1" colspan="1">Patients (<italic>n</italic>)</th><th align="center" rowspan="1" colspan="1">Stage <sc>iii</sc>/<sc>iv</sc> (%)</th><th align="center" rowspan="1" colspan="1"><sc>ps</sc> 0&#x02013;1/2 (%)</th><th align="center" rowspan="1" colspan="1">Response rate <sc>or</sc>/<sc>sd</sc>/<sc>pd</sc> (%)</th><th align="center" rowspan="1" colspan="1"><sc>ttp</sc> or <sc>pfs</sc></th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">1-Year (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">P&#x000e9;rez&#x02013;Soler <italic>et al.</italic>, 2004<xref ref-type="bibr" rid="b17-co16-1-27">17</xref></td><td align="center" rowspan="1" colspan="1">Phase <sc>ii</sc></td><td align="center" rowspan="1" colspan="1">Erlotinib 150 mg</td><td align="center" rowspan="1" colspan="1">Unselected</td><td align="center" rowspan="1" colspan="1">57</td><td align="center" rowspan="1" colspan="1">15.8/84.2</td><td align="center" rowspan="1" colspan="1">87.7/12.3</td><td align="center" rowspan="1" colspan="1">12<xref ref-type="table-fn" rid="tfn1-co16-1-27">a</xref>/35/49</td><td align="center" rowspan="1" colspan="1">9 Weeks</td><td align="center" rowspan="1" colspan="1">8.4 Months<xref ref-type="table-fn" rid="tfn1-co16-1-27">a</xref></td><td align="center" rowspan="1" colspan="1">40</td></tr><tr><td align="left" rowspan="1" colspan="1">Kasahara <italic>et al.</italic>, 2005<xref ref-type="bibr" rid="b18-co16-1-27">18</xref></td><td align="center" rowspan="1" colspan="1">Phase <sc>ii</sc></td><td align="center" rowspan="1" colspan="1">Gefitinib 250 mg</td><td align="center" rowspan="1" colspan="1">Unselected Asian</td><td align="center" rowspan="1" colspan="1">30</td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td><td align="center" rowspan="1" colspan="1">33/30</td><td align="center" rowspan="1" colspan="1">3.3 Months</td><td align="center" rowspan="1" colspan="1">10 Months</td><td align="center" rowspan="1" colspan="1">43.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Spigel <italic>et al.</italic>, 2005<xref ref-type="bibr" rid="b19-co16-1-27">19</xref></td><td align="center" rowspan="1" colspan="1">Phase <sc>ii</sc></td><td align="center" rowspan="1" colspan="1">Gefitinib 250 mg</td><td align="center" rowspan="1" colspan="1">Unselected</td><td align="center" rowspan="1" colspan="1">72</td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td><td align="center" rowspan="1" colspan="1">0/83</td><td align="center" rowspan="1" colspan="1">4<xref ref-type="table-fn" rid="tfn2-co16-1-27">b</xref>/46/26</td><td align="center" rowspan="1" colspan="1">3.7 Months</td><td align="center" rowspan="1" colspan="1">6.3 Months</td><td align="center" rowspan="1" colspan="1">24</td></tr><tr><td align="left" rowspan="1" colspan="1">Swinson <italic>et al.</italic>, 2005<xref ref-type="bibr" rid="b20-co16-1-27">20</xref></td><td align="center" rowspan="1" colspan="1">Phase <sc>ii</sc></td><td align="center" rowspan="1" colspan="1">Gefitinib 250 mg</td><td align="center" rowspan="1" colspan="1">Unselected</td><td align="center" rowspan="1" colspan="1">45</td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td><td align="center" rowspan="1" colspan="1">17/27</td><td align="center" rowspan="1" colspan="1">9.8/36.6/53.4</td><td align="center" rowspan="1" colspan="1">32 Days</td><td align="center" rowspan="1" colspan="1">82 Days</td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td></tr><tr><td align="left" rowspan="1" colspan="1">Akerley, 2006 <xref ref-type="bibr" rid="b21-co16-1-27">21</xref> and\Akerley et al., 2006<xref ref-type="bibr" rid="b22-co16-1-27">22</xref></td><td align="center" rowspan="1" colspan="1">Phase <sc>ii</sc></td><td align="center" rowspan="1" colspan="1">Erlotinib 150 mg</td><td align="center" rowspan="1" colspan="1">Unselected</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td><td align="center" rowspan="1" colspan="1">100/0</td><td align="center" rowspan="1" colspan="1">15<xref ref-type="table-fn" rid="tfn2-co16-1-27">b</xref>/28/58<xref ref-type="table-fn" rid="tfn3-co16-1-27">c</xref></td><td align="center" rowspan="1" colspan="1">22 Weeks</td><td align="center" rowspan="1" colspan="1">49 Weeks<xref ref-type="table-fn" rid="tfn3-co16-1-27">c</xref></td><td align="center" rowspan="1" colspan="1">49<xref ref-type="table-fn" rid="tfn3-co16-1-27">c</xref></td></tr><tr><td align="left" rowspan="1" colspan="1">Asahina <italic>et al.</italic>, 2006<xref ref-type="bibr" rid="b23-co16-1-27">23</xref></td><td align="center" rowspan="1" colspan="1">Phase <sc>ii</sc></td><td align="center" rowspan="1" colspan="1">Gefitinib 250 mg</td><td align="center" rowspan="1" colspan="1">Selected (<sc>egfr</sc><sup>+</sup>)<xref ref-type="table-fn" rid="tfn4-co16-1-27">d</xref> Asian</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td><td align="center" rowspan="1" colspan="1">75/6/19</td><td align="center" rowspan="1" colspan="1">8.9 Months</td><td align="center" rowspan="1" colspan="1">Not reached</td><td align="center" rowspan="1" colspan="1">Not reached</td></tr><tr><td align="left" rowspan="1" colspan="1">Giaccone <italic>et al.</italic>, 2006<xref ref-type="bibr" rid="b24-co16-1-27">24</xref></td><td align="center" rowspan="1" colspan="1">Phase <sc>ii</sc></td><td align="center" rowspan="1" colspan="1">Erlotinib 150 mg</td><td align="center" rowspan="1" colspan="1">Unselected</td><td align="center" rowspan="1" colspan="1">53</td><td align="center" rowspan="1" colspan="1">21/79</td><td align="center" rowspan="1" colspan="1">85/15</td><td align="center" rowspan="1" colspan="1">23/30/23 (84 days)</td><td align="center" rowspan="1" colspan="1">3.0 Months (391 Days)</td><td align="center" rowspan="1" colspan="1">13.9 Months</td><td align="center" rowspan="1" colspan="1">54</td></tr><tr><td align="left" rowspan="1" colspan="1">Inoue <italic>et al.</italic>, 2006<xref ref-type="bibr" rid="b25-co16-1-27">25</xref></td><td align="center" rowspan="1" colspan="1">Phase <sc>ii</sc></td><td align="center" rowspan="1" colspan="1">Gefitinib 250 mg</td><td align="center" rowspan="1" colspan="1">Selected (<sc>egfr</sc><sup>+</sup>)<xref ref-type="table-fn" rid="tfn4-co16-1-27">d</xref> Asian</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1">0/63</td><td align="center" rowspan="1" colspan="1">88/12</td><td align="center" rowspan="1" colspan="1">75<xref ref-type="table-fn" rid="tfn2-co16-1-27">b</xref>/12.5/12.5</td><td align="center" rowspan="1" colspan="1">9.7 Months</td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td></tr><tr><td align="left" rowspan="1" colspan="1">Lin <italic>et al.</italic>, 2006<xref ref-type="bibr" rid="b26-co16-1-27">26</xref></td><td align="center" rowspan="1" colspan="1">Phase <sc>ii</sc></td><td align="center" rowspan="1" colspan="1">Gefitinib 250 mg</td><td align="center" rowspan="1" colspan="1">Unselected Asian</td><td align="center" rowspan="1" colspan="1">53</td><td align="center" rowspan="1" colspan="1">13/87</td><td align="center" rowspan="1" colspan="1">76/9</td><td align="center" rowspan="1" colspan="1">32<xref ref-type="table-fn" rid="tfn2-co16-1-27">b</xref>/21/47</td><td align="center" rowspan="1" colspan="1">3.2 Months</td><td align="center" rowspan="1" colspan="1">9.4 Months</td><td align="center" rowspan="1" colspan="1">41.5</td></tr><tr><td align="left" rowspan="1" colspan="1">Niho <italic>et al.</italic>, 2006<xref ref-type="bibr" rid="b27-co16-1-27">27</xref></td><td align="center" rowspan="1" colspan="1">Phase <sc>ii</sc></td><td align="center" rowspan="1" colspan="1">Gefitinib 250 mg</td><td align="center" rowspan="1" colspan="1">Unselected Asian</td><td align="center" rowspan="1" colspan="1">42</td><td align="center" rowspan="1" colspan="1">8/85</td><td align="center" rowspan="1" colspan="1">100/0</td><td align="center" rowspan="1" colspan="1">30<xref ref-type="table-fn" rid="tfn2-co16-1-27">b</xref>/40/30</td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td><td align="center" rowspan="1" colspan="1">13.9 Months</td><td align="center" rowspan="1" colspan="1">55</td></tr><tr><td align="left" rowspan="1" colspan="1">Paz&#x02013;Ares <italic>et al.</italic>, 2006<xref ref-type="bibr" rid="b28-co16-1-27">28</xref>,<xref ref-type="bibr" rid="b29-co16-1-27">29</xref></td><td align="center" rowspan="1" colspan="1">Phase <sc>ii</sc></td><td align="center" rowspan="1" colspan="1">Erlotinib 150 mg</td><td align="center" rowspan="1" colspan="1">Selected (<sc>egfr</sc><sup>+</sup>)<xref ref-type="table-fn" rid="tfn4-co16-1-27">d</xref></td><td align="center" rowspan="1" colspan="1">37</td><td align="center" rowspan="1" colspan="1">10/90</td><td align="center" rowspan="1" colspan="1">33/55</td><td align="center" rowspan="1" colspan="1">90/5/5<xref ref-type="table-fn" rid="tfn3-co16-1-27">c</xref></td><td align="center" rowspan="1" colspan="1">13.3 Months</td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td><td align="center" rowspan="1" colspan="1">82</td></tr><tr><td align="left" rowspan="1" colspan="1">Reck <italic>et al.</italic>, 2006<xref ref-type="bibr" rid="b30-co16-1-27">30</xref></td><td align="center" rowspan="1" colspan="1">Phase <sc>ii</sc></td><td align="center" rowspan="1" colspan="1">Gefitinib 250 mg</td><td align="center" rowspan="1" colspan="1">Unselected</td><td align="center" rowspan="1" colspan="1">58</td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td><td align="center" rowspan="1" colspan="1">76/24</td><td align="center" rowspan="1" colspan="1">5/40/52</td><td align="center" rowspan="1" colspan="1">7 Weeks</td><td align="center" rowspan="1" colspan="1">29 Weeks</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Suzuki <italic>et al.</italic>, 2006 <xref ref-type="bibr" rid="b31-co16-1-27">31</xref></td><td align="center" rowspan="1" colspan="1">Phase <sc>ii</sc></td><td align="center" rowspan="1" colspan="1">Gefitinib 250 mg</td><td align="center" rowspan="1" colspan="1">Unselected Asian</td><td align="center" rowspan="1" colspan="1">34</td><td align="center" rowspan="1" colspan="1">0/100</td><td align="center" rowspan="1" colspan="1">100/0</td><td align="center" rowspan="1" colspan="1">26.5/23.5</td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td><td align="center" rowspan="1" colspan="1">14.1 Months</td><td align="center" rowspan="1" colspan="1">58.2</td></tr><tr><td align="left" rowspan="1" colspan="1">Yang <italic>et al.</italic>, 2006 <xref ref-type="bibr" rid="b32-co16-1-27">32</xref></td><td align="center" rowspan="1" colspan="1">Phase <sc>ii</sc></td><td align="center" rowspan="1" colspan="1">Gefitinib 250 mg</td><td align="center" rowspan="1" colspan="1">Unselected Asian</td><td align="center" rowspan="1" colspan="1">44</td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td><td align="center" rowspan="1" colspan="1">40/4</td><td align="center" rowspan="1" colspan="1">54.5/20</td><td align="center" rowspan="1" colspan="1">6.3 Months</td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td><td align="center" rowspan="1" colspan="1"><sc>n</sc></td></tr><tr><td align="left" rowspan="1" colspan="1">Goss <italic>et al.</italic>, 2007 <xref ref-type="bibr" rid="b33-co16-1-27">33</xref></td><td align="center" rowspan="1" colspan="1">Randomized phase <sc>ii</sc></td><td align="center" rowspan="1" colspan="1">Gefitinib 250 mg Placebo</td><td align="center" rowspan="1" colspan="1">Unselected</td><td align="center" rowspan="1" colspan="1">100<break/>101</td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td><td align="center" rowspan="1" colspan="1">0/100</td><td align="center" rowspan="1" colspan="1">6.0/&#x02013;/not available<break/>1.0/&#x02013;/not available<break/><italic>p</italic>=<sc>ns</sc><break/><italic>p</italic>=0.217</td><td align="center" rowspan="1" colspan="1"><sc>hr</sc>: 0.82 95% <sc>ci</sc>: 0.60 to 1.12<break/><italic>p</italic>=0.272</td><td align="center" rowspan="1" colspan="1"><sc>hr</sc>: 0.84 95% <sc>ci</sc>: 0.62 to 1.15</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Hesketh <italic>et al.</italic>, 2007<xref ref-type="bibr" rid="b34-co16-1-27">34</xref>,<xref ref-type="bibr" rid="b35-co16-1-27">35</xref> (<sc>swog</sc> S0341)</td><td align="center" rowspan="1" colspan="1">Phase <sc>ii</sc></td><td align="center" rowspan="1" colspan="1">Erlotinib 150 mg</td><td align="center" rowspan="1" colspan="1">Unselected</td><td align="center" rowspan="1" colspan="1">82</td><td align="center" rowspan="1" colspan="1">12/88</td><td align="center" rowspan="1" colspan="1">0/100</td><td align="center" rowspan="1" colspan="1">7<xref ref-type="table-fn" rid="tfn2-co16-1-27">b</xref>/36/42<xref ref-type="table-fn" rid="tfn3-co16-1-27">c</xref></td><td align="center" rowspan="1" colspan="1">2 Months</td><td align="center" rowspan="1" colspan="1">6 Months</td><td align="center" rowspan="1" colspan="1">24</td></tr><tr><td align="left" rowspan="1" colspan="1">Jackman <italic>et al.</italic>, 2007<xref ref-type="bibr" rid="b36-co16-1-27">36</xref></td><td align="center" rowspan="1" colspan="1">Phase <sc>ii</sc></td><td align="center" rowspan="1" colspan="1">Erlotinib 150 mg</td><td align="center" rowspan="1" colspan="1">Unselected, &#x02265;70 years of age</td><td align="center" rowspan="1" colspan="1">80</td><td align="center" rowspan="1" colspan="1">15/85</td><td align="center" rowspan="1" colspan="1">90/10</td><td align="center" rowspan="1" colspan="1">10/41/35</td><td align="center" rowspan="1" colspan="1">3.5 Months</td><td align="center" rowspan="1" colspan="1">10.9 Months</td><td align="center" rowspan="1" colspan="1">46</td></tr><tr><td align="left" rowspan="1" colspan="1">Jackman <italic>et al.</italic>, 2007<xref ref-type="bibr" rid="b37-co16-1-27">37</xref></td><td align="center" rowspan="1" colspan="1">Phase <sc>ii</sc></td><td align="center" rowspan="1" colspan="1">Erlotinib 150 mg</td><td align="center" rowspan="1" colspan="1">Selected based on patient characteristics</td><td align="center" rowspan="1" colspan="1">40 (women)</td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td><td align="center" rowspan="1" colspan="1">100/0</td><td align="center" rowspan="1" colspan="1">30<xref ref-type="table-fn" rid="tfn2-co16-1-27">b</xref>/28/25</td><td align="center" rowspan="1" colspan="1">5.6 Months</td><td align="center" rowspan="1" colspan="1">Not reached (exceeds 23 Months)</td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td></tr><tr><td align="left" rowspan="1" colspan="1">Jimenez <italic>et al.</italic>, 2007<xref ref-type="bibr" rid="b38-co16-1-27">38</xref>,<xref ref-type="bibr" rid="b39-co16-1-27">39</xref></td><td align="center" rowspan="1" colspan="1">Phase <sc>ii</sc></td><td align="center" rowspan="1" colspan="1">Erlotinib 150 mg</td><td align="center" rowspan="1" colspan="1">Unselected</td><td align="center" rowspan="1" colspan="1">437</td><td align="center" rowspan="1" colspan="1">24/76</td><td align="center" rowspan="1" colspan="1">70/30</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">6.6 Months</td><td align="center" rowspan="1" colspan="1">7.1 Months</td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td></tr><tr><td align="left" rowspan="1" colspan="1">Sugio <italic>et al.</italic>, 2007<xref ref-type="bibr" rid="b40-co16-1-27">40</xref></td><td align="center" rowspan="1" colspan="1">Phase <sc>ii</sc></td><td align="center" rowspan="1" colspan="1">Gefitinib 250 mg</td><td align="center" rowspan="1" colspan="1">Selected (<sc>egfr</sc><sup>+</sup>)<xref ref-type="table-fn" rid="tfn4-co16-1-27">d</xref> Asian</td><td align="center" rowspan="1" colspan="1">16</td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td><td align="center" rowspan="1" colspan="1">50/33/not available</td><td align="center" rowspan="1" colspan="1">8.8 Months</td><td align="center" rowspan="1" colspan="1">15.4</td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn1-co16-1-27"><label>a</label><p>Predictor of overall response (multivariate analysis): time from last chemotherapy (<italic>p</italic> = 0.033); predictors of survival (multivariate analysis): time from initial diagnosis (<italic>p</italic> = 0.0007); good performance status [PS 0&#x02013;1/2 (<italic>p</italic> = 0.04)].</p></fn><fn id="tfn2-co16-1-27"><label>b</label><p>Partial response.</p></fn><fn id="tfn3-co16-1-27"><label>c</label><p>14 Patients could not be evaluated, and 1 patient experienced early death.</p></fn><fn id="tfn4-co16-1-27"><label>d</label><p>Selected based on presence of <sc>egfr</sc> mutations.</p></fn><fn id="tfn5-co16-1-27"><p><sc>ps</sc> = performance status; <sc>or</sc> = overall response (complete response + partial response); <sc>sd</sc> = stable disease; <sc>pd</sc> = progressive disease; <sc>ttp</sc> = median time to progression; <sc>pfs</sc> = median progression-free survival; <sc>nr</sc> = not recorded; <sc>hr</sc> = hazard ratio; <sc>ci</sc> = confidence interval; <sc>swog</sc> = Southwest Oncology Group.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tII-co16-1-27" position="float"><label>TABLE II</label><caption><p>Trials involving patients with adenocarcinoma with features of bronchioloalveolar carcinoma (<sc>bac</sc>)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th colspan="2" align="center" rowspan="1">Survival</th></tr><tr><th align="left" rowspan="1" colspan="1">Reference</th><th align="center" rowspan="1" colspan="1">Design</th><th align="center" rowspan="1" colspan="1">Treatment (daily dose)</th><th align="center" rowspan="1" colspan="1">Population</th><th align="center" rowspan="1" colspan="1">Patients (<italic>n</italic>)</th><th align="center" rowspan="1" colspan="1">Stage <sc>iii</sc>/<sc>iv</sc> (%)</th><th align="center" rowspan="1" colspan="1"><sc>ps</sc> 0&#x02013;1/2 (%)</th><th align="center" rowspan="1" colspan="1">Response rate <sc>or</sc>/<sc>sd</sc>/<sc>pd</sc> (%)</th><th align="center" rowspan="1" colspan="1"><sc>pfs</sc> or <sc>ttp</sc></th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">1-Year (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Miller <italic>et al.</italic>, 2006<xref ref-type="bibr" rid="b42-co16-1-27">42</xref></td><td align="center" rowspan="1" colspan="1">Phase <sc>ii</sc></td><td align="center" rowspan="1" colspan="1">Erlotinib 150 mg</td><td align="center" rowspan="1" colspan="1"><sc>bac</sc></td><td align="center" rowspan="1" colspan="1">102</td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td><td align="center" rowspan="1" colspan="1">21<xref ref-type="table-fn" rid="tfn6-co16-1-27">a</xref></td><td align="center" rowspan="1" colspan="1">3.7 Months</td><td align="center" rowspan="1" colspan="1">17.1</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">West <italic>et al.</italic>, 2006<xref ref-type="bibr" rid="b43-co16-1-27">43</xref> (SO126)</td><td align="center" rowspan="1" colspan="1">Phase <sc>ii</sc></td><td align="center" rowspan="1" colspan="1">Gefitinib 500 mg</td><td align="center" rowspan="1" colspan="1">Previously untreated</td><td align="center" rowspan="1" colspan="1">101</td><td align="center" rowspan="1" colspan="1">7/93</td><td align="center" rowspan="1" colspan="1">90/10</td><td align="center" rowspan="1" colspan="1">17/32/33</td><td align="center" rowspan="1" colspan="1">4 Months</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Previously treated</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">6/94</td><td align="center" rowspan="1" colspan="1">86/14</td><td align="center" rowspan="1" colspan="1">9/36/36</td><td align="center" rowspan="1" colspan="1">3 Months</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Cadranel <italic>et al.</italic>, 2007<xref ref-type="bibr" rid="b44-co16-1-27">44</xref> and <sc>ifct</sc><xref ref-type="bibr" rid="b45-co16-1-27">45</xref> (IFCT0401)</td><td align="center" rowspan="1" colspan="1">Phase <sc>ii</sc></td><td align="center" rowspan="1" colspan="1">Gefitinib 250 mg</td><td align="center" rowspan="1" colspan="1">Adenocarcinoma, <sc>bac</sc></td><td align="center" rowspan="1" colspan="1">88</td><td align="center" rowspan="1" colspan="1">0/100</td><td align="center" rowspan="1" colspan="1">82/18</td><td align="center" rowspan="1" colspan="1">13/16/13</td><td align="center" rowspan="1" colspan="1">2.9 Months<xref ref-type="table-fn" rid="tfn7-co16-1-27">b</xref></td><td align="center" rowspan="1" colspan="1">13.2<xref ref-type="table-fn" rid="tfn7-co16-1-27">b</xref></td><td align="center" rowspan="1" colspan="1">53.4</td></tr></tbody></table><table-wrap-foot><fn id="tfn6-co16-1-27"><label>a</label><p>Response rate.</p></fn><fn id="tfn7-co16-1-27"><label>b</label><p>Shorter progression-free and overall survival were independently associated with non-mucinous as compared with mucinous <sc>bac</sc> (<sc>pfs</sc>: 11.3 months vs. 2.6 months; <italic>p</italic> = 0.002; <sc>os</sc>: not reached vs. 10.7 months; <italic>p</italic> = 0.003).</p></fn><fn id="tfn8-co16-1-27"><p><sc>ps</sc> = performance status; <sc>or</sc> = overall response (complete response + partial response); <sc>sd</sc> = stable disease; <sc>pd</sc> = progressive disease; <sc>pfs</sc> = median progression-free survival; <sc>ttp</sc> = median time to progression; <sc>nr</sc> = not recorded; <sc>ifct</sc> = Intergroupe Francophone de Cancerologie Thoracique.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tIII-co16-1-27" position="float"><label>TABLE III</label><caption><p>Randomized trials of first-line epidermal growth factor receptor tyrosine kinase inhibitors (<sc>egfr</sc>-<sc>tkis</sc>) in combination with platinum-based chemotherapy in patients with non-small-cell lung cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th colspan="2" align="center" rowspan="1">Survival</th></tr><tr><th align="left" rowspan="1" colspan="1">Reference</th><th align="center" rowspan="1" colspan="1">Study</th><th align="center" rowspan="1" colspan="1">Treatment</th><th align="center" rowspan="1" colspan="1">Patients (<italic>n</italic>)</th><th align="center" rowspan="1" colspan="1">Stage <sc>iii</sc>/<sc>iv</sc> (%)</th><th align="center" rowspan="1" colspan="1"><sc>ps</sc> 0&#x02013;1/2 (%)</th><th align="center" rowspan="1" colspan="1">Response rate <sc>or</sc>/<sc>sd</sc>/<sc>pd</sc> (%)</th><th align="center" rowspan="1" colspan="1"><sc>ttp</sc> or <sc>pfs</sc></th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">1-Year (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Giaccone <italic>et al.</italic>, 2004<xref ref-type="bibr" rid="b46-co16-1-27">46</xref></td><td align="center" rowspan="1" colspan="1"><sc>intact</sc> 1</td><td align="center" rowspan="1" colspan="1">Cis&#x02013;gem + placebo</td><td align="center" rowspan="1" colspan="1">363</td><td align="center" rowspan="1" colspan="1">30/69</td><td align="center" rowspan="1" colspan="1">90/10</td><td align="center" rowspan="1" colspan="1">47.2</td><td align="center" rowspan="1" colspan="1">6.0 Months</td><td align="center" rowspan="1" colspan="1">10.9 Months</td><td align="center" rowspan="1" colspan="1">44</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Cis&#x02013;gem + gefitinib 250</td><td align="center" rowspan="1" colspan="1">365</td><td align="center" rowspan="1" colspan="1">27/72</td><td align="center" rowspan="1" colspan="1">90/10</td><td align="center" rowspan="1" colspan="1">51.2</td><td align="center" rowspan="1" colspan="1">5.8 Months</td><td align="center" rowspan="1" colspan="1">9.9 Months</td><td align="center" rowspan="1" colspan="1">41</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Cis&#x02013;gem + gefitinib 500</td><td align="center" rowspan="1" colspan="1">365</td><td align="center" rowspan="1" colspan="1">33/67</td><td align="center" rowspan="1" colspan="1">90/10</td><td align="center" rowspan="1" colspan="1">50.3<break/><italic>p</italic>=<sc>ns</sc></td><td align="center" rowspan="1" colspan="1">5.5 Months<break/><italic>p</italic>=0.763</td><td align="center" rowspan="1" colspan="1">9.9 Months<break/><italic>p</italic>=0.456</td><td align="center" rowspan="1" colspan="1">43</td></tr><tr><td align="left" rowspan="1" colspan="1">Herbst <italic>et al.</italic>, 2004<xref ref-type="bibr" rid="b47-co16-1-27">47</xref></td><td align="center" rowspan="1" colspan="1"><sc>intact</sc> 2</td><td align="center" rowspan="1" colspan="1">Carbo&#x02013;pac + placebo</td><td align="center" rowspan="1" colspan="1">345</td><td align="center" rowspan="1" colspan="1">21/78</td><td align="center" rowspan="1" colspan="1">91/9</td><td align="center" rowspan="1" colspan="1">28.7</td><td align="center" rowspan="1" colspan="1">5.0 Months</td><td align="center" rowspan="1" colspan="1">9.9 Months</td><td align="center" rowspan="1" colspan="1">42</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Carbo&#x02013;pac + gefitinib 250</td><td align="center" rowspan="1" colspan="1">345</td><td align="center" rowspan="1" colspan="1">19/81</td><td align="center" rowspan="1" colspan="1">90/10</td><td align="center" rowspan="1" colspan="1">30.4</td><td align="center" rowspan="1" colspan="1">5.3 Months</td><td align="center" rowspan="1" colspan="1">9.8 Months</td><td align="center" rowspan="1" colspan="1">41</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Carbo&#x02013;pac + gefitinib 500</td><td align="center" rowspan="1" colspan="1">347</td><td align="center" rowspan="1" colspan="1">18/82</td><td align="center" rowspan="1" colspan="1">87/13</td><td align="center" rowspan="1" colspan="1">30.0<break/><italic>p</italic>=<sc>ns</sc></td><td align="center" rowspan="1" colspan="1">4.6 Months<break/><italic>p</italic>=0.056</td><td align="center" rowspan="1" colspan="1">8.7 Months<break/><italic>p</italic>=0.638</td><td align="center" rowspan="1" colspan="1">37</td></tr><tr><td align="left" rowspan="1" colspan="1">Herbst <italic>et al.</italic>, 2005<xref ref-type="bibr" rid="b48-co16-1-27">48</xref></td><td align="center" rowspan="1" colspan="1"><sc>tribute</sc></td><td align="center" rowspan="1" colspan="1">Carbo&#x02013;pac + placebo</td><td align="center" rowspan="1" colspan="1">533</td><td align="center" rowspan="1" colspan="1">18/82</td><td align="center" rowspan="1" colspan="1">99.8/0.2</td><td align="center" rowspan="1" colspan="1">19.3</td><td align="center" rowspan="1" colspan="1">4.9 Months</td><td align="center" rowspan="1" colspan="1">10.5 Months</td><td align="center" rowspan="1" colspan="1">43.8</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Carbo&#x02013;pac + erlotinib 150</td><td align="center" rowspan="1" colspan="1">526</td><td align="center" rowspan="1" colspan="1">16/84</td><td align="center" rowspan="1" colspan="1">100/0</td><td align="center" rowspan="1" colspan="1">21.5<break/><italic>p</italic>=0.36</td><td align="center" rowspan="1" colspan="1">5.1 Months<break/><italic>p</italic>=0.36</td><td align="center" rowspan="1" colspan="1">10.6 Months<break/><italic>p=</italic>0.95</td><td align="center" rowspan="1" colspan="1">46.9</td></tr><tr><td align="left" rowspan="1" colspan="1">Gatzemeier <italic>et al.</italic>, 2007<xref ref-type="bibr" rid="b49-co16-1-27">49</xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Cis&#x02013;gem + placebo</td><td align="center" rowspan="1" colspan="1">579</td><td align="center" rowspan="1" colspan="1">33/67</td><td align="center" rowspan="1" colspan="1">99/&#x0003c;1</td><td align="center" rowspan="1" colspan="1">31.5</td><td align="center" rowspan="1" colspan="1">23.7 Weeks</td><td align="center" rowspan="1" colspan="1">43 Weeks</td><td align="center" rowspan="1" colspan="1">41</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Cis&#x02013;gem + erlotinib 150</td><td align="center" rowspan="1" colspan="1">580</td><td align="center" rowspan="1" colspan="1">35/65</td><td align="center" rowspan="1" colspan="1">100/&#x0003c;1</td><td align="center" rowspan="1" colspan="1">29.9<break/><italic>p</italic>=0.74</td><td align="center" rowspan="1" colspan="1">24.6 Weeks<break/><italic>p</italic>=0.49</td><td align="center" rowspan="1" colspan="1">44.1 Weeks</td><td align="center" rowspan="1" colspan="1">42</td></tr></tbody></table><table-wrap-foot><fn id="tfn9-co16-1-27"><p><sc>ps</sc> = performance status; <sc>or</sc> = overall response (complete response + partial response); <sc>sd</sc> = stable disease; <sc>pd</sc> = progressive disease; <sc>ttp</sc> = median time to progression; <sc>pfs</sc> = median progression-free survival; <sc>intact</sc> = Iressa <sc>nsclc</sc> Trial Assessing Combination Treatment; Cis&#x02013;gem = gemcitabine 1250 mg/m<sup>2</sup> intravenously on days 1 and 8, and cisplatin 80 mg/m<sup>2</sup> intravenously on day 1 of a 21-day cycle; erlotinib 150 = erlotinib 150 mg daily; gefitinib 250 = gefitinib 250 mg daily; gefitinib 500 = gefitinib 500 mg daily; <sc>ns</sc> = statistically nonsignificant; Carbo&#x02013;pac = carboplatin <sc>auc</sc> (area under the curve) 6 intravenously on day 1, and paclitaxel 200 mg/m<sup>2</sup> intravenously on day 1 of a 21-day cycle; <sc>tribute</sc> = Tarceva Responses in Conjunction with Paclitaxel and Carboplatin.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tIV-co16-1-27" position="float"><label>TABLE IV</label><caption><p>Randomized trials of single-agent epidermal growth factor receptor tyrosine kinase inhibitors (<sc>egfr</sc>-<sc>tkis</sc>) compared with chemotherapy in chemona&#x000ef;ve patients with non-small-cell lung cancer</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1"/><th colspan="2" align="left" rowspan="1">Survival</th></tr><tr><th align="left" rowspan="1" colspan="1">Reference</th><th align="left" rowspan="1" colspan="1">Design</th><th align="left" rowspan="1" colspan="1">Treatment</th><th align="left" rowspan="1" colspan="1">Patients (<italic>n</italic>)</th><th align="left" rowspan="1" colspan="1">Stage <sc>iii</sc>/<sc>iv</sc> (%)</th><th align="left" rowspan="1" colspan="1"><sc>ps</sc> 0&#x02013;1/2 (%)</th><th align="left" rowspan="1" colspan="1">Response rate <sc>or</sc>/<sc>sd</sc>/<sc>pd</sc> (%)</th><th align="left" rowspan="1" colspan="1"><sc>ttp</sc> or <sc>pfs</sc></th><th align="left" rowspan="1" colspan="1">Median (months)</th><th align="left" rowspan="1" colspan="1">1-Year</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Crin&#x000f2; <italic>et al.</italic>, 2007<xref ref-type="bibr" rid="b50-co16-1-27">50</xref>, <xref ref-type="table-fn" rid="tfn10-co16-1-27">a</xref> (<sc>invite</sc>)</td><td align="left" rowspan="1" colspan="1">Phase <sc>ii</sc></td><td align="left" rowspan="1" colspan="1">Gefitinib</td><td align="left" rowspan="1" colspan="1">97</td><td align="left" rowspan="1" colspan="1">20/80</td><td align="left" rowspan="1" colspan="1">76/24</td><td align="left" rowspan="1" colspan="1">3.1/40</td><td align="left" rowspan="1" colspan="1"><sc>hr</sc>: 1.19</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Vinorelbine</td><td align="left" rowspan="1" colspan="1">99</td><td align="left" rowspan="1" colspan="1">26/74</td><td align="left" rowspan="1" colspan="1">83/16</td><td align="left" rowspan="1" colspan="1">5.1/48</td><td align="left" rowspan="1" colspan="1">95% <sc>ci</sc>: 0.85 to 1.65<break/><italic>p</italic>=0.310</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Riely <italic>et al.</italic>, 2007<xref ref-type="bibr" rid="b51-co16-1-27">51</xref>, <xref ref-type="table-fn" rid="tfn11-co16-1-27">b</xref></td><td align="left" rowspan="1" colspan="1">Phase <sc>ii</sc></td><td align="left" rowspan="1" colspan="1">Erlotinib 150 mg + carboplatin/paclitaxel</td><td align="left" rowspan="1" colspan="1">87</td><td align="left" rowspan="1" colspan="1"><sc>nr</sc></td><td align="left" rowspan="1" colspan="1"><sc>nr</sc></td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">12</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Erlotinib 1500 mg + carboplatin/paclitaxel</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">35</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Carboplatin/paclitaxel + erlotinib 1500 mg</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"><sc>nr</sc> (&#x0003e;9 )</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Lilenbaum <italic>et al.</italic>, 2008<xref ref-type="bibr" rid="b52-co16-1-27">52</xref>, <xref ref-type="table-fn" rid="tfn12-co16-1-27">v</xref></td><td align="left" rowspan="1" colspan="1">Phase <sc>ii</sc></td><td align="left" rowspan="1" colspan="1">Erlotinib</td><td align="left" rowspan="1" colspan="1">52</td><td align="left" rowspan="1" colspan="1">13/87</td><td align="left" rowspan="1" colspan="1">0/100</td><td align="left" rowspan="1" colspan="1">2/37/44</td><td align="left" rowspan="1" colspan="1">1.9 months</td><td align="left" rowspan="1" colspan="1">6.6 <xref ref-type="table-fn" rid="tfn12-co16-1-27">c</xref></td><td align="left" rowspan="1" colspan="1"><sc>nr</sc></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Carboplatin + paclitaxel</td><td align="left" rowspan="1" colspan="1">51</td><td align="left" rowspan="1" colspan="1">14/86</td><td align="left" rowspan="1" colspan="1">0/100</td><td align="left" rowspan="1" colspan="1">12/41/20</td><td align="left" rowspan="1" colspan="1">3.5 months</td><td align="left" rowspan="1" colspan="1">9.1 <xref ref-type="table-fn" rid="tfn12-co16-1-27">c</xref></td><td align="left" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn10-co16-1-27"><label>a</label><p>Gefitinib 250 mg daily compared with vinorelbine 30 mg/m<sup>2</sup> intravenously on days 1 and 8 in a 21-day cycle.</p></fn><fn id="tfn11-co16-1-27"><label>b</label><p>Erlotinib 150 mg on days 1 and 2, and carboplatin [area under the curve (<sc>auc</sc>) 6] and paclitaxel (200 mg/m<sup>2</sup>) on day 3; erlotinib 1500 mg on days 1 and 2, and carboplatin (<sc>auc</sc> 6) and paclitaxel (200 mg/m<sup>2</sup>) on day 3; or carboplatin (<sc>auc</sc> 6) and paclitaxel (200 mg/m<sup>2</sup>) on day 1 and erlotinib 1500 mg on days 2 and3. Patients received up to six 21-day cycles of treatment.</p></fn><fn id="tfn12-co16-1-27"><label>c</label><p>Erlotinib 150 mg daily compared with carboplatin&#x02013;paclitaxel [area under the curve (<sc>auc</sc>) 6 and 200 mg/m<sup>2</sup> respectively) for 4 cycles.</p></fn><fn id="tfn13-co16-1-27"><p><sc>ps</sc> = performance status; <sc>or</sc> = overall response (complete response + partial response); <sc>sd</sc> = stable disease; <sc>pd</sc> = progressive disease; <sc>ttp</sc> = median time to progression; <sc>pfs</sc> = median progression-free survival; <sc>nr</sc> = not recorded; <sc>invite</sc> = Iressa in <sc>nsclc</sc> vs Vinorelbine Investigation in the Elderly; <sc>hr</sc> = hazard ratio; <sc>ci</sc> = confidence interval.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tV-co16-1-27" position="float"><label>TABLE V</label><caption><p>Randomized trials of epidermal growth factor receptor tyrosine kinase inhibitors (<sc>egfr</sc>-<sc>tkis</sc>) as second- or third line therapy following progression of platinum-based chemotherapy</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th colspan="2" align="center" rowspan="1">Treatment line</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th colspan="2" align="center" rowspan="1">Survival</th><th align="center" rowspan="1" colspan="1"/></tr><tr><th align="left" rowspan="1" colspan="1">Reference</th><th align="center" rowspan="1" colspan="1">Design</th><th align="center" rowspan="1" colspan="1">Treatment</th><th align="center" rowspan="1" colspan="1">Pts (n)</th><th align="center" rowspan="1" colspan="1">2 (%)</th><th align="center" rowspan="1" colspan="1">3+ (%)</th><th align="center" rowspan="1" colspan="1">Prior platinum/taxane (%)</th><th align="center" rowspan="1" colspan="1"><sc>pd</sc> with prior chemotherapy (%)</th><th align="center" rowspan="1" colspan="1">Stage <sc>iii</sc>/<sc>iv</sc> (%)</th><th align="center" rowspan="1" colspan="1"><sc>ps</sc> 0&#x02013;1/2 (%)</th><th align="center" rowspan="1" colspan="1">Response rate <sc>or</sc>/<sc>sd</sc>/<sc>pd</sc> (%)</th><th align="center" rowspan="1" colspan="1"><sc>ttp</sc> or <sc>pfs</sc> (months)</th><th align="center" rowspan="1" colspan="1">Median (months)</th><th align="center" rowspan="1" colspan="1">1-Year (%)</th><th align="center" rowspan="1" colspan="1"><sc>os</sc><italic>p</italic> value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Fukuoka <italic>et al.</italic>, 2003 <xref ref-type="bibr" rid="b54-co16-1-27">54</xref>, <xref ref-type="table-fn" rid="tfn14-co16-1-27">a</xref> (<sc>ideal</sc> 1)</td><td align="center" rowspan="1" colspan="1">Phase <sc>ii</sc></td><td align="center" rowspan="1" colspan="1">Gefitinib 250</td><td align="center" rowspan="1" colspan="1">104</td><td align="center" rowspan="1" colspan="1">66</td><td align="center" rowspan="1" colspan="1">44</td><td align="center" rowspan="1" colspan="1">100/<sc>nr</sc></td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td><td align="center" rowspan="1" colspan="1">22/88</td><td align="center" rowspan="1" colspan="1">88/12</td><td align="center" rowspan="1" colspan="1">18.4/36/41</td><td align="center" rowspan="1" colspan="1">2.7</td><td align="center" rowspan="1" colspan="1">7.6</td><td align="center" rowspan="1" colspan="1">35</td><td align="center" rowspan="1" colspan="1">&#x0003e;0.05</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Gefitinib 500</td><td align="center" rowspan="1" colspan="1">106</td><td align="center" rowspan="1" colspan="1">67</td><td align="center" rowspan="1" colspan="1">33</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">17/83</td><td align="center" rowspan="1" colspan="1">87/13</td><td align="center" rowspan="1" colspan="1">19.0/32/42<break/><italic>p</italic>=<sc>ns</sc></td><td align="center" rowspan="1" colspan="1">2.8</td><td align="center" rowspan="1" colspan="1">8.0</td><td align="center" rowspan="1" colspan="1">29</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Kris <italic>et al.</italic>, 2003 <xref ref-type="bibr" rid="b55-co16-1-27">55</xref>, <xref ref-type="table-fn" rid="tfn15-co16-1-27">b</xref> (<sc>ideal</sc> 2)</td><td align="center" rowspan="1" colspan="1">Phase <sc>ii</sc></td><td align="center" rowspan="1" colspan="1">Gefitinib 250</td><td align="center" rowspan="1" colspan="1">102</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">40/58</td><td align="center" rowspan="1" colspan="1">100/<sc>nr</sc></td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td><td align="center" rowspan="1" colspan="1">15/85</td><td align="center" rowspan="1" colspan="1">81/19</td><td align="center" rowspan="1" colspan="1">12/&#x02013;/&#x02013;</td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td><td align="center" rowspan="1" colspan="1">7.0</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">0.54</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Gefitinib 500</td><td align="center" rowspan="1" colspan="1">114</td><td align="center" rowspan="1" colspan="1">0</td><td align="center" rowspan="1" colspan="1">42/58</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">8/92</td><td align="center" rowspan="1" colspan="1">79/20</td><td align="center" rowspan="1" colspan="1">9/&#x02013;/&#x02013;<break/><italic>p</italic>=0.51</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">6.0<break/><italic>p</italic>=0.40</td><td align="center" rowspan="1" colspan="1">24<break/><italic>p</italic>=0.54</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Shepherd <italic>et al.</italic>, 2005 <xref ref-type="bibr" rid="b56-co16-1-27">56</xref>, <xref ref-type="table-fn" rid="tfn16-co16-1-27">c</xref> (<sc>br</sc>.21)</td><td align="center" rowspan="1" colspan="1">Phase <sc>iii</sc></td><td align="center" rowspan="1" colspan="1">Erlotinib 150</td><td align="center" rowspan="1" colspan="1">488</td><td align="center" rowspan="1" colspan="1">51</td><td align="center" rowspan="1" colspan="1">49</td><td align="center" rowspan="1" colspan="1">92/<sc>nr</sc></td><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td><td align="center" rowspan="1" colspan="1">66/34<xref ref-type="table-fn" rid="tfn17-co16-1-27">d</xref></td><td align="center" rowspan="1" colspan="1">8.9/36/45</td><td align="center" rowspan="1" colspan="1">2.2</td><td align="center" rowspan="1" colspan="1">6.7</td><td align="center" rowspan="1" colspan="1">31</td><td align="center" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Placebo</td><td align="center" rowspan="1" colspan="1">243</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">50</td><td align="center" rowspan="1" colspan="1">91.8/<sc>nr</sc></td><td align="center" rowspan="1" colspan="1">28</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">68/32<xref ref-type="table-fn" rid="tfn17-co16-1-27">d</xref></td><td align="center" rowspan="1" colspan="1">&#x0003c;1/27/57<break/><italic>p&#x0003c;</italic>0.001</td><td align="center" rowspan="1" colspan="1">1.8</td><td align="center" rowspan="1" colspan="1">4.7</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Thatcher <italic>et al.</italic>, 2005 <xref ref-type="bibr" rid="b57-co16-1-27">57</xref>, <xref ref-type="table-fn" rid="tfn18-co16-1-27">e</xref> (<sc>isel</sc>)</td><td align="center" rowspan="1" colspan="1">Phase <sc>iii</sc></td><td align="center" rowspan="1" colspan="1">Gefitinib 250</td><td align="center" rowspan="1" colspan="1">1129</td><td align="center" rowspan="1" colspan="1">49</td><td align="center" rowspan="1" colspan="1">50/1</td><td align="center" rowspan="1" colspan="1">96/27</td><td align="center" rowspan="1" colspan="1">38</td><td align="center" rowspan="1" colspan="1">44/47</td><td align="center" rowspan="1" colspan="1">65/29</td><td align="center" rowspan="1" colspan="1">8/32/37</td><td align="center" rowspan="1" colspan="1">3.0</td><td align="center" rowspan="1" colspan="1">5.6</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">0.087</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Placebo</td><td align="center" rowspan="1" colspan="1">563</td><td align="center" rowspan="1" colspan="1">49</td><td align="center" rowspan="1" colspan="1">50/1</td><td align="center" rowspan="1" colspan="1">96/28</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">39/50</td><td align="center" rowspan="1" colspan="1">68/26</td><td align="center" rowspan="1" colspan="1">1/31/48<break/><italic>p</italic>&#x0003c;0.0001</td><td align="center" rowspan="1" colspan="1">2.6</td><td align="center" rowspan="1" colspan="1">5.1</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn14-co16-1-27"><label>a</label><p>Gefitinib 250 mg daily vs. gefitinib 500 mg daily.</p></fn><fn id="tfn15-co16-1-27"><label>b</label><p>Gefitinib 250 mg daily vs. gefitinib 500 mg daily.</p></fn><fn id="tfn16-co16-1-27"><label>c</label><p>Erlotinib 150 mg daily vs. placebo.</p></fn><fn id="tfn17-co16-1-27"><label>d</label><p>Includes patients with performance status 3 (8.6% in each arm).</p></fn><fn id="tfn18-co16-1-27"><label>e</label><p>Gefitinib 250 mg daily vs. placebo.</p></fn><fn id="tfn19-co16-1-27"><p>Pts = patients; <sc>pd</sc> = progressive disease; <sc>ps</sc> = performance status; <sc>or</sc> = overall response (complete response + partial response); <sc>sd</sc> = stable disease; <sc>ttp</sc> = median time to progression; <sc>pfs</sc> = median progression-free survival; <sc>os</sc> = overall survival; <sc>nr</sc> = not recorded; <sc>isel</sc> = Iressa Survival Evaluation in Lung Cancer; <sc>ideal</sc> = Iressa Dose Evaluation in Advanced Lung Cancer; <sc>ns</sc> = statistically nonsignificant.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tVI-co16-1-27" position="float"><label>TABLE VI</label><caption><p>Randomized trials of epidermal growth factor receptor tyrosine kinase inhibitors (<sc>egfr</sc>-<sc>tki</sc>s) compared with chemotherapy following progression after platinum-based chemotherapy</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th colspan="2" align="center" rowspan="1">Treatment line</th><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th align="center" rowspan="1" colspan="1"/><th colspan="2" align="center" rowspan="1">Survival</th></tr><tr><th align="center" rowspan="1" colspan="1">Reference</th><th align="center" rowspan="1" colspan="1">Design</th><th align="center" rowspan="1" colspan="1">Treatment</th><th align="center" rowspan="1" colspan="1">Pts (<italic>n</italic>)</th><th align="center" rowspan="1" colspan="1">2 (%)</th><th align="center" rowspan="1" colspan="1">3+ (%)</th><th align="center" rowspan="1" colspan="1">Prior platinum/taxane (%)</th><th align="center" rowspan="1" colspan="1"><sc>pd</sc> with prior chemotherapy (%)</th><th align="center" rowspan="1" colspan="1">Stage <sc>iii</sc>/<sc>iv</sc> (%)</th><th align="center" rowspan="1" colspan="1"><sc>ps</sc> 0&#x02013;1/2 (%)</th><th align="center" rowspan="1" colspan="1">Response rate <sc>or</sc>/<sc>sd</sc>/<sc>pd</sc> (%)</th><th align="center" rowspan="1" colspan="1"><sc>ttp</sc> or <sc>pfs</sc></th><th align="center" rowspan="1" colspan="1">Median</th><th align="center" rowspan="1" colspan="1">1-Year (%)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Cufer <italic>et al.,</italic> 2006 <xref ref-type="bibr" rid="b59-co16-1-27">59</xref>, <xref ref-type="table-fn" rid="tfn20-co16-1-27">a</xref> (<sc>sign</sc>)</td><td align="center" rowspan="1" colspan="1">Phase <sc>ii</sc></td><td align="center" rowspan="1" colspan="1">Gefitinib 250</td><td align="center" rowspan="1" colspan="1">68</td><td align="center" rowspan="1" colspan="1">97</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">91/0</td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td><td align="center" rowspan="1" colspan="1">63/37</td><td align="center" rowspan="1" colspan="1">13.2</td><td align="center" rowspan="1" colspan="1">3.0 months</td><td align="center" rowspan="1" colspan="1">7.5 months</td><td align="center" rowspan="1" colspan="1"><sc>nr</sc><xref ref-type="table-fn" rid="tfn21-co16-1-27">b</xref></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Docetaxel 75</td><td align="center" rowspan="1" colspan="1">73</td><td align="center" rowspan="1" colspan="1">99</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">96/0</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">71/29</td><td align="center" rowspan="1" colspan="1">13.7</td><td align="center" rowspan="1" colspan="1">3.4 months<break/><italic>p</italic>=0.88</td><td align="center" rowspan="1" colspan="1">7.1 months</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Natale <italic>et al.</italic>, 2006 <xref ref-type="bibr" rid="b60-co16-1-27">60</xref>, <xref ref-type="table-fn" rid="tfn22-co16-1-27">c</xref></td><td align="center" rowspan="1" colspan="1">Phase <sc>ii</sc></td><td align="center" rowspan="1" colspan="1">ZD6474</td><td align="center" rowspan="1" colspan="1">83</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">100/&#x02013;</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td><td align="center" rowspan="1" colspan="1">100/&#x02013;</td><td align="center" rowspan="1" colspan="1">&#x02013;/45/&#x02013;</td><td align="center" rowspan="1" colspan="1">11 weeks</td><td align="center" rowspan="1" colspan="1">6.1</td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Gefitinib 250</td><td align="center" rowspan="1" colspan="1">85</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">100/&#x02013;</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">&#x02013;/34/&#x02013;</td><td align="center" rowspan="1" colspan="1">8.1 weeks<break/><italic>p</italic>=0.025</td><td align="center" rowspan="1" colspan="1">7.4</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Chen <italic>et al.</italic>, 2007 <xref ref-type="bibr" rid="b61-co16-1-27">61</xref>, <xref ref-type="table-fn" rid="tfn23-co16-1-27">d</xref></td><td align="center" rowspan="1" colspan="1">Phase <sc>ii</sc></td><td align="center" rowspan="1" colspan="1">Gefitinib 250</td><td align="center" rowspan="1" colspan="1">27</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">100/&#x02013;</td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td><td align="center" rowspan="1" colspan="1">59/37</td><td align="center" rowspan="1" colspan="1">55.6</td><td align="center" rowspan="1" colspan="1">7.1 months</td><td align="center" rowspan="1" colspan="1">13.3 months</td><td align="center" rowspan="1" colspan="1">51.3</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Gefitinib 250<break/>+ vinorelbine 15</td><td align="center" rowspan="1" colspan="1">21</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">100/&#x02013;</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">76/24</td><td align="center" rowspan="1" colspan="1">52.4</td><td align="center" rowspan="1" colspan="1">12.8 months<break/><italic>p</italic>=0.133<xref ref-type="table-fn" rid="tfn24-co16-1-27">e</xref></td><td align="center" rowspan="1" colspan="1">23.4 months</td><td align="center" rowspan="1" colspan="1">75.3</td></tr><tr><td align="left" rowspan="1" colspan="1">Douillard <italic>et al.</italic>, 2007 <xref ref-type="bibr" rid="b62-co16-1-27">62</xref>, <xref ref-type="table-fn" rid="tfn25-co16-1-27">f</xref> (<sc>interest</sc>)</td><td align="center" rowspan="1" colspan="1">Phase <sc>iii</sc></td><td align="center" rowspan="1" colspan="1">Gefitinib 250</td><td align="center" rowspan="1" colspan="1">733</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">100/&#x02013;</td><td align="center" rowspan="1" colspan="1">26</td><td align="center" rowspan="1" colspan="1">14/86</td><td align="center" rowspan="1" colspan="1">88/12</td><td align="center" rowspan="1" colspan="1">9.1</td><td align="center" rowspan="1" colspan="1">2.2 months</td><td align="center" rowspan="1" colspan="1">7.6 months</td><td align="center" rowspan="1" colspan="1">32</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Docetaxel 75</td><td align="center" rowspan="1" colspan="1">733</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">100/&#x02013;</td><td align="center" rowspan="1" colspan="1">25</td><td align="center" rowspan="1" colspan="1">13/87</td><td align="center" rowspan="1" colspan="1">88/12</td><td align="center" rowspan="1" colspan="1">7.6<break/><italic>p</italic>=0.3257</td><td align="center" rowspan="1" colspan="1">2.7 months</td><td align="center" rowspan="1" colspan="1">8.0 months</td><td align="center" rowspan="1" colspan="1">34</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Herbst <italic>et al.</italic>, 2007 <xref ref-type="bibr" rid="b63-co16-1-27">63</xref>, <xref ref-type="table-fn" rid="tfn26-co16-1-27">g</xref></td><td align="center" rowspan="1" colspan="1">Phase <sc>ii</sc></td><td align="center" rowspan="1" colspan="1">Chemotherapy + placebo</td><td align="center" rowspan="1" colspan="1">41</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">100/&#x02013;</td><td align="center" rowspan="1" colspan="1">36.6</td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td><td align="center" rowspan="1" colspan="1">98/2</td><td align="center" rowspan="1" colspan="1">12.2/27</td><td align="center" rowspan="1" colspan="1">3.0 months</td><td align="center" rowspan="1" colspan="1">8.6 months</td><td align="center" rowspan="1" colspan="1">33.1</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Chemotherapy + bevacizumab</td><td align="center" rowspan="1" colspan="1">40</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">100/&#x02013;</td><td align="center" rowspan="1" colspan="1">17.5</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">100/0</td><td align="center" rowspan="1" colspan="1">12.5/40</td><td align="center" rowspan="1" colspan="1">4.8 months</td><td align="center" rowspan="1" colspan="1">12.6 months</td><td align="center" rowspan="1" colspan="1">53.8</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Bevacizumab + erlotinib</td><td align="center" rowspan="1" colspan="1">39</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">33.3</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">100/0</td><td align="center" rowspan="1" colspan="1">17.9/33</td><td align="center" rowspan="1" colspan="1">4.4 months</td><td align="center" rowspan="1" colspan="1">13.7 months</td><td align="center" rowspan="1" colspan="1">57.4</td></tr><tr><td align="left" rowspan="1" colspan="1">Lynch <italic>et al.</italic>, 2007<xref ref-type="bibr" rid="b64-co16-1-27">64</xref>, <xref ref-type="table-fn" rid="tfn27-co16-1-27">h</xref></td><td align="center" rowspan="1" colspan="1">Phase <sc>ii</sc></td><td align="center" rowspan="1" colspan="1">Erlotinib 150</td><td align="center" rowspan="1" colspan="1">50 (total)</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">&#x02014;</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1">100</td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td><td align="center" rowspan="1" colspan="1">100/&#x02013;</td><td align="center" rowspan="1" colspan="1">17/&#x02013;/&#x02013;</td><td align="center" rowspan="1" colspan="1">2.7 months</td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td><td align="center" rowspan="1" colspan="1"><sc>nr</sc></td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Erlotinib 150 + bortezomi</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">8/&#x02013;/&#x02013;</td><td align="center" rowspan="1" colspan="1">1.4 months</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Niho <italic>et al.</italic>, 2007 <xref ref-type="bibr" rid="b65-co16-1-27">65</xref>, <xref ref-type="bibr" rid="b66-co16-1-27">66</xref>, <xref ref-type="table-fn" rid="tfn27-co16-1-27">i</xref></td><td align="center" rowspan="1" colspan="1">Phase <sc>iii</sc></td><td align="center" rowspan="1" colspan="1">Gefitinib 250</td><td align="center" rowspan="1" colspan="1">244</td><td align="center" rowspan="1" colspan="1">87</td><td align="center" rowspan="1" colspan="1">13</td><td align="center" rowspan="1" colspan="1">100/&#x02013;</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">19/81</td><td align="center" rowspan="1" colspan="1">96/4</td><td align="center" rowspan="1" colspan="1">22.5/12/66</td><td align="center" rowspan="1" colspan="1">2.0 months</td><td align="center" rowspan="1" colspan="1">11.5 months</td><td align="center" rowspan="1" colspan="1">48</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Docetaxel 60</td><td align="center" rowspan="1" colspan="1">245</td><td align="center" rowspan="1" colspan="1">82</td><td align="center" rowspan="1" colspan="1">17</td><td align="center" rowspan="1" colspan="1">100/&#x02013;</td><td align="center" rowspan="1" colspan="1">15</td><td align="center" rowspan="1" colspan="1">20/79</td><td align="center" rowspan="1" colspan="1">96/4</td><td align="center" rowspan="1" colspan="1">12.8/21/66</td><td align="center" rowspan="1" colspan="1">2.0 months</td><td align="center" rowspan="1" colspan="1">14.0 months<break/><italic>p</italic>=0.33<xref ref-type="table-fn" rid="tfn24-co16-1-27">e</xref></td><td align="center" rowspan="1" colspan="1">54</td></tr></tbody></table><table-wrap-foot><fn id="tfn20-co16-1-27"><label>a</label><p>Gefitinib 250 mg daily vs. docetaxel 75 mg/m<sup>2</sup> intravenously every 3 weeks.</p></fn><fn id="tfn21-co16-1-27"><label>b</label><p>6-Month survival rates were 65.6% with gefitinib and 56.1% with docetaxel.</p></fn><fn id="tfn22-co16-1-27"><label>c</label><p>ZD6474 300 mg daily vs. gefitinib 250 mg daily.</p></fn><fn id="tfn23-co16-1-27"><label>d</label><p>Gefitinib 250 mg daily vs. vinorelbine 15 mg/m<sup>2</sup> intravenously on day 1, and gefitinib 250 mg daily on days 2&#x02013;14 every 2 weeks.</p></fn><fn id="tfn24-co16-1-27"><label>e</label><p>Overall survival.</p></fn><fn id="tfn25-co16-1-27"><label>f</label><p>Gefitinib 250 mg daily vs. docetaxel 75 mg/m<sup>2</sup> intravenously every 3 weeks.</p></fn><fn id="tfn26-co16-1-27"><label>g</label><p>Chemotherapy (docetaxel or pemetrexed); bevacizumab 15 mg daily intravenously on day 1 of each 3-week cycle (&#x000b1; 5 days); erlotinib 150 mg daily for up to 52 weeks; docetaxel over 60 minutes (&#x000b1; 10 minutes) 75 mg/m<sup>2</sup> on day 1 of a 3-week cycle (&#x000b1; 5 days); pemetrexed over 10 minutes (&#x000b1; 5 minutes) 500 mg/m<sup>2</sup> on day 1 of a 3-week cycle. <sup>h</sup> Erlotinib150 mg daily vs. erlotinib 150 mg daily + bortezomib 1.6 mg/m<sup>2</sup> intravenously on days 1 and 8 of a 21-day cycle. The study was halted as required at the planned interim analysis because of insufficient clinical activity in the erlotinib + bortezomib arm.</p></fn><fn id="tfn27-co16-1-27"><label>i</label><p>Gefitinib 250 mg daily vs. docetaxel 60 mg/m<sup>2</sup> intravenously every 3 weeks.</p></fn><fn id="tfn28-co16-1-27"><p>Pts = Patients; <sc>pd</sc> = progressive disease; <sc>ps</sc> = performance status; <sc>or</sc> = overall response (complete response + partial response); <sc>sd</sc> = stable disease; <sc>ttp</sc> = median time to progression; <sc>pfs</sc> = median progression-free survival; <sc>sign</sc> = Second-Line Indication of Gefitinib in <sc>nsclc; nr</sc> = not recorded; <sc>interest</sc> = Iressa non-small-cell lung cancer trial evaluating response and survival against Taxotere.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tVII-co16-1-27" position="float"><label>TABLE VII</label><caption><p>Trials of clinical characteristics that predict response from therapy with epidermal growth factor receptor tyrosine kinase inhibitors (<sc>egfr</sc>-<sc>tki</sc>s)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" rowspan="1" colspan="1">Reference</th><th align="center" rowspan="1" colspan="1">Study</th><th align="center" rowspan="1" colspan="1">Patients (<italic>n</italic>)</th><th align="center" rowspan="1" colspan="1">Treatment</th><th align="center" rowspan="1" colspan="1">Adenocarcinoma</th><th align="center" rowspan="1" colspan="1">Never smokers</th><th align="center" rowspan="1" colspan="1">Female sex</th><th align="center" rowspan="1" colspan="1">Asian ethnicity</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Kris <italic>et al.</italic>, 2003 <xref ref-type="bibr" rid="b55-co16-1-27">55</xref></td><td align="center" rowspan="1" colspan="1"><sc>ideal</sc> 2</td><td align="center" rowspan="1" colspan="1">216</td><td align="center" rowspan="1" colspan="1">Gefitinib 250 mg daily vs. gefitinib 500 mg daily</td><td align="center" rowspan="1" colspan="1">13% vs. 4%</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">19% vs. 3%</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Shepherd <italic>et al.</italic>, 2005 <xref ref-type="bibr" rid="b56-co16-1-27">56</xref></td><td align="center" rowspan="1" colspan="1"><sc>br</sc>.21</td><td align="center" rowspan="1" colspan="1">731</td><td align="center" rowspan="1" colspan="1">Erlotinib 150 mg daily vs. placebo</td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=427</td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=427</td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=427</td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=427</td></tr><tr><td align="left" rowspan="1" colspan="1">Clark <italic>et al.</italic>, 2006 <xref ref-type="bibr" rid="b71-co16-1-27">71</xref>, <sup>a</sup></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">13.9% vs. 4.1%</td><td align="center" rowspan="1" colspan="1">24.7% vs. 3.9%</td><td align="center" rowspan="1" colspan="1">14.4% vs. 6%</td><td align="center" rowspan="1" colspan="1">18.9% vs. 7.5%</td></tr><tr><td align="left" rowspan="1" colspan="1">Florescu <italic>et al.</italic>, 2006 <xref ref-type="bibr" rid="b72-co16-1-27">72</xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>p&#x0003c;</italic>0.001</td><td align="center" rowspan="1" colspan="1"><italic>p&#x0003c;</italic>0.001</td><td align="center" rowspan="1" colspan="1"><italic>p=</italic>0.006</td><td align="center" rowspan="1" colspan="1"><italic>p</italic>=0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">Tsao <italic>et al.</italic>, 2006 <xref ref-type="bibr" rid="b73-co16-1-27">73</xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Thatcher <italic>et al.</italic>, 2005 <xref ref-type="bibr" rid="b57-co16-1-27">57</xref></td><td align="center" rowspan="1" colspan="1"><sc>isel</sc></td><td align="center" rowspan="1" colspan="1">1439</td><td align="center" rowspan="1" colspan="1">Gefitinib 250 mg daily vs. placebo</td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=1439</td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=1439</td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=1439</td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=1439</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">11.9% vs. 4.8%</td><td align="center" rowspan="1" colspan="1">18.1% vs. 5.3%</td><td align="center" rowspan="1" colspan="1">14.7% vs. 5.1%</td><td align="center" rowspan="1" colspan="1">12.4% vs. 7.5%</td></tr></tbody></table><table-wrap-foot><fn id="tfn29-co16-1-27"><p><sc>isel</sc> = Iressa Survival Evaluation in Lung Cancer; <sc>ideal</sc> = Iressa Dose Evaluation in Advanced Lung Cancer.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tVIII-co16-1-27" position="float"><label>TABLE VIII</label><caption><p>Trials of clinical characteristics that predict survival from therapy with epidermal growth factor receptor tyrosine kinase inhibitors (<sc>egfr</sc>-<sc>tki</sc>s)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="center" rowspan="1" colspan="1">Reference</th><th align="center" rowspan="1" colspan="1">Design</th><th align="center" rowspan="1" colspan="1">Patients (<italic>n</italic>)</th><th align="center" rowspan="1" colspan="1">Treatment</th><th align="center" rowspan="1" colspan="1">Adenocarcinoma (HR)</th><th align="center" rowspan="1" colspan="1">Never smokers (HR)</th><th align="center" rowspan="1" colspan="1">Female sex (HR)</th><th align="center" rowspan="1" colspan="1">Asian ethnicity (HR)</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Gatzemeier <italic>et al.</italic>, 2005 <xref ref-type="bibr" rid="b74-co16-1-27">74</xref>,<xref ref-type="bibr" rid="b75-co16-1-27">75</xref> (<sc>talent</sc>)</td><td align="center" rowspan="1" colspan="1">Phase <sc>iii</sc></td><td align="center" rowspan="1" colspan="1">1159</td><td align="center" rowspan="1" colspan="1">Erlotinib 150 mg daily vs. chemotherapy plus erlotinib 150 mg daily</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">Never-smoker <sc>hr</sc>: 0.39<break/><italic>p=</italic>0.25<break/>Former-smoker <sc>hr</sc>: 1.05<break/><italic>p</italic>=0.86</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Thatcher <italic>et al.</italic>, 2005 <xref ref-type="bibr" rid="b57-co16-1-27">57</xref> (<sc>isel</sc>)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1439</td><td align="center" rowspan="1" colspan="1">Gefitinib 250 mg daily vs. placebo</td><td align="center" rowspan="1" colspan="1">0.84</td><td align="center" rowspan="1" colspan="1">0.69 vs. 0.92</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">0.66 vs. 0.92</td></tr><tr><td align="left" rowspan="1" colspan="1">Chang <italic>et al.</italic>, 2006 <xref ref-type="bibr" rid="b76-co16-1-27">76</xref> (<sc>isel</sc>)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">342</td><td align="center" rowspan="1" colspan="1">Gefitinib 250 mg daily vs. placebo (subset of Asian population)</td><td align="center" rowspan="1" colspan="1">0.66 vs. 0.86</td><td align="center" rowspan="1" colspan="1">0.37 vs. 0.85</td><td align="center" rowspan="1" colspan="1">0.46 vs. 0.80</td><td align="center" rowspan="1" colspan="1">All-Asian population</td></tr><tr><td align="left" rowspan="1" colspan="1">Clark <italic>et al.</italic>, 2006 <xref ref-type="bibr" rid="b71-co16-1-27">71</xref>,<xref ref-type="bibr" rid="b77-co16-1-27">77</xref>,<sup>a,b</sup></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">731</td><td align="center" rowspan="1" colspan="1">Erlotinib 150 mg daily vs. placebo</td><td align="center" rowspan="1" colspan="1">0.7 vs. 0.8</td><td align="center" rowspan="1" colspan="1">0.4 vs. 0.9</td><td align="center" rowspan="1" colspan="1">0.8 vs. 0.8</td><td align="center" rowspan="1" colspan="1">0.6 vs. 0.8</td></tr><tr><td align="left" rowspan="1" colspan="1">Florescu <italic>et al.</italic>, 2006 <xref ref-type="bibr" rid="b72-co16-1-27">72</xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Tsao <italic>et al.</italic>, 2006 <xref ref-type="bibr" rid="b73-co16-1-27">73</xref></td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Shepherd <italic>et al.</italic>, 2007 <xref ref-type="bibr" rid="b78-co16-1-27">78</xref> (<sc>br</sc>.21)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Douillard <italic>et al.</italic>, 2007 <xref ref-type="bibr" rid="b79-co16-1-27">79</xref> (<sc>interest</sc>)</td><td align="center" rowspan="1" colspan="1">Phase <sc>iii</sc></td><td align="center" rowspan="1" colspan="1">1466</td><td align="center" rowspan="1" colspan="1">Gefitinib 250 mg daily vs. docetaxel</td><td align="center" rowspan="1" colspan="1"><italic>p&#x0003e;</italic>0.05</td><td align="center" rowspan="1" colspan="1"><italic>p&#x0003e;</italic>0.05</td><td align="center" rowspan="1" colspan="1"><italic>p&#x0003e;</italic>0.05</td><td align="center" rowspan="1" colspan="1"><italic>p&#x0003e;</italic>0.05</td></tr></tbody></table><table-wrap-foot><fn id="tfn30-co16-1-27"><p><sc>hr</sc> = hazard ratio; <sc>isel</sc> = Iressa Survival Evaluation in Lung Cancer; <sc>talent</sc> = Tarceva Lung Cancer Investigation Trial; <sc>interest</sc> = IIressa non-small-cell lung cancer trial evaluating response and survival against Taxotere.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tIX-co16-1-27" position="float"><label>TABLE IX</label><caption><p>Trials of molecular characteristics that predict response from therapy with epidermal growth factor receptor tyrosine kinase inhibitors (<sc>egfr-tkis</sc>)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Reference</th><th align="center" rowspan="1" colspan="1">Design</th><th align="center" rowspan="1" colspan="1">Patients (n)</th><th align="center" rowspan="1" colspan="1">Treatment</th><th align="center" rowspan="1" colspan="1">Protein expression (<sc>ihc</sc>)</th><th align="center" rowspan="1" colspan="1">EGFR High gene copy (amplification &#x000b1; high polysomy)</th><th align="center" rowspan="1" colspan="1">Mutations</th><th align="center" rowspan="1" colspan="1">KRAS Mutations</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Bell <italic>et al.</italic>, 2005 <xref ref-type="bibr" rid="b80-co16-1-27">80</xref> (<sc>ideal</sc> 1/<sc>ideal</sc> 2, <sc>intact</sc> 1/<sc>intact</sc> 2)</td><td align="center" rowspan="1" colspan="1">Phase <sc>ii</sc>/<sc>iii</sc></td><td align="center" rowspan="1" colspan="1">425</td><td align="center" rowspan="1" colspan="1">Gefitinib monotherapy (250 mg vs. 500 mg daily)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>n</italic>=90<break/><sc>qpcr</sc><sup>+</sup> 29% vs. 15%<break/><italic>p</italic>=0.319</td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=79<break/>46% vs.10%<break/><italic>p</italic>=0.005</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">2130</td><td align="center" rowspan="1" colspan="1">Chemotherapy + gefitinib (250 mg daily or 500 mg daily)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>n</italic>=235<break/><sc>qpcr</sc><sup>+</sup> 56% vs. 53%<break/><italic>p=</italic><sc>ns</sc></td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=170<break/>mut<sup>+</sup> 72% vs. 55%<break/><italic>p=</italic><sc>ns</sc></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Eberhard <italic>et al.</italic>, 2005 <xref ref-type="bibr" rid="b82-co16-1-27">82</xref></td><td align="center" rowspan="1" colspan="1">Phase <sc>iii</sc></td><td align="center" rowspan="1" colspan="1">1079</td><td align="center" rowspan="1" colspan="1">Erlotinib 150 mg daily</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>n</italic>=245<xref ref-type="table-fn" rid="tfn31-co16-1-27">a</xref></td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=228</td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=264</td></tr><tr><td align="left" rowspan="1" colspan="1">Gatzemeier <italic>et al.</italic>, 2005<xref ref-type="bibr" rid="b74-co16-1-27">74</xref><sup>,</sup><xref ref-type="bibr" rid="b75-co16-1-27">75</xref> (<sc>talent</sc>)</td><td align="center" rowspan="1" colspan="1">Phase <sc>iii</sc></td><td align="center" rowspan="1" colspan="1">500</td><td align="center" rowspan="1" colspan="1">Chemotherapy + erlotinib 150 mg daily</td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=375<break/>No difference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>n</italic> =293<break/><italic>p</italic>=<sc>ns</sc></td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=293<break/><italic>p</italic>=<sc>ns</sc></td></tr><tr><td align="left" rowspan="1" colspan="1">Hirsch <italic>et al.</italic>, 2006 <xref ref-type="bibr" rid="b83-co16-1-27">83</xref> (<sc>isel</sc>)</td><td align="center" rowspan="1" colspan="1">Phase <sc>iii</sc></td><td align="center" rowspan="1" colspan="1">1692</td><td align="center" rowspan="1" colspan="1">Gefitinib 250 mg daily + carboplatin/paclitaxel</td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=303<break/><sc>ihc</sc><sup>+</sup> 8.2% vs. 1.5%</td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=317<break/><sc>fish</sc><sup>+</sup> 16.4% vs. 3.2%</td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=215<break/>mut<sup>+</sup> 37.5% vs. 2.6%</td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=93<break/>ras<sup>+</sup> 0% vs. 8%</td></tr><tr><td align="left" rowspan="1" colspan="1">Hirsch <italic>et al.</italic>, 2007 <xref ref-type="bibr" rid="b84-co16-1-27">84</xref> (<sc>tribute</sc>)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><sc>fish</sc><sup>+</sup> 12% vs 22%<break/><italic>p</italic>=<sc>ns</sc></td><td align="center" rowspan="1" colspan="1">mut<sup>+</sup> 53% vs. 18%<break/><italic>p&#x0003c;</italic>0.01</td><td align="center" rowspan="1" colspan="1">ras<sup>+</sup> 8% vs. 26%<break/><italic>p</italic>=0.16</td></tr><tr><td align="left" rowspan="1" colspan="1">Zhu <italic>et al.</italic>, 2008 <xref ref-type="bibr" rid="b85-co16-1-27">85</xref> (<sc>br</sc>.21)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">731</td><td align="center" rowspan="1" colspan="1">Erlotinib 150 mg daily</td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=325<break/>11% vs. 4%<break/><italic>p</italic>=0.1<xref ref-type="table-fn" rid="tfn32-co16-1-27">b</xref></td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=159<break/><sc>fish</sc><sup>+</sup> 21% vs. 5%<break/><italic>p</italic>=0.02<xref ref-type="table-fn" rid="tfn32-co16-1-27">b</xref></td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=204<break/>mut<sup>+</sup> 27% vs. 7%<break/><italic>p</italic>=0.035<xref ref-type="table-fn" rid="tfn32-co16-1-27">b</xref></td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=206<break/>ras<sup>+</sup> 5% vs. 10%<break/><italic>p</italic>=0.69</td></tr></tbody></table><table-wrap-foot><fn id="tfn31-co16-1-27"><label>a</label><p>Decrease in response.</p></fn><fn id="tfn32-co16-1-27"><label>b</label><p>Univariate analysis.</p></fn><fn id="tfn33-co16-1-27"><p><sc>ihc</sc> = immunohistochemistry; <sc>ideal</sc> = Iressa Dose Evaluation in Advanced Lung Cancer; <sc>intact</sc> = Iressa <sc>nsclc</sc> Trial Assessing Combination Treatment; <sc>qpcr</sc> = amplification determined by an increase in gene copy by a factor of 4 or more, as assessed by quantitative polymerase chain reaction; mut<sup>+</sup> = mutation present; <sc>ns</sc> = statistically nonsignificant; <sc>fish</sc> = fluorescence <italic>in situ</italic> hybridization showing amplification or high polysomy; <sc>tribute</sc> = Tarceva Responses in Conjunction with Paclitaxel and Carboplatin; <sc>talent</sc> = Tarceva Lung Cancer Investigation Trial; <sc>isel</sc> = Iressa Survival Evaluation in Lung Cancer.</p></fn></table-wrap-foot></table-wrap><table-wrap id="tX-co16-1-27" position="float"><label>TABLE X</label><caption><p>Trials of molecular characteristics that predict survival for therapy with epidermal growth factor receptor tyrosine kinase inhibitors (<sc>egfr-tkis</sc>)</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Reference</th><th align="center" rowspan="1" colspan="1">Design</th><th align="center" rowspan="1" colspan="1">Patients (n)</th><th align="center" rowspan="1" colspan="1">Treatment</th><th align="center" rowspan="1" colspan="1">Protein expression (<sc>ihc</sc>)</th><th align="center" rowspan="1" colspan="1">EGFR High gene copy (amplification &#x000b1; high polysomy)</th><th align="center" rowspan="1" colspan="1">Mutations</th><th align="center" rowspan="1" colspan="1">KRAS Mutations</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Bell 2005 <xref ref-type="bibr" rid="b80-co16-1-27">80</xref>, <xref ref-type="table-fn" rid="tfn34-co16-1-27">a</xref> (<sc>ideal</sc> and <sc>intact</sc>)</td><td align="center" rowspan="1" colspan="1"><sc>ideal</sc> 1/<sc>ideal</sc> 2, phase <sc>ii</sc>/<sc>iii</sc></td><td align="center" rowspan="1" colspan="1">425</td><td align="center" rowspan="1" colspan="1">Gefitinib monotherapy (250 mg and 500 mg daily)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>n</italic>=90<break/>No difference in survival<break/>No difference in survival</td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=119<xref ref-type="table-fn" rid="tfn36-co16-1-27">b</xref><break/><sc>ttp</sc>: 116 days vs. 57 days</td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><sc>intact</sc> 1/<sc>intact</sc> 2, phase <sc>ii</sc>/<sc>iii</sc></td><td align="center" rowspan="1" colspan="1">2130</td><td align="center" rowspan="1" colspan="1">Chemotherapy vs. Chemotherapy + gefitinib (250 mg or 500 mg daily)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>n</italic>=453<break/><sc>fish</sc><sup>+</sup><sc>hr</sc>: 2.03<break/>95% <sc>ci</sc>: 0.67 to 6.13<break/><sc>fish</sc><sup>&#x02212;</sup><sc>hr</sc>: 1.01<break/>95% <sc>ci</sc>: 0.79 to 1.29<break/><italic>p=</italic><sc>ns</sc></td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=312<break/>mut<sup>+</sup><sc>hr</sc>: 1.77<break/>95% <sc>ci</sc>: 0.5 to 6.2<break/>mut<sup>&#x02212;</sup><sc>hr</sc>: 0.91<break/>95% <sc>ci</sc>: 0.67 to 1.23<break/><italic>p=</italic><sc>ns</sc></td><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Eberhard <italic>et al.</italic>, 2005 <xref ref-type="bibr" rid="b82-co16-1-27">82</xref>, <xref ref-type="table-fn" rid="tfn37-co16-1-27">c</xref><break/>Hirsch <italic>et al.</italic>, <xref ref-type="bibr" rid="b84-co16-1-27">84</xref>, <xref ref-type="table-fn" rid="tfn38-co16-1-27">d</xref> 2007 (<sc>tribute</sc>)</td><td align="center" rowspan="1" colspan="1">Phase <sc>iii</sc></td><td align="center" rowspan="1" colspan="1">1079</td><td align="center" rowspan="1" colspan="1">Erlotinib 150 mg daily + carboplatin/paclitaxel vs. placebo + carboplatin/paclitaxel</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><italic>n</italic>=245<break/><sc>fish</sc><break/>No difference in survival<break/><sc>ttp hr</sc>: 0.59<break/>95% <sc>ci</sc>: 0.35 to 0.99<break/><sc>os</sc> similar in both treatment arms</td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=274<break/>mut<sup>+</sup><sc>ttp</sc>: 12.5 months vs. 6.6 months<break/><italic>p</italic>=0.092<break/>No difference in <sc>os</sc><break/><italic>p</italic>=0.96</td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=274<break/>ras<sup>+</sup><sc>hr</sc>: 2.1<break/>95% <sc>ci</sc>: 1.1 vs. 3.8<break/>4.4 months vs. 13.5 months<break/><italic>p</italic>=0.019 ras<sup>&#x02212;</sup> 12.1 months vs. 11.3 months</td></tr><tr><td align="left" rowspan="1" colspan="1">Gatzemeier <italic>et al.</italic>, 2005<xref ref-type="bibr" rid="b74-co16-1-27">74</xref>,<xref ref-type="bibr" rid="b75-co16-1-27">75</xref> (<sc>talent</sc>)</td><td align="center" rowspan="1" colspan="1">Phase <sc>iii</sc></td><td align="center" rowspan="1" colspan="1">500</td><td align="center" rowspan="1" colspan="1">Erlotinib 150 mg daily vs. chemotherapy + erlotinib 150 mg daily</td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=375<break/>No difference</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"><sc>os</sc>: <italic>p</italic>=0.40 (erlotinib), <italic>p</italic>=0.65 (placebo)<break/><italic>n</italic>=293<break/><sc>pfs</sc>: <italic>p</italic>=0.18 (erlotinib), <italic>p</italic>=0.74 (placebo)<break/><italic>n</italic>=293</td><td align="center" rowspan="1" colspan="1"><sc>os</sc>: <italic>p</italic>=0.51 (erlotinib)<break/><italic>n</italic>=293<break/><sc>pfs</sc>: <italic>p</italic>=0.77 (erlotinib), <italic>p</italic>=0.22 (placebo)<break/><italic>n</italic>=293</td></tr><tr><td align="left" rowspan="1" colspan="1">Clark <italic>et al.</italic>, 2006 <xref ref-type="bibr" rid="b71-co16-1-27">71</xref>,<xref ref-type="bibr" rid="b77-co16-1-27">77</xref>,<xref ref-type="table-fn" rid="tfn39-co16-1-27">e</xref><break/>Tsao <italic>et al.</italic>, 2006 <xref ref-type="bibr" rid="b73-co16-1-27">73</xref>, <xref ref-type="table-fn" rid="tfn39-co16-1-27">e</xref><break/>Zhu <italic>et al.</italic>, 2008<xref ref-type="bibr" rid="b85-co16-1-27">85</xref>, <xref ref-type="table-fn" rid="tfn39-co16-1-27">e</xref> (<sc>br</sc>.21)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">731</td><td align="center" rowspan="1" colspan="1">Erlotinib 150 mg daily vs. placebo</td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=325<break/><sc>ihc</sc><sup>+</sup><sc>hr</sc>: 0.68<break/>95% <sc>ci</sc>: 0.49 to 0.95<break/><sc>ihc</sc><sup>&#x02212;</sup><sc>hr</sc>: 0.93<break/>95% <sc>ci</sc>: 0.63 to 1.36<break/><italic>p</italic>=0.1</td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=159<break/><sc>fish</sc><sup>+</sup><sc>hr</sc>: 0.43<break/>95% <sc>ci</sc>: 0.23 to 0.78<break/><sc>fish</sc><sup>&#x02212;</sup><sc>hr</sc>: 0.80<break/>95% <sc>ci</sc>: 0.49 to 1.29<break/>Interaction <italic>p</italic>=0.12</td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=204<break/>mut<sup>+</sup><sc>hr</sc>: 0.55<break/>95% <sc>ci</sc>: 0.25 to 1.19<xref ref-type="table-fn" rid="tfn39-co16-1-27">e</xref><break/>mut<sup>&#x02212;</sup><sc>hr</sc>: 0.74<break/>95% <sc>ci</sc>: 0.52 to 1.05<break/><italic>p</italic>=0.47</td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=206<break/>ras<sup>+</sup><sc>hr</sc>: 1.67<break/>95% <sc>ci</sc>: 0.62 to 4.50<break/>ras<sup>&#x02212;</sup><sc>hr</sc>: 0.69<break/>95% <sc>ci</sc>: 0.49 to 0.97<break/><italic>p</italic>=0.09</td></tr><tr><td align="left" rowspan="1" colspan="1">Hirsch <italic>et al.</italic>, 2006<xref ref-type="bibr" rid="b83-co16-1-27">83</xref> (<sc>isel</sc>)</td><td align="center" rowspan="1" colspan="1">Phase <sc>iii</sc></td><td align="center" rowspan="1" colspan="1">1692</td><td align="center" rowspan="1" colspan="1">Gefitinib 250 mg daily and placebo</td><td align="center" rowspan="1" colspan="1"><italic>n=</italic>379<break/><sc>ihc</sc><sup>+</sup><sc>hr</sc>: 0.77<break/>95% <sc>ci</sc>: 0.56 to 1.08<break/><sc>ihc</sc><sup>&#x02212;</sup><sc>hr</sc>: 1.57<break/>95% <sc>ci</sc>: 0.86 to 2.87<break/>Interaction <italic>p=</italic>0.049</td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=370<break/><sc>fish</sc><sup>+</sup><sc>hr</sc>: 0.61<break/>95% <sc>ci</sc>: 0.36 to 1.04<break/><sc>fish</sc><sup>&#x02212;</sup><sc>hr</sc>: 1.16<break/>95% <sc>ci</sc>: 0.81 to 1.64<break/>Interaction <italic>p=</italic>0.045</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Douillard <italic>et al.</italic>, 2007<xref ref-type="bibr" rid="b79-co16-1-27">79</xref> (<sc>interest</sc>)</td><td align="center" rowspan="1" colspan="1">Phase <sc>iii</sc></td><td align="center" rowspan="1" colspan="1">1466</td><td align="center" rowspan="1" colspan="1">Gefitinib 250 mg daily vs. docetaxel</td><td align="center" rowspan="1" colspan="1"><italic>p</italic>=<sc>ns</sc></td><td align="center" rowspan="1" colspan="1"><italic>p</italic>=<sc>ns</sc></td><td align="center" rowspan="1" colspan="1"><italic>p</italic>=<sc>ns</sc></td><td align="center" rowspan="1" colspan="1"><italic>p</italic>=<sc>ns</sc></td></tr><tr><td align="left" rowspan="1" colspan="1">Garassino <italic>et al.</italic>, 2007<xref ref-type="bibr" rid="b86-co16-1-27">86</xref> (Pooled subset from <sc>isel</sc>, <sc>intact</sc>, <sc>tribute</sc>, and <sc>br</sc>.21)</td><td align="center" rowspan="1" colspan="1"/><td align="center" rowspan="1" colspan="1">1350</td><td align="center" rowspan="1" colspan="1">Gefitinib 250 mg daily vs. placebo<break/>Erlotinib 150 mg daily vs. placebo</td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=325<break/><sc>egfr</sc><sup>+</sup><sc>hr</sc>: 0.72<break/><sc>egfr</sc><sup>&#x02212;</sup><sc>hr</sc>: 1.08<break/>Interaction <italic>p</italic>=0.048</td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=578<break/><sc>fish</sc><sup>+</sup><sc>hr</sc>: 0.63<break/><sc>fish</sc><sup>&#x02212;</sup><sc>hr</sc>: 1.03<break/>Interaction <italic>p</italic>=0.022</td><td align="center" rowspan="1" colspan="1"><italic>n</italic>=447<break/>mut<sup>+</sup><sc>hr</sc>: 0.92<break/>mut<sup>&#x02212;</sup><sc>hr</sc>: 0.85<break/>Interaction <italic>p</italic>=0.796</td><td align="center" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="tfn34-co16-1-27"><label>a</label><p><sc>intact</sc> 1: Chemotherapy (gemcitabine + cisplatin, <italic>n</italic>=363) + placebo vs. chemotherapy + gefitinib 250 mg daily (<italic>n</italic>=365) vs. chemotherapy + gefitinib 500 mg daily (<italic>n</italic>=365).</p></fn><fn id="tfn35-co16-1-27"><p>Gemcitabine 1250 mg/m<sup>2</sup> intravenously on days 1 and 8; cisplatin 80 mg/m<sup>2</sup> intravenously after gemcitabine on day 1 of a 21-day cycle; <sc>intact</sc> 2: Chemotherapy (paclitaxel + carboplatin) + placebo (<italic>n</italic>=345) vs. chemotherapy + gefitinib 250 mg daily vs. chemotherapy (<italic>n</italic>=345) + gefitinib 500 mg daily (<italic>n</italic>=347). Paclitaxel 225 mg/m<sup>2</sup> intravenously on day 1; carboplatin [area under the curve (<sc>auc</sc>) 6] on day 1 of a 21-day cycle; <sc>ideal</sc> 1: gefitinib 250 mg daily (<italic>n</italic>=104) vs. gefitinib 500 mg daily (<italic>n</italic>=106); <sc>ideal</sc> 2, gefitinib 250 mg daily (<italic>n</italic>=102) vs. gefitinib 500 mg daily (<italic>n</italic>=114).</p></fn><fn id="tfn36-co16-1-27"><label>b</label><p>Median time to progression: <sc>egfr</sc> mut<sup>+</sup> &#x0003e; <sc>egfr</sc> mut<sup>&#x02212;</sup>. No effect on overall survival.</p></fn><fn id="tfn37-co16-1-27"><label>c</label><p>Univariate analysis.</p></fn><fn id="tfn38-co16-1-27"><label>d</label><p><sc>tribute</sc>: Chemotherapy (carboplatin + paclitaxel) + placebo vs. erlotinib 150 mg daily. Carboplatin [area under the curve (<sc>auc</sc>) 6] intravenously on day 1; paclitaxel 200 mg/m<sup>2</sup> intravenously on day 1 of a 21-day cycle.</p></fn><fn id="tfn39-co16-1-27"><label>e</label><p><sc>tribute</sc>: Chemotherapy (carboplatin + paclitaxel) + placebo vs. erlotinib 150 mg daily. Carboplatin [area under the curve (<sc>auc</sc>) 6] intravenously on day 1; paclitaxel 200 mg/m<sup>2</sup> intravenously on day 1 of a 21-day cycle.</p></fn><fn id="tfn40-co16-1-27"><p><sc>ihc</sc> = immunohistochemistry; <sc>ideal</sc> = Iressa Dose Evaluation in Advanced Lung Cancer; <sc>intact</sc> = Iressa <sc>nsclc</sc> Trial Assessing Combination Treatment; <sc>ttp</sc> = time to progression; <sc>fish</sc> = fluorescence <italic>in situ</italic> hybridization showing amplification or high polysomy; <sc>hr</sc> = hazard ratio; mut<sc>+</sc> = mutation present; <sc>ci</sc> = confidence interval; <sc>ns</sc> = statistically nonsignificant; <sc>tribute</sc> = Tarceva Responses in conjunction with Paclitaxel and Carboplatin; <sc>interest</sc> = Iressa non-small-cell lung cancer trial evaluating response and survival against Taxotere; <sc>isel</sc> = Iressa Survival Evaluation in Lung Cancer; <sc>talent</sc> = Tarceva Lung Cancer Investigation Trial; <sc>os</sc> = overall survival; <sc>pfs</sc> = median progression-free survival.</p></fn></table-wrap-foot></table-wrap></floats-wrap></article>